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Abstract 
As one of the central components of host anti-tumour immunity, natural killer (NK) cells exert 
cellular cytotoxicity against tumour cells and secrete a milieu of immunoregulatory cytokines to 
inhibit tumour progression. NK cell-mediated cytotoxicity requires successful progression 
through discrete activation events that begin with NK cell adhesion to a target cell and culminate 
in the polarized release of cytotoxic granules into the immunological synapse. These activation 
events are tightly regulated by a complex array of signalling molecules, the engagement of which 
by ligands on target cells can determine susceptibility to NK cell-mediated killing. Resistance to 
NK cell cytotoxicity can be attributable to a deficiency in any of the signalling requirements for 
the events leading to granule exocytosis. Tumour resistance to NK cell lysis may be overcome by 
priming of NK cells with cytokines or by binding of NK cell activating receptors to ligands 
expressed on target cells. Here, the activation profiles of normal, freshly isolated human 
peripheral blood NK cells upon tumour-priming with the NK-resistant leukemic cell line, CTV-1 
are defined, and candidate NK cell receptors involved in the delivery of the tumour-priming 
signal are identified. Results from this study demonstrate that NK cell responses to tumour-
priming are distinct from those induced by the gold standard in immunotherapy, cytokine-
priming. Tumour-priming of NK cells resulted in a significant downregulation of various 
activating NK cell receptors including CD16, NKp46, NK group 2, member D (NKG2D), and 
intracellular adhesion molecule (ICAM)-1. Tumour-primed NK cells (TpNKs) also exhibited a 
strong pro-inflammatory profile marked by ample secretion of macrophage inflammatory protein 
(MIP)-1α, MIP-1β, regulated on activation normal T cell expressed and secreted (RANTES), 
tumour necrosis factor (TNF)-α and interferon (IFN) -γ after short incubations with CTV-1. 
Their secretory profiles were distinct from the profiles of NK cells stimulated with exogenous 
cytokines or the NK-sensitive target cell line, K562. Collectively, data from this study 
demonstrates that NK cell responses can differ according to the type of stimulus, as well as the 
ligand combination presented by the target cell. The co-engagement of NK cell receptors LFA-1 
and CD2 by their respective ligands on CTV-1 cells, ICAM-1 and CD15, seems to play an 
important role in the delivery of the tumour- priming signal.  
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Chapter 1 General Introduction 
1.1 The human immune system 
The immune system is a collection of cells, tissues and molecules that act together in 
a dynamic network to protect us against the effects of pathogens, toxins and cancer 
cells (Kindt et al. 2007). Protection by the immune system involves two parts: 
recognition and response. Immune recognition is remarkable for its capacity to 
recognize molecular patterns that characterize groups of common pathogens and 
detect subtle differences that distinguish one pathogen from another. It can also 
discriminate between foreign and self-cells as well as recognize host cells that have 
undergone alterations that may lead to cancer. In a normal immunocompetent setting, 
immune recognition leads to an effector response whereby the threat is neutralized or 
eliminated. The type of threat faced by the immune system dictates how the initial 
recognition event is converted into a variety of effector responses by the multiple 
components of the immune system. 
 
1.1.1 Innate and adaptive immunity 
Traditionally, the immune system is divided into innate and adaptive arms, which 
collaborate for an effective immune response (Kindt et al. 2007). The innate immune 
system is always active and ready to mobilize, providing the initial line of defense 
against any threat to the immune system. The main components of the innate 
immune system are physical epithelial barriers, phagocytic leukocytes, dendritic cells 
(DCs), natural killer (NK) cells, and circulating plasma proteins. The molecular and 
cellular mechanisms involved in innate defense are developed before the encounter 
with pathogen or stressed cell and most infections are prevented or eliminated within 
hours of initial encounter. The adaptive immune system is called into action against 
pathogens that are able to evade innate responses or persist in spite of them. It adapts 
to recognize, eliminate and then remember the invading pathogen, such that if the 
same, or a closely related, pathogen infects the body, memory cells provide the 
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means for the adaptive cells to mount a rapid and more potent secondary response. 
There are two types of adaptive immune responses: humoral immunity, mediated by 
antibodies produced by B lymphocytes, and cell-mediated immunity, mediated by T 
lymphocytes.  
 
1.1.2 Immune cells, tissues and organs 
Hematopoiesis, the formation and development of red and white blood cells, begins 
in the embryonic yolk sac during the first few weeks of development. Subsequently, 
the BM becomes the major site of hematopoiesis; where hematopoietic stem cells 
(HSCs) differentiate along two separate pathways into two main types of progenitor 
cells, myeloid and lymphoid. Myeloid progenitors give rise to neutrophils, 
eosinophils, basophils, monocytes, mast cells, and DCs (Edvardsson et al. 2006), 
whereas lymphoid progenitors develop into B, T and NK cells (Rolink et al. 2007). 
Some of these immune cells complete their maturation in the BM, whereas others 
migrate through the circulatory system to other tissues where they achieve full 
maturation and acquire further physiological and functional characteristics. The 
primary lymphoid organs (BM and thymus) provide the appropriate 
microenvironment required for the development and maturation of lymphocytes. The 
secondary lymphoid organs and tissues (lymph nodes and spleen) are sites where 
mature lymphocytes can optimally interact with antigen presenting cells (APCs) and 
antigen captured from nearby tissues. Blood vessels and lymphatic systems connect 
the various organs and tissues into a whole that functions to maintain homeostatic 
conditions. Abnormality or dysfunction of the immune system may lead to disease; 
for example, immune responses can be mounted against self-antigens, resulting in 
autoimmune diseases that include Crohn’s disease etc.  
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1.1.2.1 Lymphocytes 
Lymphocytes comprise 20–40% of white blood cells and are the only cells in the 
body capable of recognizing specific antigens through an array of highly specific cell 
surface receptors (Kindt et al. 2007). The three major lymphocytic subpopulations, B 
cells, T cells and NK cells, each bear their own distinctive family of cell surface 
receptors. Before antigen exposure, B and T cells are referred to as naïve or 
unprimed, characterized by a small morphology and a short life span of up to a few 
weeks. The interaction of naïve lymphocytes with antigen induces their enlargement 
into lymphoblasts, which eventually differentiate into effector and memory cells. 
Memory cells from B or T cell progeny persist to provide lifelong immunity against 
many pathogens. 
 
1.1.2.1.1 B cells 
B cells mature in the BM, where they come to express a unique antigen-binding 
receptor on their membrane, known as an antibody. Antibodies are glycoproteins that 
consist of two identical polypeptides called the heavy chains and two shorter, 
identical polypeptides called the light chains. Each heavy chain is joined to a light 
chain by disulfide bonds and the heavy/light chains are joined to each other by 
additional disulfide bonds. The amino-terminal ends of the pairs of heavy and light 
chains form the receptor site to which the antigen binds. The antigen specificity of 
each B cell is determined by the antibody expressed by the cell. As a B cell matures 
in the bone marrow, its specificity is created by random rearrangements of a series of 
gene segments that encode the antibody molecule. At maturity, each B cell possesses 
a single functional gene encoding the antibody heavy chain and a single functional 
gene encoding the antibody light chain. All antibody molecules on a given B 
lymphocyte have identical specificity, giving each B lymphocyte and the clone of 
daughter cells to which it gives rise, a distinct specificity for a single antigen. When a 
naïve B cell encounters antigen that matches its specific antibody, it rapidly divides 
into effector cells known as plasma cells and memory B cells. Plasma cells are highly 
specialized for antibody secretion and have little or no membrane-bound antibody, 
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whereas memory B cells express the same membrane-bound antibody as their parent 
B cell. 
1.1.2.1.2 T cells 
T cells arise in the BM but migrate to the thymus gland in order to complete their 
maturation. Maturing T cells express a unique antigen-binding molecule on their 
membranes called the T-cell receptor (TCR). In contrast to membrane-bound 
antibodies on B cells, which recognize free antigen, most T cell receptors can only 
recognize antigen that is bound to major histocompatibility complex (MHC) 
molecules. MHC molecules are polymorphic glycoproteins found on cell 
membranes, and fall into two groups: class I MHC molecules and class II MHC 
molecules. Class I MHC molecules are expressed by nearly all nucleated cells of 
vertebrate species, whereas class II MHC molecules are expressed only by APCs. 
Similar to B cell maturation, the process of T cell maturation also includes random 
rearrangements of a series of gene segments that encode the cell’s antigen-binding 
receptor, to generate an enormous number of unique antigenic specificities. Once a 
naïve T cell recognizes antigen combined with MHC, it proliferates and 
differentiates into effector and memory T cells. T cell effector cells include cytokine-
secreting CD4
+
 T helper cells (TH), as well as cytotoxic CD8
+
 T lymphocytes 
(CTLs). TH cells can further differentiate into several subtypes upon activation, 
including TH1, TH2, and TH17, all with their distinct cytokine secretion profiles. 
CTLs degranulate to release cytotoxic granules that kill infected or stressed cells.  
Memory T cells confer lifelong immunity against a specific antigen, such that any 
subsequent encounters with the same antigen generates a faster and more potent 
immune response. A small subset of T cells known as gamma delta T cells (γδ T 
cells) possess a distinct TCR on their surface and don’t appear to be MHC-restricted 
in their recognition of target cells (Morita et al 2000).  
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1.1.2.1.3 NK cells 
NK cells comprise 5–15% of circulating lymphocytes and are characterized by a 
large, granular morphology. They are not exclusively found in peripheral blood (PB) 
but populate different tissues and organs including the gut, liver, lungs and uterus 
(Carrega and Ferlazzo 2012). With a wide array of cell surface receptors designed for 
robust immune surveillance, NK cells are strongly equipped to act as initiators of 
immune responses upon recognition of infected or malignant cells. They secrete a 
milieu of cytokines including tumour necrosis factor (TNF)-α and interferon (IFN)-γ, 
and exert cellular cytotoxicity against tumour targets and infected cells (Vivier et al. 
2008). Unlike B and T cells, they perform these effector functions without the 
requirement for prior exposure to antigen or somatic rearrangement of their surface 
receptors during maturation. The importance of NK cells in host protection is 
illustrated by studies showing that the selective absence of these cells or impairment 
in their function results in increased episodes of viral infections (Biron et al. 
1989;Eidenschenk et al. 2006;Etzioni et al. 2005) and a reduced ability to control the 
development of some tumours (Ballas et al. 1990;Waldhauer and Steinle 2008a;Yang 
et al. 2002). Recent studies have also shown their protective role against bacteria 
(Small et al. 2008), fungi (Schmidt et al. 2011) and parasites (Korbel et al. 2004). 
Although many questions regarding their distribution, development, activation and 
response specificity remain unanswered, the last two decades have brought major 
advances in our understanding of NK cell biology; these advances have challenged 
the classical view of NK cells as simple effector cells that are classified within the 
innate immune system. 
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1.2 NK cell defence: innate or adaptive? 
NK cells were discovered in 1975 based on their ability to spontaneously or 
‘naturally’ lyse tumour cells without prior sensitization (Herberman et al. 
1975a;Herberman et al. 1975b;Kiessling et al. 1975a;Kiessling et al. 1975b). They 
were initially believed to have a short life span and were characterized by their rapid 
response, and invariant, germ-line encoded receptors. Now a growing body of 
evidence suggests that under certain experimental conditions NK cells share some of 
the attributes of adaptive immunity, including priming, antigen specificity, clonal 
expansion and immunologic memory (Paust et al. 2010b).  
 
1.2.1 Priming 
For many years, NK cell effector functions were believed to be triggered completely 
independently of prior stimulation. However, recent findings in mice (Ganal et al. 
2012;Lucas et al. 2007) and humans (Bryceson et al. 2006b;North et al. 2007;Sabry 
et al. 2011;Sabry and Lowdell 2013) have shown that NK cell priming is necessary 
to generate full NK cell effector responses. In vivo, NK cells can be primed by DCs, 
which produce and trans-present IL-15 to resting NK cells to stimulate cytokine 
production and cytotoxicity (Lucas et al. 2007). Mononuclear phagocytes have also 
been shown to be another important source for in vivo priming of NK cells during 
viral infections (Ganal et al. 2012). Bryceson et al showed that pre-treatment with 
IL-2 is a requirement for resting NK cells to exhibit natural cytotoxicity against 
target cells expressing a single ligand for an NK cell activating receptor (Bryceson et 
al. 2006). Similar studies have also reported that pre-activation of NK cells by IL-12 
or IL-15 enhances cytokine production and cytotoxicity against tumour target cells 
(Hart et al. 2005;Strowig et al. 2010). Our group has shown that tumour cells can 
also prime resting NK cells to kill previously resistant targets (North et al. 2007). 
Thus, NK cell priming appears to induce more potent NK cell effector functions by 
increasing their cytotoxic armoury and lowering the threshold for NK cell activation.  
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1.2.2 Antigen specificity and clonal expansion 
Antigen specificity and diversity allow adaptive lymphocytes to distinguish subtle 
differences between pathogens and respond by clonal expansion and rapid 
proliferation of antigen-specific cells. This ability is in contrast to the pattern 
recognition molecules of innate immune cells which can only distinguish broad 
families of pathogens. NK cells have a wide array of activating cell surface receptors 
that bind a variety of ligands on target cells stressed with a pathogen infection or 
transformation. Many of these NK cell receptors are shared with adaptive T 
lymphocytes and activate a common killing mechanism that relies on cytotoxic 
molecules stored within secretory lysosomes (Narni-Mancinelli et al. 2011). 
Diversity in adaptive recognition is achieved by employing recombination-activating 
gene (RAG) proteins to generate random rearrangements of V(D)J gene segments for 
B and T cell receptors. Transient expression of RAG proteins and incomplete V(D)J 
recombination were recently reported to be observed in low frequency during NK 
cell development (Borghesi et al. 2004;Igarashi et al. 2002;Pilbeam et al. 
2008;Yokota et al. 2003). In addition, NK cell behaviour resembling clonal 
expansion by adaptive lymphocytes has also been shown to occur. For example, in 
mice infected with murine cytomegalovirus (MCMV), an NK cell subset expands in 
an antigen-dependent manner to exhibit long-lasting functional changes (Dokun et al. 
2001). Specifically, NK cells expressing the surface receptor Ly49H, which binds the 
viral protein m157, were shown to proliferate following receptor engagement, and 
persist up to several months after clearance of infection. These Ly49H
+
 NK cells 
demonstrated higher functional competence relative to naïve NK cells that had not 
been exposed to the virus, and were 10 times more efficient at mediating protection 
against MCMV in adoptive transfer experiments. Several viral infections in humans 
have also been reported to result in the clonal expansion of a specific NK cell subset, 
with more potent effector functions than its naïve counterparts (Rolle et al. 2013). 
For instance, the expansion of NKG2C
+
 NK cells was observed in human 
cytomegalovirus (HCMV) (Foley et al. 2012;Lopez-Verges et al. 2011), acute 
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hantavirus (Bjorkstrom et al. 2011), chikungunya virus (Petitdemange et al. 2011), 
hepatitis B virus (HBV) (Beziat et al. 2012) and human immunodeficiency virus 
(HIV)-1 (Brunetta et al. 2010). The selective proliferation of this NK cell subset, 
which could be detected over a month later and exhibited enhanced cytolytic and 
cytokine-producing effector functions upon restimulation with the virus, is 
reminiscent of memory T cells.  
 
1.2.3 Immunologic memory 
Although the innate immune system is commonly considered to lack the capacity for 
immunologic memory, recent studies have shown that specificity and memory might 
exist in invertebrates, which rely solely on innate defence (Kurtz 2005). The half-life 
of mature NK cells has been estimated to be 17 days in steady-state conditions 
(Jamieson et al. 2004), but some mature NK cells can be long-lived to mount a robust 
recall response upon restimulation. The first evidence of NK cell-mediated, antigen-
specific adaptive recall responses was observed in a model of hapten-induced contact 
hypersensitivity mice devoid of T and B cells (O'Leary et al. 2006). Haptens, which 
are compounds that chemically modify proteins, were used to provoke a 
hypersensitivity reaction that was transferable to naïve animals by adoptive NK cell 
transfer. This NK cell-mediated response persisted for at least 4 weeks, and was 
triggered only by haptens to which mice were previously sensitized. Further studies 
extended these observations to NK cell recall responses against viruses including 
MCMV, influenza, vesicular stomatitis virus (VSV), and HIV-1 (Paust et al. 
2010a;Sun et al. 2009). In some cases such as MCMV, memory NK cells isolated 
from the first host can be adoptively transferred to a second recipient and undergo 
subsequent rounds of proliferation in response to the virus (Sun et al. 2009). These 
memory NK cells were detected in essentially all tissues including spleen, lymph 
nodes, liver, lung and kidney after 2 months from the initial infection with MCMV 
virus. In addition to the specific antigens that drive the expansion of NK subsets and 
the formation of NK cell memory, the involvement of cytokines for the generation of 
long-lived NK cell populations with superior effector function has been reported. 
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Recent studies in both mouse and human NK cells indicate that a short in vitro 
exposure to a combination of IL-12, IL-15, and IL-18 yields memory-like NK cells 
that display superior effector function and longevity in vitro and in vivo, and those 
properties are also inheritable to daughter cells (Cooper et al. 2009;Ni et al. 
2012;Romee et al. 2012;Sun et al. 2009). Thus, NK cells appear to remember their 
past, a trait initially considered possible only for the adaptive immune system. 
1.3 NK cell subsets and development 
Human NK cells are phenotypically defined by their surface expression of the neural 
cell adhesion molecule CD56 and lack of the T cell receptor CD3. Two main NK cell 
subsets can be identified according to the cell surface density of CD56 (Cooper et al. 
2001). CD56
dim
 NK cells constitute the majority of PB NK cells and express high 
levels of CD56 and the low affinity IgG receptor CD16. In contrast, CD56
bright
 NK 
cells express high levels of CD56, but display little or no CD16 expression. 
CD56
bright
 and CD56
dim
 NK cells have unique phenotypic and functional attributes. 
Mouse NK cells resemble their human counterparts in many regards, but the murine 
homolog for CD56 has not been identified, which has made it difficult to translate 
our knowledge from mouse to human NK cell biology. 
1.3.1 CD56bright NK cells  
CD56
bright
 NK cells comprise approximately 10% of PB NK cells, and are classically 
viewed as the predominant source of NK cell immunoregulatory cytokines (Cooper 
et al. 2001;Jacobs et al. 2001). The CD56
bright
 subset lacks perforin and displays 
weak cytotoxic activity against target cells. However, recent evidence suggests that 
this may be dependent on the type of stimulation. Following cytokine stimulation, 
CD56
bright
 NK cells produce significantly greater levels of cytokines such as IFN-γ, 
and TNF-β, than their CD56dim counterparts (Cooper et al. 2001). CD56bright NK cells 
primed with IL-2 also demonstrate enhanced cytotoxicity compared to their resting 
counterparts. By contrast, CD56
bright
 NK cells exhibit weak cytokine production 
(Fauriat et al 2010) and cytotoxicity (Penack et al. 2005) after target cell stimulation. 
Thus, CD56
bright
 NK cells may be the cytokine-responsive NK cell subset. 
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1.3.2 CD56dim NK cells 
CD56
dim
 NK cells are the most abundant subset in circulating NK cells and are 
considered to be the main cytolytic subset (Campbell et al. 2001; Cooper et al. 2001; 
Jacobs et al. 2001). Most CD56
dim
 NK cells co-express CD16 and have high levels of 
perforin and granzymes (Jacobs et al. 2001). They also exhibit a strong capacity to 
form conjugates, which enables them to mediate potent cytotoxicity. Recent studies 
have shown that following target cell recognition or crosslinking of NK cell 
activating receptors; CD56
dim
 NK cells secrete substantial levels of inflammatory 
cytokines (De et al. 2011; Fauriat et al. 2010; Juelke et al. 2010). This suggests that 
in addition to mediating cytotoxicity CD56
dim
 NK cells can be an important source of 
cytokines and chemokines following target cell stimulation. This suggests that 
CD56
dim
 NK cells may be the target-responsive subset (Zhang and Yu 2010).  
1.3.3 NK cell development model 
In contrast to other lymphocytes, many of the details of human NK cell development 
and differentiation remain unclear. An important role for the bone marrow was 
identified early on by selective bone marrow ablation studies in mice (Kumar et al. 
1979;Seaman et al. 1978). These studies provided the first evidence that NK cells are 
bone marrow-derived, and for more than three decades it was believed that NK cell 
development occurs solely in the bone marrow (Farag and Caligiuri 2006). Although 
it was clear that CD34
+
 hematopoietic progenitor cells (HPCs) within the bone 
marrow gave rise to NK cells, many details of the process, including the in vivo 
stages of human NK differentiation and the maturation sites remained 
uncharacterized (Galy et al. 1995). The discovery of CD56
bright
 NK cells in human 
lymph nodes and tonsils, revealed a potential role for the secondary lymphoid tissue 
(SLT) in human NK cell development (Freud et al 2005). Although CD56
dim
 NK 
cells dominate the bone marrow, blood and spleen, CD56
bright
 NK cells are more 
abundant in the SLT, where there is a selective enrichment of CD34
+
 and CD45RA
+
 
pre-NK cells (Freud et al. 2005). Moreover, the SLT contains an abundance of DCs 
and other APCs that express membrane-bound IL-15, a critical requirement for NK 
cell maturation (Mrozek et al. 1996). All of this evidence suggested that the SLT 
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may be an important site for human NK cell development.  
 
Distinct stages in NK cell development are characterized through expression analysis 
of CD34, CD117, CD94 and CD56 cell surface antigens. Stage 1 of NK cell 
development begins with multi-potent CD34
+
CD117
−
CD56
−
CD94
−
 cells, which is 
followed by the gain of CD117 (stage 2; CD34
+
CD117
+
CD56
−
CD94
−
). Cells from 
stage 1 and 2 can give rise to other cell lineages including T cells and DCs. In the 
first part of stage 3, CD34 expression is lost (stage 3a; CD34
−
CD117
+
CD56
−
CD94
−
) 
(Eissens et al 2012). The second part of stage 3 is defined by loss of multi-potency 
and acquirement of NK cell lineage commitment through CD56 acquisition (stage 
3b; CD34
−
CD117
+
CD56
+
CD94
−
). Subsequently, cells gain CD94 expression and 
develop into immature CD56
bright
NK cells (stage 4; CD34
−
CD117
+
CD56
+
CD94
+
). 
CD56
bright 
NK cells are believed to be precursors of CD56
dim
 NK cells (Takahashi et 
al. 2007), as evidenced by observations that CD56
bright
 NK cells have longer 
telomeres than CD56
dim
 NK cells (Romagnani et al. 2007), are more abundant in 
blood at an early stage following hematopoietic stem cell transplantation (HSCT) 
(Shilling et al. 2003) and differentiate into CD56
dim
 NK cells in humanized mice 
engrafted with human HSCs (Huntington et al. 2009). CD56
dim
cells continue to 
develop first through loss of CD117 (stage 5a; CD34
−
CD117
−
CD56
+
CD94
+
), 
followed by loss of CD94 expression (stage 5b; CD34
−
CD117
−
CD56
+
CD94
−
). After 
the linear progression from CD56
bright
 to CD56
dim
 NK cells, the mature CD56
dim 
NK 
cells were thought to retain the same phenotypic and functional properties until 
recent studies demonstrated that CD56
dim
 NK cells continue to differentiate. The 
differentiation process is accompanied by loss of NKG2A and CD62L expression, 
acquisition of killer cell inhibitory immunoglobulin-like receptors (KIRs) and the T 
cell terminal differentiation marker CD57, as well as a gradual decline in 
proliferative capacity (Bjorkstrom et al. 2010). Collectively, studies involving ex vivo 
analysis of NK cell phenotype, function, telomere length, and age-dependent 
frequencies suggest that CD56
dim
CD62L

CD57
+
 NK may be the terminally 
differentiated NK cell subset (Lopez-Verges et al. 2010). Figure 1.1 illustrates an NK 
cell development model modified from the models proposed by Freud et al. and 
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Eissens et al. to include studies discussed above (Freud et al. 2006; Freud and 
Caligiuri 2006; Eissens et al. 2012).  
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Figure 1.1  NK cell development model 
NK cells exhibit different maturational stages with distinct NK cell populations from CD34
+
CD45RA
+
 HPCs to CD3
-
CD56
bright
 NK cells. After linear 
progression from CD56
bright
 to CD56
dim
 NK cells, CD56
dim
CD62L
+
 NK cells appear as an intermediary stage, before CD62L expression is lost and expression 
of the terminally differentiation marker CD57 is acquired. 
HSC indicates hematopoietic stem cell; iNK, immature NK; PB, peripheral blood; SLT, secondary lymphoid tissue. 
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1.4 NK cell recognition and regulation 
Prior to the discovery of NK cell receptors, it was unclear how NK cells could distinguish 
target cells from normal cells for lysis. The ‘missing-self’ hypothesis was proposed based on 
the observation that NK cells kill targets with reduced or absent self MHC class-I molecules, 
a characteristic common to virally-infected and transformed cells (Karre et al. 
1986;Ljunggren and Karre 1990). The subsequent characterization of NK cell inhibitory 
receptors supported this hypothesis by explaining the molecular mechanisms by which NK 
cells sensed the downregulation of MHC class I expression (Brooks et al. 1997;Carretero et 
al. 1997;Colonna and Samaridis 1995;D'Andrea et al. 1995;Karlhofer et al. 1992;Lazetic et 
al. 1996;Moretta et al. 1994;Phillips et al. 1996;Sivori et al. 1996;Wagtmann et al. 1995). The 
missing-self could also explain the hybrid resistance phenomenon, in which (AxB) F1 mice 
rejected BM transplants from either parent, despite the fact that the transplant did not express 
foreign MHC molecules (Murphy et al. 1987). Further confirmation came from experiments 
demonstrating selective rejection of an MHC class I-deficient version of the tumour cell line 
RMA in mouse models, in which the results were reversed after treating the mice with an 
NK-depleting agent (Karre et al. 1986). However, when studies began to show that the 
absence of MHC class I molecules on tumour cells was insufficient to trigger NK cell lysis, it 
became clear that our understanding of NK cell target recognition was incomplete (Costello 
et al. 2002;Ruggeri 2002). As a wide array of activating receptors started to be uncovered, the 
‘dynamic equilibrium’ hypothesis was formulated, postulating that the integration of 
opposing signals from activating and inhibitory receptors determines the functional outcome 
of NK cell activity (Brumbaugh et al. 1998).  
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1.4.1 Inhibitory NK cell receptors 
Human NK cell inhibitory receptors fall into two groups: the killer immunoglobulin-like 
receptors (KIRs), and the lectin-like receptor NKG2A, which forms a complex with CD94. 
KIRs have a two- or three-domain extracellular structure and bind to human leukocyte 
antigen (HLA)-A, -B, or -C, whereas the NKG2/CD94 complexes ligate HLA-E. Human 
KIRs contain either two (KIR2D) or three (KIR3D) immunoglobulin (Ig)-like domains in 
their extracellular domain. KIR2D receptors recognize HLA-C alleles, whereas KIR3D 
receptors recognize HLA-A or HLA-B alleles. The cytoplasmic domains of KIRs can be 
either short (S) or long (L), corresponding to their function as either activating or inhibitory, 
respectively (Biassoni et al. 2001). Another KIR-related inhibitory receptor, LILRB1 (also 
known as LIR-1, CD85j, or ILT2), is also expressed on human NK cells and recognizes a 
shared epitope present in all humans MHC class I proteins (Chapman et al. 1999). The 
common pathway generated by ligation of inhibitory receptors is characterized by tyrosine 
phosphorylation of immune tyrosine-based inhibitory motifs (ITIM) that recruit tyrosine 
phosphatases such as the Src homology 2 domain-containing phosphatase (SHP)-1 and SHP-
2, which are responsible for the inhibition of various NK cell effector functions (Lanier 
2005). Recent studies suggest that the intrinsic responsiveness of NK cells to activation 
stimuli may be determined by interaction of inhibitory receptors with MHC-1 in a way that is 
dependent on the ITIM (Kim et al. 2005a). 
1.4.2 NK cell education 
NK cell education refers to the mechanisms through which inhibitory input by MHC class I 
during development translates into functional responsiveness in mature NK cells (Anfossi et 
al. 2006). Unlike the educational processes in T- or B- cell development, NK cell education 
remains a topic of intense debate, with several models proposed to explain how NK cell 
responsiveness relates to inhibitory signaling. NK cells that lack ITIM-bearing inhibitory 
receptors for self-MHC-I and NK cells from hosts that lack MHC-1 ligands for ITIM-bearing 
inhibitory receptors have a reduced responsiveness to activation signals, such as stimulation 
by sensitive target cells or cross-linking of NK cell activating receptors (Anfossi et al. 2006; 
Fernandez et al. 2005;Johansson et al. 2005;Kim et al. 2005b). These results have led to the 
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two main models in NK cell education. The first ‘disarming’ model proposes that in the 
absence of inhibition, continuous stimulation of NK cells leads to a state of 
hyporesponsiveness (Raulet and Vance 2006). The second model proposes that inhibitory 
receptors provide an ITIM-dependent signal to the NK cells that renders them responsive 
(Yokoyama and Kim 2006). This model is referred to as ‘arming’ (Raulet and Vance 2006) or 
‘licensing’ (Kim et al 2005), although the latter term is now understood to include any 
process by which NK cells that receive signals through inhibitory receptors for self-MHC-I 
gain responsiveness (Elliott and Yokoyama 2011). Studies reporting that NK cell 
responsiveness is calibrated according to the strength of inhibitory signals received (Brodin et 
al. 2009;Johansson et al. 2005;Joncker and Raulet 2008), have led to a third ‘rheostat’ model 
that aimed to reconcile the two opposing models, and account for the quantitative tuning of 
NK cell responsiveness (Hoglund and Brodin 2010;Joncker et al. 2009;Joncker and Raulet 
2008). The rheostat model postulates that NK cell responsiveness is dynamically calibrated 
based on the strength of inhibitory signals received.  More recent data demonstrating that NK 
cell ‘tuning’ or ‘licensing’ may be set by transient signals and can be reversible have led to an 
updated model known as the ‘revocable license’ (Long et al. 2013). The revocable license 
model argues that NK cells can keep their license as long as they are tightly regulated by 
inhibitory signals, but once this inhibitory input is lost, their license is revoked. Many 
questions regarding the molecular basis of licensing and the effect of subsequent activation 
signals on licensed vs. unlicensed cells remain unanswered. In many cases, the original 
concept of ‘missing-self’ and the self-tolerance of NK cells in an MHC-1-devoid 
environment cannot be explained without the involvement of NK cell activating receptors. 
Table 1-1 summarizes the human NK cell receptors and their cognate ligands (Bryceson et al. 
2006a;Lanier 2003;Lanier 2005;Long et al. 2013;Sutlu and Alici 2009). 
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Table 1-1 Human NK cell receptors 
Receptor Name Type of 
Signal 
Specificity 
CD16 (FcγRIIIA) 
NKG2D (CD314) 
NKp46 (CD335) 
NKp44 (CD336) 
NKp30 (CD337) 
NKp80 
DNAM-1 (CD226) 
LFA-1 (CD11a) 
MAC-1 (CD11b) 
LFA-2 (CD2) 
Leu3 (CD7) 
VLA-4 
VLA-5 
CRACC (CD319) 
CD44 
CD59 
CD69 
CD25 
TACTILE (CD96) 
BY55 (CD160) 
Lag3 (CD223) 
KIR2DS1 
KIR2DS2 
KIR2DS3-6 
KIR3DS1 
CD94/NKG2C(CD159c) 
CD94/NKG2E/H 
2B4 (CD244) 
NTB-A 
Activating 
Activating 
Activating  
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Activating 
Act/inhib 
Act/inhib 
IgG 
ULBP-1-4, MICA/B 
Viral haemagglutin 
Viral haemagglutin 
BAT3, B7-H6 
AICL 
PVR (CD155), CD112 
ICAM-1,-2 and -3 
ICAM-1, fibrinogen 
LFA-3 (CD58), CD15 
SECTM1, galectin 
VCAM-1, fibronectin 
Fibronectin 
CRACC (319) 
Hyaluronan 
C8, C9 
Unknown 
Unknown 
PVR (CD155) 
HLA-C 
HLA class II 
Group 2 HLA-CAsn77 Lys80 
Group 1 HLA-CSer77 Asn80 
Unknown 
Unknown 
HLA-E 
Unknown 
CD48 
NTB-A 
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KIR2DL4 (CD158d) 
KIR2DL2 and/or KIR2DL3 
KIR2DL1 
KIR3DL1 
KIR3DL2 
LIR-1 
 
KLRG1 
NKR-P1A 
CD94/NKG2A 
Siglec7 and Siglec9 
LAIR-1 (CD305) 
CCR6  
Act/inhib 
Inhibitory 
Inhibitory 
Inhibitory 
Inhibitory 
Inhibitory 
 
Inhibitory 
Inhibitory 
Inhibitory 
Inhibitory 
Inhibitory 
Inhibitory 
HLA-G (soluble) 
HLA-Cw3 
HLA-Cw4 
HLA-Bw4 
HLA-A3 and HLA-A11 
HLA Class I molecules, HLA-G and HCMV-
encoded UL18Cadherins 
LLT1 
HLA-E 
Sialic acid 
Collagen 
CCL20 
MIP-3α 
 
AICL indicates activation-induced C-type lectin; BAT-3, HLA-B-associated transcript-3; CCL20, 
chemokine C-C motif ligand 20; CD, cluster of differentiation; CRACC, CD2-like receptor for 
activating cytotoxic cells; DNAM-1, DNAX accessory molecule-1; HCMV, human cytomegalovirus; 
HLA, human leukocyte antigen; ICAM-1,-2 and- 3, intracellular adhesion molecule-1, -2, and 3; KIR, 
killer immunoglobulin-like receptor; KLRG-1, killer cell lectin-like receptor subfamily G member 1; 
Lag3, lymphocyte activation gene-3; LAIR-1, leukocyte-associated Ig-like receptor; LFA-1,-2 and -3, 
lymphocyte function-associated antigen-1, -2 and -3; LIR-1, leukocyte Ig-like receptor 1; LLT-1, 
lectin-like transcript 1; MAC-1, macrophage-1 antigen; MICA/B, MHC class I chain-related 
molecules A and B; MIP-3α, macrophage inflammatory protein- α; NKG2D, NK group 2 member D; 
NKR-P1A, NK Receptor- Protein 1A; NTB-A, NK, T and B cell antigen; PVR, poliovirus receptor; 
SECTM1, secreted and transmembrane 1; TACTILE, T cell-activated increased late expression; 
UBLP, UL16-binding protein; VCAM-1, vascular cell adhesion molecule-1; VLA-4 and 5, very late 
antigen-4 and 5. 
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1.4.3 Activating NK cell receptors 
Activating NK cell receptors can be grouped into three categories: those that associate with 
immunoreceptor tyrosine-based activation motif (ITAM)-containing subunits, the DAP10-
associated NK group 2 member D (NKG2D) receptor and a number of other receptors 
including DNAX accessory molecule-1 (DNAM-1), CD2 and 2B4. Receptors that associate 
with the ITAM-containing adapter proteins transmit signals through the recruitment of 
tyrosine kinases Syk or ZAP70, and include CD16, which mediates antibody-dependent 
cellular cytotoxicity (Moretta et al. 2002), and the natural cytotoxicity receptors (NCRs) 
NKp30, NKp44, NKp46 and NKp80, which are known to play an important role in NK-
mediated cytotoxicity against tumour cells. NKp30 and NKp46 are constitutively expressed 
on all peripheral blood NK cells, whereas NKp44 is expressed only on activated NK cells. 
NKp30 binds the nuclear factor HLA-B-associated transcript (BAT)-3, NKp46 binds to 
influenza haemagglutin (Mandelboim et al. 2001) and the cellular ligand for NKp80 is the 
activation-induced C-type lectin (AICL). NKG2D associates with the DAP10 adaptor protein 
and signals through a phosphoinositide 3-kinase (PI3K)-binding motif. It binds several 
ligands associated with stress, infection or transformation including MHC class I chain-
related protein A (MICA) and MICB and the UL16-binding proteins 1-4 (UBLP1-4) (Mistry 
and O'Callaghan 2007).  
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1.4.4 NK cell activation  
NK cells require the co-engagement of multiple activating receptors in order to exhibit 
natural cytotoxicity against tumour target cells (Bryceson et al 2006). Work by our group 
further defined this co-stimulation into two discrete stages: priming and triggering (North et 
al. 2007). The priming signal can be delivered by an activating cytokine in the tumour 
microenvironment or a target cell expressing the appropriate intensity and combination of 
ligands for NK cell activating receptors. The second stage, ‘triggering’, requires the co-
engagement of at least one additional NK cell activating receptor, specific to stressed cells, in 
order to avoid autoreactivity. Upon encounter with potential target cells, an immunological 
synapse forms at the point of contact between the NK cell and the target cell, where NK cell 
receptors can interact with their respective ligands. Given sufficient activation signals, NK 
cell cytoskeletal rearrangements are initiated, which result in the polarization of NK cell lytic 
granules toward the immunological synapse, where they eventually fuse and release their 
cytotoxic contents on to the target cell (Orange 2008) (Figure 1.2). In contrast to CTLs, NK 
cells have their cytotoxic granules preformed before target cell recognition, and so their 
release is initially constrained until sufficient signaling is achieved (Orange 2008). NK cells 
have also been shown to establish cytoskeletal polarity more slowly than CTLs, and to have a 
unique sensitivity to minor interference with cytoskeletal dynamics (Wulfing et al. 2003). 
This stepwise progression in activation events with specific requirements for synergistic 
signaling may provide a mechanistic explanation of how the spontaneous cytotoxic capacity 
of NK cells is regulated.  
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Figure 1.2 NK cell activation events.  
NK cell encounter with a tumour cell target generates an immunological synapse at the point of 
contact. If the ligand combination on the tumour target engages NK cell activating receptors 
sufficiently, cytoskeletal rearrangements take place resulting in granule polarization and the eventual 
release of cytotoxic granules on to the target cell.  
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1.5 NK cells and cancer 
1.5.1 Cancer immunosurveillance by NK cells 
The theory of cancer immunosurveillance, as proposed by Burnet and Thomas in 1957 
(Burnet 1957), postulates that immune cells continuously monitor the body such that any 
threat to the immune system is detected and eliminated. Although the theory was abandoned 
shortly after for lack of sufficient experimental evidence (Rygaard and Povlsen 
1974a;Rygaard and Povlsen 1974b;Stutman 1974;Stutman 1979), the subsequent discovery 
of NK cells led to considerable enthusiasm over the possibility that they function as one of 
the main effector cells of immunosurveillance (Herberman and Holden 1978). Recent data 
from both mouse and human studies clearly show the existence of cancer 
immunosurveillance and support the concept that NK cells play a critical role in tumour 
control and eradication (Waldhauer and Steinle 2008). The two main anti-tumoural effector 
functions observed by NK cells are target cell elimination and cytokine secretion (Vivier et 
al. 2008). Until recently, these two effector functions were thought to follow similar 
mechanisms of activation, but now it is recognized that cytokine secretion by NK cells is 
distinct from cytotoxicity (Reefman et al. 2010).  
1.5.1.1 Target cell elimination 
NK cells can directly eliminate malignant cells through granule exocytosis or death receptor 
ligation. Following target cell recognition and formation of an activating immunological 
synapse (1.4.4), NK cells release the membrane disrupting protein perforin and a family of 
serine proteases termed granzymes, which are the critical effector molecules contained in 
their granules (Smyth et al. 1999). After its release from secretory lysosomes, perforin results 
in the disruption of endosomal trafficking and binds in a calcium-dependent manner to 
phospholipid components of the lipid bilayer to facilitate entry of granzymes into the target 
cell cytosol (Lavrik et al. 2005). Once granzymes enter the target cell, they induce apoptosis, 
or programmed cell death. In addition to granule exocytosis, NK cells can directly eliminate 
target cells through the engagement of cell surface death receptors. NK cells express Fas 
ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL), which are both members 
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of the TNF family and are shown to induce target cell apoptosis when they bind their 
receptors on target cells (Lavrik et al. 2005).   
 
1.5.1.2 Cytokine secretion 
Resting NK cells secrete a plethora of cytokines that help eliminate target cells and amplify 
activation signals for a more efficient immune response. Cytokine or target cell stimulation of 
NK cells can result in enhanced secretion of immunoregulatory cytokines, which in turn 
influence the activity of resting NK cells and other immune cells. Pro-inflammatory 
cytokines secreted by NK cells, which include IL-1, IL-6, IL-8 and IL-12, can enhance the 
activation and proliferation of T cells, DCs and macrophages (Elenkov and Chrousos 2002). 
By contrast, anti-inflammatory cytokines such as IL-4 and IL-10 suppress T cell and 
macrophage function, but activate humoral responses (Elenkov and Chrousos 2002) 
Chemokines, which are chemotactic cytokines, play an important role in directing various 
immune cells to target sites, such that more potent responses are achieved. Chemokines 
released by NK cells include the macrophage inflammatory protein (MIP)-1α and MIP-1β; 
chemokine (C-C motif) ligand 5 (CCL5), also known as regulated on activation normal T cell 
expressed and secreted (RANTES); monocytes chemoattractant protein (MCP)-1; and eotaxin 
(Cuturi et al. 1989;Roda et al. 2006). Similar to cytotoxicity, a hierarchy is observed for 
cytokine release by NK cells, whereby chemokine secretion precedes other cytokines and 
requires less stimulation through the engagement of NK cell activating receptors (Bryceson et 
al. 2009;Fauriat et al. 2010). The signaling requirements for cytokine/chemokine secretion 
are different from degranulation and NK cell cytotoxicity (Bryceson et al. 2009). Thus, target 
cells that are unsusceptible to NK cell-mediated killing can still trigger cytokine release by 
NK cells. The signaling pathways and mechanisms required for cytokine secretion also 
appear to be distinct from secretion of cytotoxic granules (Reefman et al. 2010). The 
localization and trafficking of IFN-γ and TNF-α were shown to take place in compartments 
and vesicles that do not overlap with perforin or other late endosome granule markers. 
Recycling endosomes (REs) are not needed for release of perforin, but are required for 
cytokine secretion in NK cells. Although perforin granules are released in a polarized fashion 
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at lytic synapses, distinct carriers transport both IFN-γ and TNF-α to points all over the cell 
surface, including within the synapse, for non-polarized release.  
1.5.2 Cancer evasion of NK cells 
Although the development of any malignancy is under surveillance by immune cells, 
malignant cells obtain means to escape from the immune system and proliferate. The recent 
addition of immune evasion as an emerging ‘hallmark’ of cancer, supports the revival of 
support for the theory of immunosurveillance (Hanahan and Weinberg 2011). It is now 
believed that tumours acquire a set of biological capabilities during their development that 
allow them to overcome challenges posed by the immune system, one of which is likely to be 
NK cell-mediated anti-tumour immunity. These capabilities are acquired with the help of 
recruited inflammatory cells and soluble factors in the tumour microenvironment, which play 
an active role in the process of tumourigenesis. Early on in the study of NK cell interactions 
with tumours, Kiessling et al. (Kiessling et al. 1999) proposed that cancer evasion of NK 
cells involves two stages: the early stages of tumour formation and growth are associated 
with antigen-specific tolerance, whereas the later stages elicit a more generalized state of 
immunodeficiency. The concept of cancer immunoediting, as introduced by Dunn et al.  
argues that the immune system plays a role during tumour formation by selecting less 
immunogenic variants for survival in an immunologically intact environment (Dunn et al. 
2002). Tumours are thus ‘imprinted’ by the immunologic environment in which they form, 
and only those that have acquired capabilities to evade or suppress immune attack remain. 
Based on evidence for a two-stage hypothesis for NK cell-mediated killing of tumours, we 
propose that tumours evade NK cell attack directly by lacking either the priming or triggering 
ligands such that the activation threshold for NK cell granule exocytosis is not met. Once 
successful evasion of NK cell attack is achieved, the tumour begins to create the 
microenvironment necessary for its continued growth. Direct evasion of NK cells by tumour 
targets can be accompanied by various other escape mechanisms. For example, tumours have 
been shown to minimally express or shed ligands for important NK cell receptors, such as 
NKG2D ligands UL16-binding protein 2, major histocompatibility complex (MHC) class I 
chain-related molecules A and B molecules (MICA/MICB). They have also been reported to 
upregulate MHC class I, soluble MIC and FasL expression in order to increase inhibitory 
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signaling (Bennett et al. 1998;Costello et al. 2002;Maki et al. 1998;Yamauchi et al. 1996). 
The release of immunosuppressive factors such as IL-10, TGF-β and indoleamine 2,3-
dioxygense (IDO) by tumour targets has also been reported, which can suppress the adaptive 
anti-tumour immune response or skew the immune response toward a Th2 response with 
significantly less anti-tumour capacity (Morse et al. 2002;Orleans-Lindsay et al. 2001;Shields 
et al. 2010;Yang et al. 2010;Zagury and Gallo 2004) (Figure 1.3). Indirect mechanisms for 
NK cell evasion by tumours can involve numerous cell types from the immune system. 
Recruitment of inflammatory cells that are actively immunosuppressive has been 
demonstrated, including regulatory T cells (Tregs), myeloid-derived suppressor cells 
(MDSCs) and phagocytes secreting reactive oxygen species (ROS) (Romero et al. 2006). 
Some tumours alter their expressions of IL-6, IL-10, vascular epithelial growth factor or GM-
CSF, impairing DC function and maturation, and, thereby, NK cell priming. Tumour growth 
has also been shown to decrease NK cell count by reducing the numbers of its lymphoid 
progenitor (Richards et al. 2008).  
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Figure 1.3 Tumour Evasion Strategies.  
Tumour cells can evade NK cell attack via direct or indirect mechanisms. Direct mechanisms include: 
(a) shedding soluble ligands for NK cell activating receptors;  
(b) upregulation of HLA molecules; and (c) release of inhibitory cytokines. Indirect 
mechanismsinclude: (d) activation of inhibitory regulatory T cells; (e) dendritic cell killing; and (f) 
phagocyte-derived inhibitory cytokines. Tumour cells have also been shown to decrease the number 
of NK progenitor cells (g), thereby lowering NK cell counts.  
HLA indicates human leukocyte antigen; iDC, immature dendritic cell; IDO, indoleamine 2,3-
dioxygense; IL-10, interleukin-10; MICA/B, MHC- class I chain-related molecules A and B; ROS, 
reactive oxygen species; TGF-β, transforming growth factor-beta; Treg, regulatory T cell 
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1.5.3 NK cell modulation for cancer therapy 
The ability of NK cells to kill tumour cells has made them very attractive in immunotherapy. 
NK cell impairments associated with tumour development and progression have been 
frequently reported in cancer patients, including weakened effector functions and an altered 
phenotype with downregulation of activating NK cell receptors (Sutlu and Alici 2009). 
Different strategies have been employed to repair, replace or enhance the biological functions 
of autologous or allogeneic NK cells in vivo and ex vivo. In a clinical setting, the key factors 
to be considered are the number, purity, proliferative capacity and activation state of NK cells 
(Sutlu and Alici 2009). The most limiting of these factors is obtaining a sufficient number of 
NK cells, hence the extensive development of ex vivo expansion methods for NK cell 
adoptive immunotherapy applications. Genetic modification of NK cells is another approach 
for the induction of better proliferation, survival and targeting of malignant cells. The 
genetically modified NK-92 cell line expresses high levels of activating receptors and low 
levels of inhibitory ones (Gong et al. 1994), is easily grown and expanded under good 
manufacturing practice (GMP) conditions, and can be readily available for adoptive NK-cell 
therapy. Preclinical and clinical studies in melanoma, leukemia, lymphoma, refractory renal 
cell cancer and breast cancer suggest that it is well-tolerated and can be beneficial. The 
delivery of IL-2, IL-12 and IL-15 genes to NK cell lines has also been shown to enhance 
proliferative and cytotoxic capabilities. These cytokines are known to play important roles in 
the enhancement of survival and activation of many immune cells including T cells, B cells 
and NK cells. Strategies to enhance endogenous NK cell function in vivo through cytokines 
were pioneered by Rosenberg et al. who demonstrated great initial potential for IL-2 
administration in advanced cancer patients (Rosenberg et al. 1987). In vitro stimulation of 
NK cells by activating cytokines such as IL-2 is known as the lymphokine-activated killer 
(LAK) phenomenon (Grimm et al. 1982). In early experiments, NK cells were activated ex 
vivo and adoptively transferred to patients with advanced metastatic renal cancer and 
melanoma along with IL-2 infusions (Rosenberg et al. 2009). However, overall data from 
clinical trials since then have failed to provide a convincing proof of efficacy (Sutlu and Alici 
2009). LAK therapy requires continual IL-2 administration which carries a strong dose-
limiting toxicity. Our group has previously reported an alternative tumour-priming approach, 
in which human NK cells are activated by co-incubation with the CTV-1 acute lymphoblastic 
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leukemia cell line in the absence of IL-2. The resulting tumour-primed NK cells (TpNKs) are 
cytotoxic to a range of NK-resistant tumour cells in vitro (North et al. 2007). Moreover, their 
clinical potential has been explored in acute myeloid leukemia and multiple myeloma with 
promising results in autologous and allogeneic settings (Katodritou et al. 2011). The TpNK 
primed state is maintained in the absence of IL-2 and is even retained after cryopreservation, 
which suggests that this approach can yield many clinical benefits in the future.  
 
1.6 Thesis Aims 
This central objective of this thesis was to provide novel mechanistic insights into the 
efficacy of cancer immunotherapy involving TpNKs, by analyzing resting NK cell responses 
to tumour-priming and dissecting the tumour-induced changes responsible for NK cell 
activation. The experimental aims of the thesis were as follows: 
 
1. To compare the activation profiles of TpNKs with cytokine-primed NK cells by 
investigating: a) antigen expression (Chapter 3) and b) cytokine/chemokine secretion 
(Chapter 4). 
 
2. To identify the specific NK cell receptors involved in the delivery of the tumour-priming 
signal (Chapter 5). 
 
3. To replicate this stimulatory signal in an artificial priming system in the absence of tumour 
cells or cytokines using antibody-coated beads (Chapter 5). 
48 
 
Chapter 2 Materials and Methods 
2.1 Blood Donors 
Fresh blood samples were obtained from normal healthy donors and used within 3 
hours after collection unless stated otherwise. Informed consent was obtained in 
accordance with the declaration of Helsinki and the study was approved by the Royal 
Free NHS Trust Research and Development review board. Blood samples were taken 
directly using needle and syringe by phlebotomist staff in the Academic 
Haematology Department at the Royal Free Hospital, London and were dispensed 
into 50 ml tubes (Nalge Nunc, Rochester, NY, USA). 
2.2 Cell Lines 
All cell lines were obtained from the Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (Braunschweig, Germany) or from the Laboratory of the Government 
Chemist (London, UK) and cultured as recommended by the repository. The main 
cell lines used in this thesis are described below: 
CTV-1: Human T cell leukemia cell line that was originally reported to be of 
myeloid origin, but was recently re-classified as a T cell acute lymphoblastic 
leukemia (T-ALL). CTV-1 cells have been shown to express cyCD3, CD6, CD7 and 
CD15, but lack expression of CD2, smCD3, CD4, CD5, CD8, CD13, CD19, CD33, 
CD34, HLA-DR, TCRalpha/beta and TCRgamma/delta. These cells are round or 
multiformed and are single cells or clustered in suspension.  
RAJI: Human Burkitt lymphoma cell line that is one of the prototypical NK-resistant 
lines. RAJI cells express CD10, CD19, CD20, CD37, CD38, cyCD79a, CD80, HLA-
DR and cyIgM, but do not express the markers CD3, CD13, CD34, CD138, 
sm/cyIgG, smIgM, sm/cykappa or sm/cylamda. They appear as round single cells in 
suspension, but can form clusters or clumps.  
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K562: Human erythroleukemia cell line that is a prototypical NK-sensitive cell line, 
which lacks expression of HLA molecules. K562 cells also stain negatively for CD3, 
CD14 and CD19, but express CD15, CD33, CD71 and CD235a. These cells are non-
adherent and rounded.  
2.3 Cell Culture Medium 
Cell cultures were performed in complete medium (CM), which consisted of Roswell 
Park Memorial Institute medium with Glutamax  (RPMI 1640; Life Technologies, 
Paisley, UK) supplemented with 10% fetal calf serum (FCS), penicillin (100 IU), and 
streptomycin (100 IU) (Invitrogen, Carlsbad, CA, USA). All cell lines were 
maintained in continuous suspension culture and harvested in exponential growth 
phase to use as stimulator or target cells. For culture involving short term activation 
of NK cells, CM was supplemented with cytokines, as outlined in Section 2.9.  
2.4 Cell Counting and Viability Assessment 
Viable cell number was estimated using the Trypan Blue exclusion method; a 10 l 
aliquot of cell suspension was mixed with 90 l of 0.4% Trypan Blue solution 
(Sigma-Aldrich), which is extruded by viable cells but taken up by non-viable cells. 
After mixing thoroughly, 10ul of the cell mixture was loaded onto a bright-line 
haemocytometer counting chamber (Hawksley, Sussex, UK) under a glass cover slip. 
Cells were counted using a phase contrast microscope (Nikon) excluding non-viable 
cells that appeared in blue. The number of cells in the central 25 squares was counted 
and the cell concentration (x10
6
/ml) was calculated by multiplying the total number 
of cells by 10
4
. Unless otherwise specified, cells were resuspended and used at 
concentrations of 10
6
 viable cells/ml in CM.  
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2.5 Cryopreservation of Cells 
Cells were brought to a minimum concentration of 1x10
7
/ml in CM and left on ice to 
reach a temperature of 4º C. Freezing medium was made up with 80% of 4.5% 
human serum albumin (HSA, Bio Products Laboratory) and 20% dimethylsufoxide 
(DMSO, Sigma-Aldrich). The cryopreserving solution was mixed drop by drop 
under mild agitation to an equal volume of cells, up to a maximum total volume of 
1.5 ml in cryopreservation vials (Nalge Nunc, Rochester, NY, USA) and placed in 
isopropanol freezing containers (Mr Frosty, Nalgene) at 80º C for 24 hours. The 
vials were then transferred for storage in liquid nitrogen at –196º C or vapour phase 
nitrogen at -152 ºC. 
2.6 Thawing of Frozen Cells 
Frozen cells were transferred from nitrogen storage straight into a 37 ºC water bath. 
Cryopreservation vials were partially immersed and gently agitated until partially 
thawed. The cells were then pipetted into a 15ml Falcon tube containing 10ml of 
complete RPMI 1640 medium and centrifuged at 200xg for 10 minutes at room 
temperature. Cells were washed once more in 15ml RPMI 1640 medium to remove 
any DMSO and the cell pellet was resuspended for future use. The cell viability of 
frozen cells was usually between 80–90%. Cells were allowed to recover for 2 hours 
prior to magnetic separation or immunofluorescence labelling. .  
2.7  Isolation of Peripheral Blood Mononuclear Cells (PBMCs) 
All blood samples from human donors for research into innate immunity to leukemia 
were obtained with informed consent, and the research was approved by the 
institutional ethical review board. Fresh peripheral blood samples obtained from 
normal healthy donors were added to 100 l of preservative-free heparin 
(Monaparin) and diluted with Hanks Balanced Salt Solution (HBSS, Life 
Technologies) at a 1:1 ratio. An equal volume of whole blood was layered over an 
equal volume of Lymphoprep (Axis Shield Diagnostics). Tubes were centrifuged at 
400xg for 20 minutes at room temperature with the brake off. PBMCs were collected 
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from the interface layer using Pasteur pipettes into 50ml Falcon tubes and the cells 
were washed twice by centrifugation at 200xg for 10 minutes at room temperature 
with HBSS. The resulting cell pellet was resuspended in CM.  
2.8 Isolation of Human NK cells 
Human NK cells were isolated from PBMCs using magnetic-activated cell sorting 
(MACS, Miltenyi Biotec), a cell separation system that comprises three components: 
MACS MicroBeads, MACS Columns and MACS Separators (Miltenyi Biotec). Cells 
were separated by labeling with magnetic microbeads conjugated to an antibody of 
choice, and running through a column placed in the magnetic field of a separator. 
The labeled cells were magnetically retained in the column and the unlabeled cells 
pass through. Thus, cells could be positively or negatively selected with respect to 
the particular antigen.  
CD56
+
 cells were positively selected by labeling PBMCs with CD56 MicroBeads 
(Miltenyi Biotec). An LS-25 column (Miltenyi Biotec) was prepared by inserting 
into an MACS separator, with a collection tube placed under the column. The 
column was rinsed by applying 3 ml of MACS buffer on top of the column and 
letting the buffer run through. The effluent was discarded and the collection tube 
changed. PBMCs were resuspended at 10
8
 cells in 500 l of buffer. The cell 
suspension was then applied onto the prepared column, where the unlabeled cells 
passed through to be collected into a negative fraction tube. The column was washed 
three times with 3ml buffer, adding buffer each time the column reservoir was 
empty. The column was removed from the separator and placed onto a new 
collection tube. After pipetting 5 ml of buffer onto the column, the positive fraction 
was immediately flushed out by firmly applying the plunger supplied with the 
column.  
CD56
+
CD16
+
 NK cells were isolated from human PBMCs using the CD56
+
CD16
+
 
NK Cell Isolation Kit (Miltenyi Biotec). First, non-NK cells were labeled with a 
cocktail of biotin-conjugated antibodies and anti-biotin microbeads and subsequently 
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depleted by separation over an LS column, which was placed in the magnetic field of 
a MACS separator. In the second step, cells were labeled with CD16 microbeads and 
isolated from the pre-enriched cell fraction by positive selection over a second MS 
column (Miltenyi Biotec). MACS buffer was prepared using phosphate-buffered 
saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA) and 2mM EDTA by 
diluting MACS BSA stock solution 1:20 with autoMACS rinsing solution. Buffer 
and CD56 microbeads were kept cold during handling, and air bubbles were avoided 
to prevent clogging of the column and to ensure high quality of separation. All 
selected cells were confirmed as ≥ 97% positive, and electronic gating on 
CD56
+
CD3

 identified the pure NK cell population using flow cytometry.  
2.9 In vitro stimulation of NK cells 
Human PB NK cells were isolated from the PBMCs of normal healthy donors by 
magnetic sorting for CD56
+
 cells. In vitro stimulation of NK cells was achieved by 
incubating freshly isolated NK cells (1x10
6
 cells/ml) with CTV-1 or K562 cells 
(2x10
6 
cells/ml) or the exogenous cytokines IL-2 (200IU/ml) IL-7, IL-15, IL-21 (10 
ng/ml), or IL-12 (20 ng/ml) (R&D Systems, Minneapolis, Minnesota, USA) for 20 
hours at 37ºC, 5 % CO2 in CM, unless stated otherwise. Activation marker 
expression (CD69, CD25 and median fluorescence intensity [MFI] expression) and 
the capacity to kill RAJI cells in a 4 hour cytotoxicity assay were used as measures 
of NK cell activation.  
2.10 Immunophenotyping of NK Cells 
Cell surface staining was carried out in 12 x 75 mm polystyrene tubes (Sarstedt, city 
country). A total of 10
5
 cells were routinely used in a final volume of 100 l HBSS. 
Between 5–20 l of fluorochrome conjugated antibodies were added to purified 
CD56
+
 PBMCs (titration experiments confirmed adequate cell labeling) and 
incubated in the dark at room temperature for 15 minutes. Cells were then diluted in 
2 ml of HBSS and centrifuged at 200g for 5 minutes at room temperature, and the 
cell pellet was resuspended in approximately 300 l FACS Flow (Becton Dickenson, 
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Oxford, UK). Samples were kept at 4 ºC and acquired within 8 hours of labelling on 
a FACS Aria (Becton Dickenson, Oxford, UK) using FACS Diva software or on the 
MACS Quant (Miltenyi Biotec, Surrey, UK) using MACS Quantify software for up 
to 8 parameters. A minimum of 20,000 CD56
+
CD3

 events were acquired after 
gating of viable cells using forward scatter (FSC) and side scatter (SSC) signals and 
data analysed using MACS Quantify and FlowJo v7.6 software (TreeStar, Olten, 
Switzerland). Appropriate controls matched for isotype, fluorochrome and 
manufacturer, as well as single labelled and non-labelled samples were used to set 
voltages and compensation.  
2.10.1 Monoclonal Antibodies 
Monoclonal antibodies (mAbs) used were conjugated to the following 
fluorochromes: 
B1: Fluorescein isothiocyanate (FITC) 
B2: Phycoerythrin (PE) 
B3: Peridinin Chlorophyll Protein Cyanine-5.5 (PerCPCy5.5), Phycoerythrin 
Cyanine-5 (PE-Cy5) 
B4: Phycoerythrin Cyanine-7 
R1: Allophycocyanin (APC) 
R2: Allophycocyanin Cyanine-7 (APC Cy7) 
V1: Violet Blue, Pacific Blue, eFluor450 
V2: Violet Green 
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A summary of all mAbs used in this thesis is shown in Table 2.1. A forward-
scattered light (FSC) versus side-scattered light (SSC) dot plot was created for each 
sample and a gate drawn around the area of live lymphocytes (Figure 2.1). The live 
lymphocyte gate was projected onto a second dot plot of CD56 versus FSC and a 
second gate drawn to identify the CD56
+
 lymphocytes. For the assessment of antigen 
expression on CD56
+
CD3
–
 NK cells, a new dot plot was constructed.  
Table 2-1 Monoclonal antibodies used in this Thesis. 
mAb Fluorochro
me 
Clone Manufacturer Cat. # 
CD2 PerCPCy5.5 RPA-2.10 BD 560643 
CD3 APC-H7 SK7 BD 641397 
CD7 (Leu-9) FITC 4H9 BD 347483 
CD11a PE HI111 eBioscience 12-0119-73 
CD15 APC HI98 BD 551376 
CD15 FITC MEM-158 AbD Serotec MCA2458F 
CD16 Pacific Blue 3G8 BD 558122 
CD16 Violet Green VEP13 Miltenyi Biotec 130-096-879 
CD25 APC M-A251 BD 555434 
CD25 PerCp-Cy5.5 M-A251 BD 560503 
CD49d PE 9F10 BD 555503 
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CD54 FITC RR1/1 eBioscience BMS108FI 
CD56 PECy5 B159 BD 555517 
CD56 PE-Cy7 B159 BD 557747 
CD57 eFluor450 TB01 eBioscience 48-0577042 
CD62L FITC DREG-56 BD 555543 
CD69 APC L78 BD 340560 
CD69  PE L78 BD 341652 
CD107a PE-Cy5 eBioH4A3 eBioscience 15-1079-42 
CD159a (NKG2A) APC 131411 R&D FAB1059A 
CD178 (Fas Ligand) PE NOK-1 eBioscience 12-9919-41 
CD181 (CXCR1) FITC 8F1/CXCR1 BioLegend 320605 
CD184 (CXCR4) APC 12G5 BD 560936 
CD196 (CCR6) PE 11A9 BD 561019 
CD226 (DNAM-1) FITC DX11 BD 559788 
CD244 (2B4) PE M-A251 BD 550816 
CD253 (TRAIL) PE RIK-2 BioLegend 308205 
CD314 (NKG2D) PE 1D11 BD 557940 
56 
 
CD335 (NKp46) PE 9E2 BD 557991 
CD336 (NKp44) APC 253415 R&D FAB22491A 
CD337 (NKp30) PE p30-15 BD 558407 
CXCR7 PE 8F11-M16 BioLegend 331104 
NKp80 FITC 4A4.D10 Miltenyi Biotec 130-094-843 
α4β7 (LPAM-1) FITC FIB504 eBioscience 11-5867-41 
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Figure 2.1 Basic gating strategy for flow cytometric analysis. 
A FSC versus SSC plot was created for each sample and a gate drawn around the area of live 
lymphocytes. The live lymphocyte gate was projected onto a second dot plot of CD56 versus 
CD3 and a second gate drawn to identify CD56
+
CD3
–
 NK cells.   
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2.11 Analysis of NK cell secretory profiles 
An aliquot (2 x 10
5
) of resting NK cells were washed twice and mixed with 4x10
5 
CTV-1 or K562 cells (4 x 10
5
), and IL-2 (200IU/ml) IL-7, IL-15, IL-21 (10 ng/ml), 
or IL-12 (20 ng/ml) Cells were incubated for 6 hours or overnight at 37 ºC in 5% 
CO2. Thereafter, supernatants were collected and stored at –20 ºC pending 
measurement. The concentrations of cytokines were quantified by a multiplex 
immunoassay (Luminex 100 IS; Invitrogen) using a kit that simultaneously 
quantifies 25 different cytokines, listed below in four multiplex groupings for 
analysis.  
Inflammatory Panel: IL-1β, IL-1RA, IL-6, IL-8 and TNF-α 
Th1/Th2 Panel: IFN-γ, IL-2, IL-2R, IL-4, IL-5 and IL-10 
Cytokine II Panel: IFN-α, IL-7, IL-12p40/p70, IL-13, IL-15 and IL-17 
Chemokine Panel: Eotaxin, IP-10, MCP-1, MIG, MIP-1α, MIP-1β and RANTES 
This multiplex assay relies on polystyrene beads (5.6m), which are internally dyed 
with red and infrared fluorophores of differing intensities. Each bead has a unique 
number or bead region that allows differentiation of one bead from another. Beads of 
defined spectral properties are conjugated to protein-specific capture antibodies and 
added along with samples (including standards of known protein concentration, 
control samples and test samples), into the wells of a filter-bottom microplate where 
proteins bind to the capture antibodies over the course of a 2 hour incubation. After 
the beads were washed, protein-specific biotinylated detector antibodies were added 
and incubated with the beads for 1 hour. During this incubation, the protein-specific 
biotinylated detector antibodies bind to the appropriate immobilized proteins. After 
removal of excess biotinylated detector antibodies, streptavidin conjugated to the 
fluorescent protein R-Phycoerythrin (Streptavidin-RPE) was added and allowed to 
incubate for 30 minutes. The Streptavidin-RPE binds to the biotinylated detector 
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antibodies associated with the immune complexes on the beads, forming a four-
member solid phase sandwich. After washing to remove unbound Streptavidin-RPE, 
the beads were analyzed with the Luminex detection system. By monitoring the 
spectral properties of the beads and the amount of associated RPE fluorescence, the 
protein concentrations in test samples were determined from standard curves 
constructed from samples of known protein concentration, using Graphpad Prism 
v6.0 (Graphpad Software, California, USA) (Figure 2.2). The mean fluorescence 
values of blank samples were subtracted from each test sample for the equivalent 
protein. In the case of target cell-stimulated NK cells, the mean baseline value 
subtracted from test samples also included the corresponding values from target cells 
incubated alone. 
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Figure 2.2 Standard curves for analysis of cytokine secretion. 
Typical standard curves collected from analytes assayed with the Human Cytokine 
25-Plex Panel using GraphPad Prism v 6.  
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2.12 PKH-26 labelling of Target Cells 
Target cell were washed by adding HBSS and centrifuging at 200xg for 10 minutes 
with brake on. The cell pellet was resuspended in 1 ml of Diluent C and pipetted 
gently to insure complete dispersion.  In a separate polypropylene tube, a dye 
solution was prepared by adding 2 µl of the PKH67 to 1 mL of Diluent C.  The dye 
solution was mixed well to disperse and rapidly added to the sample and immediately 
mixed by pipetting.  The staining was stopped by adding an equal volume of serum 
(neat FCS) or other suitable protein solution (e.g., 1% BSA) and leaving to incubate 
for 1 minute in order to allow binding of excess dye. After the 1 minute incubation, 
the sample was centrifuged at 200x g for 10 minutes at 20-25 °C and the supernatant 
was carefully removed. The pellet was resuspended in 10 mL CM, transferred to a 
fresh sterile conical poly-propylene tube, and centrifuged again at 200x g for 10 
minutes with brake on, to ensure removal of unbound dye. After the wash was 
complete, the cell pellet was resuspended in complete medium at 1x10
6
 cells/ml.  
2.13 Cytotoxicity Assays 
Target cells were recovered from suspension culture and washed in HBSS before 
resuspension in 1 ml PKH-26-labeling diluent at a concentration of 4x10
6
/ml. A 4 l 
aliquot of PKH-26 was added to 1.0 ml labeling diluent and then added to the target 
cell suspension for 2 min at room temperature. The labeling reaction was stopped by 
the addition of 1 ml neat FCS for 1 min. Finally, the labeled cells were washed twice 
in CM and resuspended in CM at 10
6
/ml. A total of 1x10
5 
PKH-26-labeled target 
cells in 100 µl RPMI 1640 (10% FCS) were added to 5x10
5
 NK cells in 400 µl 
(effector:target [E:T] cell ratio of 5:1), pelleted at 200 x g for 1 min at room 
temperature, and then incubated for 4 h at 37°C and 5% CO2. After the incubation 
period, the cells were resuspended in a solution of TO-PRO-3 iodide (Life 
Technologies, Paisley, UK) in PBS (1 M) and analyzed by flow cytometry. At least 
10
4
 target cells were acquired with 1024-channel resolution after electronic gating on 
PKH-26 positivity, and the mean proportion of TO-PRO iodide-positive cells from 
the triplicate samples was determined. Background target cell death was determined 
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from the spontaneous lysis of cells incubated in the absence of effector cells. Cell-
mediated cytotoxicity was calculated as the mean (percentage cell death minus 
percentage background cell death). Less than 5% spontaneous lysis of target cells 
was observed in these experiments.  
2.14 CD107a Degranulation Assay 
PBMCs were isolated by density gradient centrifugation on a discontinuous density 
gradient (Lymphoprep), and CD56
+
 cells were positively selected using CD56 
microbeads (Miltenyi Biotec). To detect spontaneous degranulation, a control sample 
without target cells was included in every experiment. An E:T ratio of 1:1 (2x10
5
 
target cells in a volume of 200 l) was used in all experiments. In each tube 
containing 200 l E/T cell suspensions, 15 l of PE-Cy5 conjugated anti-CD107a 
mAb was added prior to incubation. NK cells and target cells were co-incubated at 
37ºC for 3 h in total; after the first hour, 5 l of the secretion inhibitor monensin 
(Sigma; 2mM in 100% ethanol) was added. Cells were then washed and stained with 
mAbs (CD56 and CD3) for flow cytometric analysis.  
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2.15 Antibody blocking experiments 
To investigate the involvement of NK cell receptor-ligand interactions in CTV-1-
mediated priming, purified CD56
+
 NK cells from normal healthy donors were pre-
incubated with Anti-CD2 (RPA 2.10), CD15 (MEM158), and/or NKG2D (149810) 
mAbs, and CTV-1 cells were pre-treated with anti-Intercellular Adhesion Molecule-1 
(ICAM-1) mAb. After a 16 h incubation, activation marker expression (CD69, CD25 
and MedCF expression) and the capacity to kill RAJI cells in a 4 h cytotoxicity assay 
were used as measures for NK cell priming.  
To investigate the involvement of LFA-1, CD2 and NKG2D in CTV-1-mediated NK 
cell priming, purified CD56
+
 NK cells from normal donors were pre-incubated for 30 
mins at room temperature in the presence or absence of saturating concentrations of 
antibodies. After washing with HBSS, and overnight co-incubation of NK cells 
(1x10
6 
cells) with CTV-1 (2x10
6
 cells) immunophenotyping was carried out for the 
analysis of antigen expression (MACS Quant Analyzer) with isotype controls used 
for every experiment. NK cell activation was also determined by comparing NK cell 
activity against NK-resistant RAJI cells in a 4h cytotoxicity assay. Statistical 
comparisons between treatments were performed using the paired t-test. Results are 
presented as mean ± SD. Corrected P values < 0.05 were considered statistically 
significant. Statistical analyses were performed with GraphPad Prism v.6 software. 
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2.16  Bead Stimulation 
2.16.1 Dynabeads Sheep anti-mouse IgG  
Dynabeads Sheep anti-Mouse IgG have a diameter of 4.5m. They are uniform 
superparamagnetic polystyrene beads coated with polyclonal Sheep anti-Mouse IgG 
antibodies. Dynabeads were washed before use by resuspending in the vial, 
transferring 50 l to a tube and adding 1ml of PBS buffer with 0.1% BSA, pH 7.4. 
The tube was placed in a magnet for 1 minute and the supernatant was discarded. 
After removing the tube from the magnet, the Dynabeads were resuspended in the 
same volume of buffer as the initial volume of Dynabeads used (50 l). Thereafter, 
washed beads were transferred to a tube and 1.5 g of each primary monoclonal 
antibody (mAb) added: anti-LFA-1 (R7.1), anti-CD2 (RPA 2.11) and anti-NKG2D 
(149810). After incubation for 1 hour at 4 ºC with rotation, the antibody-beads 
complex was washed again by placing in a magnet for 1 min and discarding the 
supernatant. The beads were washed twice using 1ml of buffer. After removing the 
tube from the magnet, Dynabeads were resuspended in 50 l PBS buffer with 0.1% 
BSA, pH 7.4. Beads were then used to stimulate NK cells at a ratio of 8 beads per 
cell. Dynabeads (4 × 10
6
) coated with saturating amounts of mAb, were incubated 
with resting NK cells (5 × 10
5) in 500 μl RPMI supplemented with 10% human 
serum for the indicated duration at 37°C. The cultures were rotated end-over-end 
during the stimulation. For each primary mAb, coating of Dynabeads was ≥ 98% 
efficient as determined by flow cytometry.  
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2.16.2 Dynabeads Protein G  
Dynabeads coupled to Protein G were then used to generate an artificial priming 
signal so that cognate ligands, instead of mAbs, engaged activating NK cell 
receptors. Dynabeads Protein G have a diameter of 2.5m. Beads were resuspended 
by vortexing for >30 seconds and then transferred to a fresh tube. The tube was 
placed on a magnet to separate the beads from the solution, and the supernatant was 
removed. The tube was removed from the magnet, and 1.5 g of recombinant Human 
ICAM-1 Fc Chimera, recombinant Human MICA Fc Chimera, or anti-CD2 (RPA 
2.11) were added to the Dynabeads. CD15 was not used as it is not commercially 
available. The beads were then incubated for 30 minutes at room temperature with 
rotation. Thereafter, the tube was placed on a magnet and the supernatant removed. 
Beads were then used to stimulate NK cells at a ratio of 8 beads per cell. Dynabeads 
(4 × 10
6
) coated with saturating amounts of mAb, were incubated with resting NK 
cells (5 × 10
5) in 500 μl RPMI supplemented with 10% human serum for the 
indicated duration at 37°C. The cultures were rotated end-over-end during the 
stimulation. Coating of Dynabeads was ≥ 98% efficient as determined by flow 
cytometry.  
2.17 Statistical Analyses 
Statistical comparisons between pairs of unstimulated-stimulated NK cells were 
tested for significant differences in their means by the multiple t test, corrected for 
multiple comparisons with the Holm-Sidak method. Results are presented as mean ± 
SD. Corrected p values < 0.05 were considered statistically significant. Unless stated 
otherwise, p values are indicative of significant difference relative to unstimulated 
NK cells at the same time point. Statistical analyses were performed with GraphPad 
Prism v.6 software. 
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Chapter 3 Phenotypic profiles of Tumour-primed NK cells 
3.1  Introduction 
NK cell activation occurs through engagement of germ-line encoded membrane 
receptors, which trigger downstream signalling pathways that culminate in the 
secretion of lytic granules onto a susceptible target cell. In recent years, it has 
become clear that NK cells represent a heterogeneous population, displaying 
differences in phenotype, function, tissue localization and activation status. NK cells 
also exhibit heterogeneity in responses to varying stimuli, be it a target cell or an 
activating cytokine. Human NK cells are phenotypically defined by their surface 
expression of CD56 and lack of the T cell receptor CD3. Two main NK cell subsets 
can be identified according to the cell surface density of CD56 and the low affinity 
IgG receptor CD16 (Cooper et al. 2001). Approximately 90% of NK cells found in 
blood are CD56
dim
CD16
+
, displaying high cytotoxicity, but little capacity for 
cytokine production. In contrast, about 10% of circulating NK cells are 
CD56
bright
CD16
dim/-
; these are potent cytokine producers, but with little or no ability 
to spontaneously kill tumour cell targets. Studies aiming to further dissect the 
heterogeneity of CD56
dim
 NK cells, have characterized other subsets according to the 
expression of markers related to differentiation, migration or competence (Juelke et 
al. 2010;Lopez-Verges et al. 2010;Yu et al. 2010).  
 
Exposure to activating cytokines such as interleukin (IL)-2 or IL-12 is known to 
enhance NK cell effector function. Work by our group previously showed that 
tumour-mediated priming of resting NK cells is equivalent to cytokine-mediated 
priming, as measured by activation marker expression, interferon (IFN)-γ secretion 
and the ability to kill NK-resistant RAJI cells (North et al. 2007). In this Chapter, the 
characteristics of tumour-primed PB NK cells were investigated, in term of 
expression of differentiation markers, activating receptors, and chemokine receptors, 
in comparison with cytokine-primed NK cells.  
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3.2  Experimental Aims 
The aim of the set of experiments described in this Chapter was to characterize the 
antigen expression profile of PB NK cells after tumour-priming, and compare it with 
that observed after priming with a panel of innate cytokines, namely, IL-2, IL-7, IL-
12 and IL-15. These cytokines each play distinct physiological roles in NK cell 
biology in vivo, and trigger different NK cell signalling pathways, thus providing a 
broad panel of expression profiles against which tumour-mediated priming of NK 
cells could be compared. Furthermore, to investigate heterogeneity in NK cell 
responses associated with different phenotypes, the expression of CD107a, a 
degranulation marker (Alter et al. 2004), was used to analyse different subsets of 
resting, tumour-primed and cytokine-primed NK cells. 
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3.3 Methods 
Human PB NK cells were isolated from the PBMCs of normal healthy donors by 
magnetic sorting for CD56
+
 cells. They were then incubated overnight alone (1x10
6 
cells), with CTV-1 cells (2x10
6
 cells), IL-2 (200IU/ml), IL-7 (10ng/ml), IL-12 
(20ng/ml) or IL-15 (10ng/ml). After washing the cells the next day with HBSS, 
immunophenotyping was carried out for the analysis of antigen expression (MACS 
Quant Analyzer, Miltenyi Biotec) and the CD107a degranulation assay was 
performed. CD56
dim
CD16
+
 NK cells were positively selected from PBMCs when 
stated, to investigate specific responses of this NK cell subset (MACS, Miltenyi 
Biotec). Statistical comparisons between pairs of unstimulated-stimulated NK cells 
were tested for significant differences in their means by multiple t tests, corrected for 
multiple comparisons with the Holm-Sidak method. Results are presented as mean ± 
SD. Corrected p values < 0.05 were considered statistically significant. Unless stated 
otherwise, p values are indicative of significant difference relative to unstimulated 
NK cells at the same time point. Statistical analyses were performed with GraphPad 
Prism v.6 software. Antigen expression analysis was divided into 3 groups for 
simplicity:  
 
1) Differentiation receptors (CD56, CD16, CD57 and CD62L) 
2) Activating receptors (NKp30, NKp44, NKp46, NKp80, LFA-1, CD2, ICAM-1, 
NKG2D, DNAM-1 and 2B4)  
3) Homing receptors (CD49d, CXCR1, CXCR4, CXCR7 and α4β7) 
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3.4 Results 
3.4.1 Differentiation markers 
3.4.1.1 CD56 expression 
In the initial set of experiments, I set out to investigate differences in the proportion 
of cells belonging to the two main NK cell subsets, CD56
bright
 and CD56
dim
, 
following stimulation. CD56 expression in resting and primed NK cells is shown in 
Figure 3.1. Consistent with previous studies (Cooper et al. 2001), the mean 
percentage of CD56
bright
 NK cells within resting PB NK cells was (2.37 ± 1.94%, 
n=10). Tumour-priming with CTV-1 cells did not result in a significant change in the 
mean percentage of NK cells belonging to the CD56
bright
 NK cell subset (2.13 ± 
1.39%, n=6). By contrast, exogenous cytokine stimulation by IL-12 increased the 
mean percentage of CD56
bright
 NK cells to 16.35 ± 2.70% (n=5; p < 0.0001). 
However, IL-2, IL-7, and IL-15 did not have a significant effect on the proportion of 
NK cells belonging to the CD56
bright
 NK cell subset (mean, 3.34 ± 2.75, n=5; 2.47 ± 
1.95, n=5; 2.77± 2.09, n=5, respectively). 
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Figure 3.1 CD56 expression in resting and primed NK cells. 
 (A) Percentage of CD56
bright
 NK cells; (B) representative FACS analysis of CD56
bright
 NK 
cells from one donor. Freshly isolated resting NK cells (1x10
6
) were incubated alone or with 
CTV-1 cells (2x10
6
), IL-2 (200 IU/ml), IL-7 (10ng/ml), IL-12 (20ng/ml) or IL-15 (10 ng/ml) 
overnight. Thereafter, cells were washed with HBSS and stained with anti-CD56 (clone 
B159) and anti-CD3 (clone SK7). After electronic gating on the viable lymphocyte 
population and CD56
+
CD3
–
 NK cells, the percentage of cells belonging to the CD56
bright 
and 
CD56
dim
 NK cell sub-populations was compared. For each treatment group, the mean 
percentage expression is indicated by a horizontal line. 
 
FSC indicates forward-scattered light; LAK-2,-7,-12 and-15, lymphokine-activated NK cell 
using IL-2, -7,-12 or -15; rNK, resting NK cells; TpNK, tumour-primed NK cells with CTV-
1; %#, percentage of NK cell population; *P <0.05; **P <0.005; ***P < 0.0005.  
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3.4.1.2 CD16 expression 
CD16 expression in resting and primed NK cells is shown in Figure 3.2. A high 
percentage of resting NK cells expressed the CD16 marker (mean, 93.14 ± 1.62%, n= 
10). In accordance with our previously published findings (North et al. 2007;Sabry et 
al. 2011), co-incubation with CTV-1 led to a significant reduction in the percentage 
of cells expressing CD16 (mean decrease, 25.60  3.43%, n= 10; p < 0.0001). The 
median fluorescence intensity (MFI) was also significantly lower in tumour-primed 
NK cells compared with resting NK cells (mean decrease, 29.40 ± 8.10%, n= 10; p < 
0.0001). By contrast, priming with exogenous cytokines had no effect on CD16 
expression by NK cells (LAK-2 mean, 91.78 ± 3.76, n=10; LAK-7 mean 95.23 ± 
13.46, n=3; LAK-12 mean 95.33 ± 11.08, n=3; LAK-15 mean 94.22 ± 2.95, n=3). 
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Figure 3.2 CD16 expression in resting and primed NK cells.  
(A) Percentage of CD16
+
 NK cells; (B) representative FACS analysis of CD16
+
 NK cells 
from one donor. Freshly isolated resting NK cells (1x10
6
) were incubated alone or with 
CTV-1 cells (2x10
6
), IL-2 (200 IU/ml), IL-7 (10ng/ml), IL-12 (20ng/ml) or IL-15 (10 ng/ml) 
overnight. Thereafter, cells were washed with HBSS and stained with anti-CD56 (clone 
B159), anti-CD3 (clone SK7) and anti-CD16 (clone VEP13). After electronic gating on the 
viable lymphocyte population and CD56
+
CD3
–
 NK cells, the percentage of cells expressing 
CD16 was analysed. 
FSC indicates forward-scattered light; LAK-2,-7,-12 and-15, lymphokine-activated NK cell 
using IL-2, -7,-12 or -15; rNK, resting NK cells; TpNK, tumour-primed NK cells with CTV-
1; %#, percentage of NK cell population, *P <0.05; **P <0.005; ***P < 0.0005.  
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3.4.1.3 CD62L expression 
CD62L is an NK cell homing receptor, the expression of which was recently shown 
to define an intermediate stage in NK cell development between CD56
bright
 and 
CD56
dim
CD62L

 NK cells (Juelke et al. 2010). CD62L expression in resting and 
primed NK cells is shown in Figure 3.3. The proportion of CD62L
+
 resting NK cells 
in normal donors ranged between 18–52%. Priming by co-incubation with CTV-1 
resulted in a significant decrease in the number of CD62L
+
 cells (mean decrease, 
50.10 ± 6.22%, n= 4; p = 0.026) and a more modest decrease in CD62L MFI (mean 
decrease, 35.4 ± 7.45%, n=4). Exposure to IL-2 or IL-15 had a similar effect on NK 
cells, significantly reducing the proportion of CD62L
+
 NK cells (LAK-2 mean 
decrease, 55.00 ± 7.45%, n= 4; p = 0.017), (LAK-15: mean decrease, 54.90 ± 9.80%, 
n=4; p = 0.017) and decreasing CD62L MFI (LAK-2: mean decrease 50.2 ± 7.45%, 
n=4; p = 0.021) (LAK-15: mean decrease, 56.9 ± 7.45%, n=4; p = 0.027).  
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Figure 3.3 CD62L expression in resting and primed NK cells  
(A) Percentage of CD62L
+
 NK cells; (B) representative FACS analysis of CD62L
+
 NK cells 
from one donor. Freshly isolated resting NK cells (1x10
6
) were incubated alone or with 
CTV-1 cells (2x10
6
), IL-2 (200 IU/ml), IL-7 (10ng/ml), IL-12 (20ng/ml) or IL-15 (10 ng/ml) 
overnight. Thereafter, cells were washed with HBSS and stained with anti-CD56 (clone 
B159), anti-CD3 (clone SK7) and anti-CD62L (clone DREG-56). After electronic gating on 
the viable lymphocyte population and CD56
+
CD3
-
 NK cells, the number of CD62L
+
 was 
compared.  For each treatment group, the mean percentage expression is indicated by a 
horizontal line. 
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FSC indicates forward-scattered light; LAK-2,-7,-12 and-15, lymphokine-activated NK cell 
using IL-2, -7,-12 or -15, rNK, resting NK cells; TpNK, tumour-primed NK cells with CTV-
1; %#, percentage of NK cell population; *P <0.05; **P <0.005; ***P < 0.0005.  
3.4.1.4 CD57 expression 
CD57 is a T cell senescence marker that was recently described to mark the terminal 
differentiation of NK cells (Lopez-Verges et al. 2010) CD57 expression in resting 
and primed NK cells is shown in Figure 3.4 . The mean percentage of CD57
+
 resting 
NK cells was 56.5  19.57%. Tumour-priming led to a significant increase in the 
proportion of CD57
+
 NK cells in culture (mean increase, 23.6  9.75%, n= 10; p = 
0.024) and a non-significant increase in CD57 expression (mean increase in MFI, 
6.14  4.28%, n=10). However, cytokine-mediated priming did not result in any 
significant changes in CD57 expression (LAK-2 mean 62.44 ± 22.31%, n=3; LAK-7 
mean 60.83 ± 23.02%, n=3; LAK-12 mean 52.32 ±27.15%, n=3; LAK-15 mean 
59.56 ±21.19%, n=3). 
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Figure 3.4 CD57 expression in resting and primed NK cells 
(A) Percentage of CD57
+
 NK cells; (B) CD57 MFI of rNK and TpNK. Freshly isolated 
resting NK cells (1x10
6
) were incubated alone or with CTV-1 cells (2x10
6
), IL-2 (200 
IU/ml), IL-7 (10ng/ml), IL-12 (20ng/ml) or IL-15 (20 ng/ml) overnight. Thereafter, cells 
were washed with HBSS and stained with anti-CD56 (clone B159), anti-CD3 (clone SK7) 
and anti-CD57 (clone TB01). After electronic gating on the viable lymphocyte population 
and CD56
+
CD3
-
 NK cells, percentage CD57 positive and MFI were compared. For each 
treatment group, the mean percentage expression is indicated by a horizontal line. 
LAK-2,-7,-12 and-15 indicate lymphokine-activated NK cell using IL-2, -7,-12 or -15; rNK, 
resting NK cells; TpNK, tumour-primed NK cells with CTV-1; MFI, median fluorescence 
intensity; *P <0.05; **P <0.005; ***P < 0.0005. 
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3.4.1.5 Compound expression of NK cell differentiation receptors 
It was hypothesized that tumour-priming completes NK cell maturation toward better 
effector function. Thus, the compound expression of several NK cell differentiation 
receptors was analysed. An increase in the proportion of the terminally differentiated 
CD56
dim
CD62L
–
CD57
+ 
NK cell subset was observed after tumour-priming of resting 
NK cells (mean increase, 61.2 ± 5.4%, n= 4; p = 0.02) (Figure 3.5), which suggests a 
tumour-priming role in promoting a more mature NK phenotype. However, a 
heterogeneity in response to tumour-priming was observed between different NK cell 
subsets, as defined by their expression of differentiation markers. CD56
dim
 NK cells 
uniquely downregulated CD16 expression following stimulation with CTV-1 cells 
(mean decrease, 28.18  5.43%, n=3; p < 0.001). In contrast, CD56bright NK cells 
responded to tumour-priming by upregulating CD16 expression (mean increase, 
19.81 ± 1.12%, n=3), as did CD56
bright
 NK cells primed by IL-2, IL-12, and IL-15. 
Validation studies to investigate the nature of the CD56
dim
CD16
– 
population 
emerging after tumour-priming are described in 3.4.4. 
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Figure 3.5 Tumour-priming completes NK cell maturation 
Freshly isolated resting NK cells (1x10
6
) were incubated alone or with CTV-1 cells (2x10
6
) 
overnight. Thereafter, cells were washed with HBSS and stained with anti-CD56 (clone 
B159), anti-CD3 (clone SK7) anti-CD62L (clone DREG-56) and anti-CD57 (clone TB01). 
After electronic gating on the viable lymphocyte population, CD56
+
CD3
–
 and CD56
dim
 NK 
cells, the proportion of CD56
dim
CD62L
–
CD57
+ 
NK cells
 
was compared. NK cell priming 
with CTV-1 resulted in a decrease in the proportion of CD56
dim
CD62L
–
CD57
+ 
NK cells. One 
representative donor and percentage of CD56
dim
CD62L
–
CD57
+ 
NK cells as analysed by flow 
cytometry shown.  
rNK indicates resting NK cells; TpNK, tumour-primed NK cells with CTV-1. 
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3.4.2 Activating receptors 
3.4.2.1 Natural cytotoxicity receptors 
NK cell natural cytotoxicity receptors (NCRs) are important mediators of NK cell 
cytotoxicity, through recognition of various cognate cellular and viral ligands (Lanier 
2005). Resting NK cells showed constitutive expression of NKp30 (mean percentage 
expression, 87.36 % ± 1.8%, n=3), NKp46 (mean percentage expression, 94.18 ± 
1.3%, n=5) and NKp80 (mean percentage expression, 95.11% ± 1.22%, n=3), but 
little or no expression of NKp44 (mean percentage expression, 1.93 ± 0.8%, n=3), 
which is known to be up-regulated post-cytokine stimulation (Lanier 2005). Figure 
3.6 shows that the percentage of cells expressing NKp46 was significantly lower in 
tumour-primed NK cells compared with resting NK cells (mean decrease, 27.6 ± 
15.55%, n= 4; p = 0.002), whereas cytokine-mediated priming did not result in a 
significant change in NKp46 expression (LAK-2 mean, 92.86 ± 4.15%, n=3; LAK-7 
mean, 94.57 ± 3.04 %, n=3; LAK-12 mean, 95.58 ± 1.74%, n=3; LAK-15 mean, 
91.02 ± 6.94%, n=3). Tumour-priming also resulted in a non-significant decrease in 
NKp30 expression (MFI mean decrease, 19.3 ± 2.7%, n= 3) and NKp80 expression 
(MFI mean decrease 29.4 ± 2.18%, n=3). In contrast, cytokine-mediated priming 
resulted in similar or in some cases higher NCR expression in NK cells. For 
example, IL-2 or IL-15 stimulation of resting NK cells resulted in a significant 
increase in NKp44 expression (LAK-2 mean increase  147.3 ± 2.91%, n=3; p <0.01) 
(LAK-15 mean increase 184.2 ±1.57%, n=3; p <0.01). 
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Figure 3.6 NKp46 expression by resting and primed NK cells 
(A) Percentage of NKp46
+
 NK cells; (B) representative FACS analysis of CDNKp46
+ 
NK 
cells from one donor.
 
 Freshly isolated resting NK cells (1x10
6
) were incubated alone or with 
CTV-1 cells (2x10
6
) or IL-2 (200IU/ml) overnight. Thereafter, cells were washed with 
HBSS and stained with anti-CD56 (clone B159), anti-CD3 (clone SK7), and anti-NKp46 
(clone 9E2) mAbs. After electronic gating on the viable lymphocyte population and 
CD56
+
CD3
-
 NK cells, NKp46 expression was analysed (MACS Quant Analyser).  
 
FSC indicates forward-scattered light; LAK-2,-7,-12 and-15, lymphokine-activated NK cell 
using IL-2, -7,-12 or -15, rNK, resting NK cells; TpNK, tumour-primed NK cells with CTV-
1; %#, percentage of NK cell population; *P <0.05; **P <0.005; ***P < 0.0005.  
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3.4.2.2 Adhesion receptors 
NK cell interactions with target cells must be stabilized by cell-cell adhesion forces, 
and the formation of stable conjugates, prior to cytolysis (Davis 2009). Adhesion 
signals can be provided by receptor-ligand interactions, some of which can also 
promote activation signalling such as LFA-1 (Barber et al. 2004) and CD2 (Bryceson 
et al. 2006). Figure 3.7 shows ICAM-1 expression by resting and primed NK cells. 
Resting NK cells constitutively expressed high levels of lymphocyte function-
associated antigen (LFA)-1 (mean, 98.3 ± 1.3%, n=4) and its cognate ligand 
intracellular adhesion molecule (ICAM)-1 (mean, 94.5 ± 1.9%, n=7) as well as CD2 
(mean, 61.3 ± 2.67%, n=3). Tumour-priming resulted in a loss of ICAM-1 
expression (MFI mean decrease 26.4%, SD± 1.43, n=5; p = 0.05) and a decrease in 
the number of cells expressing ICAM-1 (mean decrease 17.8%, SD± 1.52, n=5; p = 
0.05). Cytokine-mediated priming did not affect ICAM-1 expression, (LAK-2 mean, 
96.74 ± 1.95%, n=5; LAK-7 mean 90.93 ± 3.71%, n=5; LAK-12 mean 93.16 ± 5.88, 
n=3; LAK-15 mean 95.08 ± 3.58, n=3). Neither priming mechanisms had any 
significant changes on LFA-1 (TpNK mean, 93.96 ± 6.23, n= 7; LAK-2 mean, 98.02 
± 1.34%, n=7; LAK-7 mean 98.27 ± 0.58 %, n=3; LAK-12 mean 99.16 ± 2.45%, 
n=3; LAK-15 mean 97.14 ± 2.23%, n=3) or CD2 expression (TpNK mean, 95.76. ± 
3.16%, n= 7; LAK-2 mean, 97.21 ± 1.91%, n=7; LAK-7 mean 98.56 ± 1.79 %, n=3; 
LAK-12 mean 96.55 ± 2.18, n=3; LAK-15 mean 96.04 ± 2.41, n=3).  
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 Figure 3.7 ICAM-1 expression by resting and primed NK cells 
(A) Percentage of ICAM-1
+
 NK cells; (B) representative FACS analysis of ICAM-1
+ 
NK 
cells from one donor.
 
Freshly isolated resting NK cells (1x10
6
) were incubated alone or with 
CTV-1 cells (2x10
6
) or IL-2 (200IU/ml) overnight. Thereafter, cells were washed with 
HBSS and stained with anti-CD56 (clone B159), anti-CD3 (clone SK7), and anti-ICAM-1 
(clone RR1/1) mAbs. After electronic gating on the viable lymphocyte population and 
CD56
+
CD3
-
 NK cells ICAM-1 expression was analysed (MACS Quant Analyser).  
 
FSC indicates forward-scattered light; rNK, resting NK cells; TpNK, tumour-primed NK 
cells with CTV-1; LAK-2,-7,-12 and-15, lymphokine-activated NK cell using IL-2, -7,-12 or 
-15; %#, percentage of NK cell population; *P <0.05; **P <0.005; ***P < 0.0005. 
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3.4.2.3 Co-activating receptors  
In resting NK cells, co-engagement of several activating receptors is required for the 
triggering of natural cytotoxicity (Bryceson et al 2006; Bryceson et al. 2009). 
NKG2D expression by resting and primed NK cells is shown in Figure 3.8. Resting 
NK cells expressed high levels of the co-activating receptors NKG2D (mean, 92.4 ± 
4.52%, n= 5), DNAM-1 (mean, 87.1 ± 5.3%, n=3), but little or no expression of 2B4 
(mean, 0.98 ± 0.81%, n=3). Tumour-priming resulted in a significant down-
regulation of NKG2D expression (mean decrease, 33.7 ± 2.7%, n= 5; p = 0.001) and 
non-significant downregulation of DNAM-1 expression (mean decrease, 11.5 ± 
3.2%, n=3). Although cytokine-priming did not significantly affect NKG2D or 
DNAM-1 expression relative to resting NK cells, in most cases expression levels 
were similar or higher than those expressed by unstimulated NK cells. IL-2 and IL-
15 resulted in a 4.3 ± 2.91 %, and 5.15 ± 1.12% increase in the number of NK cells 
expressing NKG2D, compared to resting NK cells, respectively. Although tumour-
priming did not change 2B4 expression, cytokine-priming by IL-2 consistently 
increased the proportion of cells expressing 2B4 (mean increase, 23.5 ± 1.2%, n=3) 
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Figure 3.8 NKG2D expression by resting and primed NK cells 
(A) Percentage of NKG2D
+ 
NK cells; (B) representative FACS analysis of NKG2D
+  
NK 
cells from one donor Freshly isolated resting NK cells (1x10
6
) were incubated alone or with 
CTV-1 cells (2x10
6
) or IL-2 (200IU/ml) overnight. Thereafter, cells were washed with 
HBSS and stained with anti-CD56 (clone B159), anti-CD3 (clone SK7), and anti-NKG2D 
(clone 1D11) mAbs. After electronic gating on the viable lymphocyte population and 
CD56
+
CD3
-
 NK cells NKG2D expression was analysed (MACS Quant Analyser).  
FSC indicates forward-scattered light; rNK, resting NK cells; TpNK, tumour-primed NK 
cells with CTV-1; LAK-2,-7,-12 and-15, lymphokine-activated NK cell using IL-2, -7,-12 or 
-15; %#, percentage of NK cell population; *P <0.05; **P <0.005; ***P < 0.0005.  
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3.4.3 Homing receptors 
Tumour-primed and cytokine-primed NK cells may traffic to distinct sites. Thus, 
following on from the investigation of the expression of CD62L (section 3.4.1.3), 
which serves as a differentiation marker as well as being involved in NK cell 
trafficking to lymph nodes (Frey et al. 1998), other receptors were investigated, 
including CD49d: extravasation (Berlin et al. 1995); CXCR4 and CXR7: homing to 
the bone marrow (Beider et al. 2003;Hartmann et al. 2008;Peled et al. 1999); α4β7 
integrin: trafficking to the gut (Hamann et al. 1994;Kellersmann et al. 2002); and 
CXCR1: inflammatory sites (Maghazachi 2010). CXCR-1, -4 and -7 expression by 
resting and primed NK cells are shown in Figure 3.9. Tumour-primed NK cells 
upregulated CXCR1 (mean increase, 43.4 ± 9.25%, n=3) and CXCR7 (mean 
increase, 41.1 ± 3.45%, n=3) relative to resting NK cells. Resting NK cells 
constitutively expressed CXCR4 (mean, 88.7 ± 6.2%, n=3). Tumour-priming 
resulted in a significant reduction in CXCR4 expression (mean decrease, 54.6 ± 
12.9%, n=3; p = 0.002). Similarly cytokine-priming by IL-2 (mean decrease, 84.05 ± 
15.41%, n=3; p < 0.0001), IL-12 (mean decrease, 94.13 ± 7.86%, n=3; p <0.001) and 
IL-15 (mean decrease, 36.37 ± 2.32%, n=3; p = 0.001), but not IL-7 (mean decrease, 
xx ± xx%; p = 0.xx), resulted in the downregulation of CXCR4 expression. High 
levels of CD49d (mean, 99.88 ± 0.078%, n=3)) and α4β7 (mean, 66.44 ± 4.37%, n=3 
) were expressed by resting NK cells.  Neither tumour- nor cytokine-priming had any 
significant effect on the expression levels of CD49d (TpNK mean, 99.7 ± 0.32, n= 3; 
LAK-2 mean, 99.8 ± 0.11%, n=3; LAK-7 mean 99.9 ± 0.05 %, n=3; LAK-12 mean 
99.8 ± 0.09 %, n=3; LAK-15 mean 99.7 ± 0.08%, n=3) or α4β7 (TpNK mean, 61.10 
± 5.2%, n= 3; LAK-2 mean, 69.08 ± 6.2 %, n=3; LAK-7 mean, 62.19 ± 4.34 %, n=3; 
LAK-12 mean, 69.67 ± 12.14 %, n=3; LAK-15 mean, 61.54 ± 8.73%, n=3). 
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Figure 3.9 CXCR-1, -4 and -7 expression by resting and primed NK cells 
Freshly isolated resting NK cells (1x10
6
) were incubated alone or with CTV-1 cells (2x10
6
) 
or IL-2 (200IU/ml) overnight. Thereafter, cells were washed with HBSS and stained with 
anti-CD56 (clone B159), anti-CD3 (clone SK7), and anti-CXCR1 (clone 8F1/CXCR1), anti-
CXCR4 (clone 12G5) or anti-CXCR7 (clone 8F11-M16) mAbs. After electronic gating on 
the viable lymphocyte population and CD56
+
CD3
-
 NK cells, CXCR-1, -4, and -7 expression 
was analysed (MACS Quant Analyser).  
 
LAK-2,-7,-12 and-15 indicate lymphokine-activated NK cell using IL-2, -7,-12 or -15; rNK, 
resting NK cells; TpNK, tumour-primed NK cells with CTV-1; *P <0.05; **P <0.005; ***P 
< 0.0005  
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3.4.4 CD107a expression and different NK cell subsets  
To investigate heterogeneity in NK cell responses associated with different 
phenotypes, the expression of CD107a, a degranulation marker (Alter et al. 2004), 
was used to analyse different subsets of resting, tumour-primed and cytokine-primed 
NK cells.  
  
3.4.4.1 Correlation between CD107a expression and cytotoxicity 
Firstly, correlation between NK cell cytotoxicity and CD107a expression was 
confirmed. Resting or primed NK cells were incubated with NK-resistant RAJI target 
cells in a 3h assay, in the presence of PE-conjugated anti-CD107a mAbs, with 
monensin added an hour after the start of incubation. Figure 3.10 shows that 
upregulation of CD107a expression correlated with an increase in killing capacity 
observed by primed NK cells (r=0.5, p=NS). 
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Figure 3.10 Correlation between NK cell cytotoxicity and CD107a expression 
NK cell cytotoxicity against NK-resistant RAJI cells was measured by pre-labelling 
the target cells with PKH-67 (FITC) and co-incubating them in a 3 hr assay at 37ºC. 
CD107a PE was added at the start of the assay and monensin was added after 1hr of 
incubation with target cells. After 3 h, the samples were washed and stained with 
anti-CD56 and CD3 mAbs. TO-PRO (APC) was added before acquisition of samples 
and percentage lysis was calculated after subtracting the value for the RAJI + no NK 
cells negative control. Upregulation of CD107a expression in primed NK cells 
correlated with acquired capacity for RAJI killing by primed NK cells.  
 
LAK-2 indicates lymphokine-activated NK cell using IL-2; rNK, resting NK cells; TpNK, 
tumour-primed NK cells. 
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3.4.4.2 CD107a expression in resting and primed NK cells 
Figure 3.11 shows that resting NK cells incubated with NK-sensitive K562 cells 
displayed higher CD107a expression (mean, 6.41 ± 0.14%, n=3) than NK cells 
incubated without target cells (mean, 0.33 ± 0.12%, n=3), or with NK-resistant RAJI 
cells (mean, 1.66 ± 0.47%, n=3). Tumour-primed NK cells and NK cells primed with 
IL-2 showed higher CD107a expression levels in a 3h cytotoxicity assay against 
RAJI cells, compared with resting NK cells (TpNK mean, 9.58 ± 1.55, n=3; LAK-2 
mean, 6.79 ± 2.43, n=3).  
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Figure 3.11 CD107a expression in resting and primed NK cells 
Freshly isolated resting NK cells were incubated alone or with tumour target cells after 
tumour- or cytokine-priming. (A) Co-incubation with NK-sensitive K562 tumour targets 
induces degranulation and upregulation of CD107a in NK cells compared with resting NK 
cells incubated without targets (B) NK cells primed with CTV-1 or IL-2, but not resting NK 
cells, degranulate after exposure to NK-resistant RAJI cells in a 4h assay, displaying 
elevated levels of CD107a. Data presented from FACS analysis of cells from one 
representative donor. 
FSC indicates forward-scattered light; LAK-2, lymphokine-activated NK cell using IL-2; 
rNK, resting NK cells; TpNK, tumour-primed NK cells using CTV-1 cells. 
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3.4.4.3 CD107a expression in different NK cell subsets 
CD107a expression was low in CD56
bright 
NK cells (mean, 0.91 ±0.57%, n=3) 
(Figure 3.12), in accordance with previously published data (Grzywacz et al. 2007) 
in a degranulation assay against NK-sensitive K562 cells. Also consistent with 
previous findings, CD56
dim
CD16
-
 NK cells expressed higher levels of CD107a 
(mean, 12.91 ± 5.4%, n=3) than CD56
dim
CD16
+
 NK cells (mean, 1.71 ± 0.7%, n=3) 
against K562 cells. Since resting CD56
dim
 NK cells shed CD16 in response to 
tumour-priming, CD56
dim
CD16
+
 NK cells were positively selected before co-
incubation with CTV-1 cells, and CD107a expression was analysed after co-
incubation with NK-resistant RAJI cells. The CD56
dim
CD16
–
 phenotype that 
emerged following tumour-priming, confirmed that the CD56
dim
CD16
+
 subset is the 
source of NK cells with reduced CD16 expression and higher CD107a levels (mean, 
13.91 ± 1.05, n=3) (Figure 3.13). 
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Figure 3.12 CD107a expression in different NK cell subsets 
Freshly isolated NK cells from a normal healthy donor were co-incubated with K562 target 
cells (effector:target ratio, 2:1). NK cell subpopulations were defined by surface expression 
density of CD56 and CD16 (A). CD56
dim
CD16
+ 
NK cells (B) and CD56
bright
 NK cells (D) 
showed little or no degranulation in response to target cell stimulation, whereas 
CD56
dim
CD16
–
 NK cells displayed higher degranulation and expression of CD107 (C). 
FSC indicates forward scatter. 
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Figure 3.13 CD107a expression in different subsets of tumour-primed NK cells 
Freshly isolated PBMCs from a normal healthy donor were positively selected for 
CD56
dim
CD16
+
 expression (1x10
6
) and incubated with CTV-1 cells (2x10
6
) overnight for 
priming. Immunophenotyping for surface expression of CD56 and CD16 was carried out 
pre- and post-sorting, as well as post tumour-priming the following day to verify CD16 
shedding (A). The CD56
dim
CD16
–
 NK cell subpopulation that emerged following stimulation 
with CTV-1, expressed higher levels of CD107a than its CD56
dim
CD16
+
 counterpart in a 3h 
degranulation assay against NK-resistant RAJI cells.  
 
FSC indicates forward scatter. 
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3.5  Discussion 
The NK cell development model presented by Freud et al. (Freud et al. 2006;Freud 
and Caligiuri 2006) proposes that NK cells exhibit different maturational stages with 
distinct NK cell populations progressing from CD34
+
CD45RA
+ 
HPCs to CD3
–
CD56
bright
 NK cells. After further linear progression from CD56
bright
 to CD56
dim
 NK 
cells, CD56
dim
CD62L
+
 NK cells appear as an intermediary stage (Juelke et al. 2010), 
before CD62L expression is lost and expression of the terminal differentiation 
marker CD57 is acquired. The resulting CD56
dim
CD62L
–
CD57
+
 NK cell 
subpopulation is known to display high cytotoxicity against tumour targets and have 
a decreased proliferative capacity (Lopez-verges et al. 2010). In this Chapter, the 
antigen expression profile of tumour-primed NK cells was compared with that of 
cytokine-primed NK cells. Tumour-priming generated an increase in the overall 
number of CD56
dim
CD62L
–
CD57
+
 NK cells, supporting its role in promoting NK 
cell maturation toward a phenotype with enhanced effector functions. 
 
The expansion of CD56
bright
 NK cells was observed in response to cytokine- but not 
tumour-priming. Although this observation has been commonly reported in various 
conditions, such as during the reconstitution of the immune system after bone 
marrow transplantation or in patients who are treated with a daily dose of IL-2 
(Carson and Caligiuri 1996), many questions remain unanswered regarding the 
mechanism of expansion. CD56
bright 
cells have been postulated to play an important 
regulatory role by virtue of their ability to produce ample amounts of cytokines that 
modulate adaptive immune responses. It is possible that CD56
bright
 cells are released 
in high numbers to serve as precursors for CD56
dim
 NK cells, which have a high 
turnover. It is also possible that CD56
bright
 NK cells are selectively expanded in 
response to certain stimuli, because of their distinct regulatory role involving 
cytokine production. Thus, the expansion of CD56
bright
 NK cells observed here might 
be a specific NK cell response to cytokine stimulation. Of the four cytokines tested 
(IL-2, IL-7, IL-12 and IL-15), IL-12 was the only cytokine tested that resulted in 
expansion of the CD56
bright
 population. Previous studies demonstrating selective 
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expansion of the CD56
bright
 sub-population in response to cytokine stimulation used 
combinations of IL-2, IL-12 and IL-15 (Takahashi et al. 2007). It is possible that the 
stimulating conditions used here, with exposure to individual cytokines over 20 
hours was not strong enough to induce this effect.  
 
Interestingly, the downregulation of CD16 in response to tumour-priming was only 
observed in the CD56
dim
 NK cell population. In contrast, CD56
bright
 NK cells 
responded to both cytokine- and tumour-priming by upregulating CD16 expression. 
This suggests that both priming mechanisms promote the progression of 
CD56
bright
CD16
–
 NK cells towards the more mature CD56
dim
CD16
+
 phenotype. NK 
cells that are further along the differentiation path, then go on to downregulate CD16 
expression upon stimulation with CTV-1. This CD56
dim
CD16
–
 NK cell 
subpopulation was demonstrated in this Chapter to be the main subset responsible for 
cytotoxicity against tumour target cells, as measured by expression of the 
degranulation marker CD107a. When Penack et al. first introduced the CD107a 
assay as a method to investigate NK cell subsets responsible for target cell lysis, they 
reported CD56
dim
CD16
–
 NK cells as the main degranulating subset, following co-
incubation with tumor target cells (Penack et al. 2005). This led to the conclusion 
that this NK cell subset was exclusively responsible for cytotoxicity against target 
cells given that other NK cell subsets (CD56
bright
CD16
–/+
 and CD56
dim
CD16
+
) did 
not express CD107a, which seemed at odds with previous studies reporting 
CD56
dim
CD16
+
 NK cells as the main cytotoxic subset in NK cells (Nagler et al. 
1989). Zimmer et al. subsequently challenged this conclusion, by questioning the 
method of NK cell isolation used, and arguing that without careful exclusion of 
CD3
+
 cells, contamination by NKT cells (CD56
+
CD3
+
) is likely to account for this 
observation. Zimmer’s reasoning was that the majority of CD56dimCD16– cells in 
peripheral blood are CD3
+
 T cells, and it is these cells that are responsible for the 
observed cytotoxic activity (Zimmer et al. 2005). Following on from this study, 
Grzywacz et al. (Grzywacz et al. 2007) investigated the true nature of the 
CD56
dim
CD16
–
 NK cell population reported in these studies, by employing various 
NK cell purification methods, ensuring exclusion of CD3+ cells. Their results 
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confirmed that the contribution of CD56
dim
CD16
– 
cells to NK cytotoxicity is 
marginal. Upon culture with K562 cells however, a fraction of CD56
dim
CD16
–
 NK 
cells emerged, expressing CD107a. To confirm that the CD56
dim
CD16
+ 
subset was 
the source of cells with reduced CD16 expression, purified CD56
+
CD16
+
 cells were 
cultured with or without target K562 cells. In the absence of targets, these cells did 
not express CD107a, and retained CD16 expression. However, following co-culture 
with K562 cells, a proportion of CD56
+
CD16
+ 
NK cells gained CD107a and 
downregulated CD16 expression. This finding was replicated in this Chapter in order 
to demonstrate that CD56
dim
CD16
+
 NK cells shed CD16 upon target cell stimulation 
with CTV-1. The CD56
dim
CD16
–
 population that emerges following this exposure to 
CTV-1 tumour target cells is the main degranulating population upon exposure to 
subsequent targets, as demonstrated by tumour-primed NK cells in a cytotoxicity 
assay against NK-resistant RAJI cells. In accordance with other studies, CD107a 
expression wasn’t limited to the CD56dim subset, but CD107a expression was much 
lower (almost negligible in most cases) on CD56
bright
 NK cells. Collectively, my 
results are aligned with Nagler et al., Penack et al., Grzywacz et al. as well as 
previous work done by our group (North et al. 2007; Sabry et al. 2011), supporting 
the assertion that CD56
dim
CD16
+
 NK cells are the main cytotoxic population in PB.  
 
It has been postulated that the loss of CD16 expression in precursor CD56
dim
CD16
+
 
NK cells is probably mediated by matrix metalloproteases (MMPs) (Juelke et al. 
2010). A disintegrin and metalloprotease-17 (ADAM-17) was recently shown to 
specifically induce downregulation of CD16 and CD62L expression upon NK cell 
stimulation. The results in this Chapter also show downregulation of CD62L 
expression in response to both tumour- and cytokine-priming. The combined loss of 
CD16 and CD62L in response to CTV-1 stimulation was interpreted here as evidence 
for the dual role of tumour-priming in the promotion of NK cell progression toward a 
more mature differentiation stage and enhanced activation status. Loss of both those 
receptors may indeed play an important role in the synergistic release of molecules 
such as CD3-ζ or other signaling proteins downstream from metalloproteases 
activation that result in better NK cell effector function. When Romee et al. 
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investigated the expression of other NK cell activating receptors, including NCRs, 
CD2, DNAM-1, NKG2D and CD57, none of these were found to be downregulated 
following cytokine stimulation (Romee et al. 2013). The results presented here show 
that many of these activating receptors like are uniquely downregulated in response 
to CTV-1, which is suggestive of a highly specific response to target cell stimulation 
and perhaps priming with CTV-1. It is possible that receptors such as NKp46 or 
NKG2D are involved only in the priming stage of NK cell activation, and are thus 
shed following stimulation with CTV-1 and completion of priming. 
 
Another NK cell activating receptor that is likely to be involved in the delivery of the 
tumour-priming signal is LFA-1. In addition to acting as a central mediator of NK 
cell adhesion to target cells, LFA-1 also plays an important role in the delivery of 
early signals in NK cell cytotoxicity (Barber et al. 2004). Moreover, it was recently 
identified as one of the signalling components that define the minimal requirements 
of NK cell-mediated natural cytotoxicity (Bryceson et al. 2009). LFA-1 binding 
induces changes in conformation and spatial distribution, such that receptor affinity 
and avidity are modified (Kim et al. 2004). Signals that enhance receptor affinity by 
inducing an open conformation in LFA-1 are known as ‘inside-out’ signals. 
Antibodies which selectively bind to open conformations of LFA-1 are not 
commercially available. Thus, although LFA-1 was observed here to be expressed at 
uniformly high levels on resting NK cells, with no change following tumour- or 
cytokine-mediated priming, it is likely that the conformation-independent mAbs used 
are a limitation of the experiments described in this Chapter. Further studies 
investigating the role of LFA-1 in tumour-mediated priming are explored in later 
chapters of this Thesis.  
 
In conclusion, both tumour- and cytokine-priming led to a more mature NK cell 
profile, which is likely to be a requirement for enhanced effector functions. Both 
priming mechanisms also resulted in similar homing signatures and trafficking 
towards pro-inflammatory sites. Notable differences between the two stimulation 
profiles were observed, however, in the observed downregulation of important NK 
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cell activating receptors including CD16, NKG2D, NKp46, DNAM-1 and ICAM-1 
by tumour-priming. The observation that tumour-primed NK cells exhibit enhanced 
effector functions, despite the loss of these important activating receptors, argues 
against NK cell impairment or loss of function. It is possible that the shedding of 
these receptors is an integral part of the mechanism of target cell stimulation of NK 
cell effector functions. It is also possible that these receptors are shed following 
stimulation to complete the priming stage of NK cell activation, with other receptors 
being involved in the ‘triggering’ stages. Different ligand combinations presented to 
NK cells through sensitive or insensitive targets are likely to induce different 
responses in NK cells. The secretory profiles of NK cells stimulated with different 
cytokines are compared in the next Chapter, to get a better understanding of the full 
picture of NK cell responses to different stimuli. 
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Chapter 4 Secretory profiles of tumour-primed NK cells 
4.1 Introduction 
NK cells were originally defined by their ability to lyse tumour cells ‘naturally’ 
without prior sensitisation, but it was later recognised that NK cell effector functions 
include both cytokine production and cytotoxicity (Vivier et al. 2008). NK cell 
responses are influenced by their cytokine microenvironment and interactions with 
stressed cells undergoing a pathogen infection or malignant transformation. Exposure 
to cytokines and other immune cells, such as DCs during inflammation can result in 
non-specific priming of NK cells, and the generation of more potent effector 
functions (Lucas et al. 2007). Target cells can also prime NK cells for greater 
effector potential through direct engagement of NK cell activating receptors (North 
et al. 2007). A variety of different priming mechanisms can trigger the secretion of a 
plethora of cytokines, which can eliminate target cells, relay the activation signals, 
and recruit other immune cells for a more directed and efficient immune response. 
Factors released by NK cells have different activation thresholds and regulatory 
effects on the immune response. NK cells produce chemokines, such as MIP-1α and 
MIP-1β, RANTES, MCP-1, monokine induced by IFN-γ (MIG), eotaxin and IFN-γ-
induced protein (IP)-10 (Cuturi et al. 1989;Roda et al. 2006). These chemokines have 
a lower stimulation threshold for their release compared with other cytokines 
secreted by NK cells and play a pivotal role in the recruitment of other immune cells 
to the target tissue (Bryceson et al. 2009;Fauriat et al. 2010a). Other prominent 
cytokines secreted by NK cells include TNF-α and IFN-γ, which have greater 
stimulatory requirements relative to chemokines, and contribute to host inflammatory 
responses (Bryceson et al. 2006a;Fauriat et al. 2010). Pro-inflammatory cytokines, 
such as IL-1 , IL-6, IL-8 and IL-12 promote Th1 responses and stimulate the 
activation and proliferation of cytotoxic T cells, DCs and macrophages; whereas 
anti-inflammatory cytokines, such as IL-4 and IL-10, promote Th2 immune 
responses and humoral immunity, but suppress T cell and macrophage function 
(Elenkov and Chrousos 1999;Elenkov and Chrousos 2002). The balance between 
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Th1/Th2 and pro-/anti-inflammatory cytokines in the NK-target cell 
microenvironment can thus modulate immune responses toward activation or 
suppression, and influence the progression of disease. 
NK cell responses to target cell stimulation vary according to the degree and 
combination of ligand expression on target cells for NK cell activating receptors 
(Bryceson et al. 2006;Bryceson et al. 2009). NK-sensitive tumour target cells like 
K562 provide ligands that engage NK cell activating receptors through the 
previously described priming and triggering stages (North et al. 2007), resulting in 
NK cell lysis. The NK-resistant CTV-1 tumour cell line has a markedly different 
ligand expression profile from that of K562 cells; it provides the NK cell priming 
signal only, without triggering cytotoxicity (North et al. 2007). The secretory 
responses of resting NK cells stimulated with K562 were recently reported (Fauriat 
et al. 2010) and NK cell responses to exogenous cytokines have been extensively 
studied (Fehniger et al. 1999).  In Chapter 3, I showed that tumour-priming of resting 
NK cells through co-incubation with CTV-1 generates an NK cell antigen expression 
profile that is distinct from exogenous cytokine stimulation. In this Chapter, the 
effect of CTV-1 target cell stimulation on NK cell cytokine secretory responses was 
investigated and compared with the previously reported effects of K562 and 
exogenous cytokine stimulation. 
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4.2 Experimental Aims 
The aim of this chapter was to define the cytokine secretion profiles of NK cells 
stimulated with NK-sensitive K562 cells, NK-resistant CTV-1 tumour cells, and 
exogenous cytokines IL-2, IL-7, IL-12, IL-15 and IL-21. The kinetics of cytokine 
secretion by NK cells were studied by quantifying cytokine secretion levels at 6 
hours and 16 hours post-stimulation. 
4.3 Methods 
Human NK cells were isolated from the PBMCs of normal healthy donors by 
magnetic sorting for CD56
+
 cells. Resting NK cells (2 x 10
5
) were washed twice and 
mixed with CTV-1 or K562 cells (4 x 10
5
), IL-2 (200IU/ml) IL-7, IL-15, IL-21 (10 
ng/ml), or IL-12 (20 ng/ml) for 16 hours at 37ºC, 5 % CO2 in CM. Thereafter, 
supernatants were collected and stored at   -80°C pending measurement. The 
concentrations of cytokines were quantified by a multiplex immunoassay kit 
(Luminex 100 IS; Invitrogen) that detected 25 cytokines grouped into 4 different 
panels: pro-inflammatory (IL-1β, IL-1RA, IL-6, IL-8, GM-CSF and TNF-α), 
Th1/Th2 (IL-2, IL-2Rα, IL-4, IL-5, IL-10, IFN-γ), cytokines II (IL-7, IL-12p40, IL-
13, IL15, IL-17 and IFN-α) and chemokines (eotaxin, IP-10, MCP-1, MIG, MIP-1α 
and MIP-1β). Statistical comparisons between pairs of unstimulated-stimulated NK 
cells were tested for significant differences in their means by multiple t test, 
corrected for multiple comparisons with the Holm-Sidak method. Results are 
presented as mean ± SD. Corrected p values < 0.05 were considered statistically 
significant. Unless stated otherwise, p values are indicative of significant difference 
relative to unstimulated NK cells at the same time point. Blank control values were 
subtracted from all samples before interpolation of X values (secretion at pg/ml) 
from absorbance. In the case of target cell stimulated NK cells, values of (blank 
controls + target cells incubated alone) were subtracted from samples before 
interpolation. Statistical analyses were performed with GraphPad Prism v.6 software.  
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4.4 Results 
4.4.1 Inflammatory cytokines  
Levels of the inflammatory cytokines IL-1β, IL-1receptor antagonist (IL-1RA), IL-6, 
IL-8, granulocyte macrophage colony-stimulating factor (GM-CSF) and TNF-α 
secreted by resting,   target cell-stimulated and cytokine-stimulated NK cells are 
shown in Figures 4.1 and 4.2, respectively. Secretion levels of inflammatory 
cytokines produced by CTV-1 and K562 target cells are shown in Figure 4.3. 
Inflammatory cytokine secretion by NK cells after 6 hours and 16 hours of 
stimulation are shown in Figure 4.4. 
4.4.1.1 IL-1β 
Resting NK cells produced low levels of the pro-inflammatory cytokine IL-1β, 
(mean at 6h, 6.03 ± 2.9 pg/ml; n = 4) (mean at 16h, 12.08 ± 1.8 pg/ml; n = 4). Target 
cell stimulation with CTV-1 or K562 cells for 6 hours induced a 7-fold (mean, 43.95 
±28.36 pg/ml; n=4) and 4-fold (mean, 21.99 ± 3.53 pg/ml; n=4) increase in IL-1β 
levels, respectively, compared with resting NK cells. Overnight incubation with 
K562 cells resulted in an 8-fold increase in IL-1β (mean, 38.27 ± 15.29 pg/ml; n=3) 
compared with resting NK cells. By contrast, NK cells incubated with CTV-1 cells 
overnight secreted lower levels of IL-1β (mean, 16.44 ± 24.94 pg/ml; n=3) than those 
observed after a 6-hour incubation. Stimulation with IL-2 for 6 hours generated a 7-
fold increase in IL-1β production (mean, 40.69 ± 40.56 pg/ml; n=3) compared with 
resting NK cells, and IL-2 levels increased a further 5-fold (mean, 192.1 ± 211.1 
pg/ml; n=3) after overnight incubation. Overnight incubation with the activating 
cytokines IL-7, IL-12, or IL-15 induced a 2-fold (mean, 19.62 ± 25.47 pg/ml; n=3), 
12-fold (mean, 142.81 ±165.6 pg/ml; n=3) and 2-fold (mean, 22.56 ± 32.40 pg/ml; 
n=3) increase in IL-1β production, respectively, compared with resting NK cells. 
Stimulation with IL-21 showed no difference from resting NK cell secretion levels 
(mean, 14.77 ± 12.35 pg/ml; n=3). IL-1β was not detected in supernatants harvested 
from CTV-1 or K562 cells incubated alone. 
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4.4.1.2 IL-1RA 
Low to intermediate levels of IL-1 receptor antagonist (IL-1RA), a natural inhibitor 
of the pro-inflammatory effect of IL-1β (Perrier et al. 2006) were secreted by resting 
NK cells (mean at 6h, 6.4 ± 2.3 pg/ml; n = 4) (mean at 16h, 43.21 ± 43.01 pg/ml; n = 
4) . Stimulation with CTV-1 or K562 induced a 7-fold increase (mean, 45.12 ± 45.48 
pg/ml; n=4, and 43.30 ± 10.37 pg/ml; n=4, respectively) in IL-1RA production after 
6 hours, compared with resting NK cells. Overnight incubation with K562 cells 
increased IL-1RA secretion 2-fold (mean, 88.75 ± 26.01 pg/ml; n=4), compared with 
resting NK cells. Conversely, overnight incubation with CTV-1 cells resulted in 
lower levels of IL-1RA secretion (mean, 35.75 ± 25.32 pg/ml; n=4) than those 
detected after a 6-hour incubation. IL-2 stimulation resulted in a 4-fold increase in 
IL-1RA secretion after 6 hours of incubation with NK cells (mean, 26.98 ± 23.07 
pg/ml; n=4), which further increased 4-fold after overnight incubation (mean, 108.9 
± 78.95 pg/ml; n=3). An overnight incubation with IL-7, IL-12, IL-15 or IL-21 
induced a 3-fold (mean, 142.5 ± 61.75 pg/ml; n=3), 4-fold (mean, 171.3 ± 127.4 
pg/ml; n=3), 3-fold (mean, 119.2 ± 116.8 pg/ml; n=3), and 2-fold (mean, 95.63 ± 
47.21 pg/ml; n=3) increase in IL-1RA production, respectively, compared with 
resting NK cells. K562 and CTV-1 cells incubated alone secreted low levels of IL-
1RA (mean, 2.25 ± 1.3 pg/ml; n=3, and mean, 3.92 ± 8.2 pg/ml;n=3). 
4.4.1.3 IL-6 
Moderate levels of IL-6 were secreted by resting NK cells (mean at 6h, 25.7 ± 11.7 
pg/ml, n = 4) (mean at 16h, 157.8 ± 148.6 pg/ml, n = 4). Stimulation with CTV-1 or 
K562 cells for 6 hours induced a 2-fold (mean, 41.86 ± 31.33 pg/ml; n=4) and 3-fold 
(mean, 83.15 ± 20.98 pg/ml; n=4) increase in IL-6 secretion compared with resting 
NK cells, respectively. These levels increased a further 2-fold (mean, 67.07± 46.73 
pg/ml; n=3) and 3-fold (mean, 247.7 ± 111.1 pg/ml; n=3) after overnight incubation 
with CTV-1 or K562 cells, respectively. IL-6 levels detected in supernatants from 
NK cells stimulated with IL-2 for 6 hours were 4-fold higher (mean, 95.55 ± 102.9 
pg/ml; n=3) than resting NK cells incubated alone. Overnight incubation with IL-2 
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increased IL-6 levels a further 9-fold (mean, 868 ± 976.4 pg/ml; n=3) after overnight 
incubation. NK cells incubated with IL-7, IL-12, IL-15 or IL-21 overnight showed a 
4-fold (mean, 582.9 ± 769 pg/ml; n=3), 4-fold (mean, 665.4 ± 767.6 pg/ml; n=3), 3-
fold (mean, 478.1 ± 715.5 pg/ml; n=3) and 2-fold (mean, 346.3 ± 421.2 pg/ml; n=3) 
increase in IL-6 secretion compared with resting NK cells, respectively. Supernatants 
from CTV-1 cells incubated alone did not show detectable levels of IL-6, whereas 
K562 cells secreted low levels of IL-6 (mean, 12.60 ± 2.29 pg/ml; n=3). 
4.4.1.4 IL-8 
Resting NK cells incubated without target cells or exogenous cytokines produced 
high amounts of IL-8 (mean at 6h, 215.09 ± 100.3 pg/ml; n = 4) (mean at 16h, 4171 
± 5347 pg/ml; n = 4). After 6 hours of stimulation, CTV-1 increased IL-8 production 
3-fold (mean, 624.4 ± 467.5 pg/ml; n=4, p=0.0002), and K562 increased IL-8 
production 12-fold (mean, 2570 ± 365.9 pg/ml; n=4, p<0.0001), compared with 
resting NK cells. IL-8 levels detected in supernatants from NK cells stimulated with 
IL-2 for 6 hours were 3-fold higher (mean 675.8 ± 630.8 pg/ml; n=3, p=0.001) than 
resting NK cells incubated alone. Overnight stimulation with K562, IL-7 or IL-21 
resulted in IL-8 levels that were 3-fold (mean, 11509 ± 5799 pg/ml; n=3, p<0.0001), 
3-fold (mean, 10956 ± 3006 pg/ml; n=3, p<0.0001) and 2-fold (mean, 8189 ± 4736 
pg/ml; n=3, p=0.0067) higher than resting NK cells, respectively, whereas overnight 
incubation with CTV-1, IL-2, IL-12 or IL-15 resulted in the secretion of IL-8 at 
levels that were equal to or lower than those secreted by resting NK cells. Both CTV-
1 and K562 cells secreted low levels of IL-8 (mean, 58.88 ± 33.24 pg/ml, n=3 and 
mean, 207.1 ± 37.96 pg/ml, n=3, respectively). 
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4.4.1.5 GM-CSF 
GM-CSF was not detected in supernatants collected from resting or target cell-
stimulated NK cells. Exogenous cytokine stimulation by IL-2 (mean, 73.45 ± 81.60 
pg/ml; n=3), IL-7 (mean, 9.767 ± 14.24 pg/ml; n=3), IL-12 (mean, 33.12 ± 39.98 
pg/ml; n=3) and IL-15 (mean, 78.42 ± 129.8 pg/ml; n=3), but not IL-21 induced GM-
CSF secretion by NK cells after overnight incubation. GM-CSF was not detected in 
supernatants from CTV-1 or K562 cells incubated alone.  
4.4.1.6 TNF-α 
Trace amounts of TNF-α were detected in supernatants from resting NK cells 
incubated alone (mean at 6h, 1.92 ± 0.899 pg/ml; n = 6) (mean at 16h, 7.38 ± 
4.7pg/ml; n = 6). Target cell stimulation for 6 hours with CTV-1 or K562 induced a 
24-fold (mean, 46.51 ± 48.52 pg/ml; n=4) and 4-fold (mean, 8.231± 4.67 pg/ml; n=4) 
increase in TNF-α production compared with resting NK cells, respectively. 
Overnight incubation with CTV-1 resulted in lower levels of TNF-α (mean, 8.361 ± 
15.03 pg/ml; n=3), than levels observed after a 6-hour incubation with the leukemic 
cell line. Conversely, NK cells co-incubated with K562 cells overnight showed a 2-
fold increase (mean, 13.67 ± 3.284 pg/ml; n=3) in TNF-α production compared with 
that collected after 6 hours. IL-2 stimulated NK cells secreted moderate levels of 
(mean, 24.74 ± 33.57pg/ml; n=4) and higher levels after incubation for 16 hours 
(mean, 75.01 ± 55.57 pg/ml; n=6). Overnight stimulation with other exogenous 
cytokines lead to the secretion of moderate to high levels of TNF-α (LAK-7 mean, 
58.95 ± 36.58; n=3; LAK-12 mean, 125.9 ± 146.38; n=3; LAK-15 mean, 51.25 ± 
73.99; n=3). CTV-1 cells, but not K562 cells were shown to secrete low levels of 
TNF-α (mean, 2.821 ± 6.41 pg/ml; n=3).  
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Figure 4.1 Secretion of inflammatory cytokines by resting and target cell-stimulated 
NK cells 
Freshly isolated resting NK cells (2 x 10
5
) were incubated alone, with CTV-1 (4 x 10
5
), or 
K562 (4 x 10
5) target cells in 200 μl CM. After a 6-hour incubation at 37°C and 5% CO2, 
supernatants were harvested and the cytokines IL-1β, IL-1Rα, IL-6, IL-8, GM-CSF and 
TNF-α were quantified using a multiplex immunoassay. Graph represents mean values ± SD 
of 3-6 donors, p values < 0.05 were considered statistically significant and are indicative of 
significant difference relative to unstimulated NK cells at the same time point. 
rNK indicates resting NK cells; *P<0.05; **P<0.005; ***P < 0.0005. 
 
rNK 
NK+CTV-1 
NK+K562  
*** 
*** 
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Figure 4.2 Secretion of inflammatory cytokines by cytokine-stimulated NK cells.  
Resting NK cells (2 x 10
5
) were washed twice and mixed with  IL-2 (200IU/ml) IL-7, IL-15, 
IL-21 (10 ng/ml), or IL-12 (20 ng/ml).  After a 16-hour incubation at 37ºC, 5 % CO2 in CM, 
supernatants were harvested and the cytokines IL-1β, IL-1Rα, IL-6, IL-8, GM-CSF and 
TNF-α were quantified using a multiplex immunoassay. Graph represents mean values ± SD 
of 3-6 donors, p values < 0.05 were considered statistically significant and are indicative of 
significant difference relative to unstimulated NK cells at the same time point. 
LAK-2, -7, -12 and-15 indicate lymphokine-activated NK cells using IL-2, -7, -12 or -15; 
*P<0.05; **P<0.005; ***P < 0.0005.  
LAK-7 
LAK-21 
LAK-12 
LAK-2 
*** 
** 
LAK-15 
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Figure 4.3 Secretion of inflammatory cytokines by tumour cells.  
CTV-1 or K562 cells (2 x 10
5 
in 200 l CM) were incubated at 37°C and 5% CO2 for 16 
hours. Supernatants were harvested and the cytokines IL-1β, IL-1Rα, IL-6, IL-8, GM-CSF 
and TNF-α were quantified using a multiplex immunoassay. Graph represents mean values ± 
SD of 3-6 replicates.  
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Figure 4.4 Kinetics of NK cell secretion of inflammatory cytokines upon stimulation 
with CTV-1, K562 or IL-2. 
Freshly isolated resting NK cells (2 x 10
5
) were incubated with CTV-1 (4 x 10
5
), K562 (4 x 
10
5
) or IL-2 (200IU/ml) in 200 μl CM at 37°C and 5% CO2 . Supernatants were harvested at 
6 hours and 16 hours and the concentrations of IL-1β, IL-1Rα, IL-6, IL-8, GM-CSF and 
TNF-α were determined by a multiplex immunoassay. Values represent the mean of 3–6 
donors.  
NK+CTV-1 
NK+K562 
NK+IL-2 
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4.4.2 Th1/Th2 cytokines  
Levels of Th1/Th2 cytokines (IL-2, IL-2R, IL-4, IL-5, IL-10, IFN-γ) secreted by 
resting,  target cell-stimulated and cytokine-stimulated NK cells are shown in Figures 
4.5 and 4.6, respectively. Th1/Th2 cytokine secretion levels of CTV-1 and K562 
target cells are shown in Figure 4.7. Th1/Th2 cytokine secretion by NK cells after 6 
hours and 16 hours of stimulation are shown in Figure 4.8. 
4.4.2.1 IFN-γ 
Resting NK cells did not secrete detectable levels of IFN-γ after 6 hours of 
incubation alone and secreted trace amounts after overnight incubation (mean, 1.72 ± 
0.8 pg/ml; n = 4). Short incubations with the target cell lines CTV-1 or K562 induced   
the release of low amounts of IFN-γ production (mean, 11.61 ± 13.64 pg/ml; n=4) 
and (mean, 1.6 ± 1.3 pg/ml; n=4), respectively. Overnight incubation with K562 led 
to a slight increase in IFN-γ levels (mean, 2.3 ± 1.72 pg/ml; n=3), whereas co-
incubation with CTV-1 overnight did not (mean, 6.7 ± 9.19 pg/ml; n=3). IL-2 
stimulation for 6 hours induced a 60-fold increase in IFN-γ secretion (mean, 68.8 ± 
80.34 pg/ml; n=3) compared with resting NK cells, which increased a further 15-fold 
after an overnight incubation (mean 928.6, ± 559.9 pg/ml; n=3, p<0.0001). 
Overnight exposure to the cytokines IL-7, IL-12, IL-15 or IL-21 induced a 25-fold 
(mean, 43.1  ± 67.7 pg/ml; n=3), 300-fold (mean, 513.2 ± 609.5 pg/ml; n=3, 
p=0.0001), 326-fold (mean, 554.7 ± 822.2 pg/ml; n=3, p=0.001) and 7-fold (mean, 
12.5 ± 14.33 pg/ml; n=3) increase in IFN-γ production compared with resting NK 
cells, respectively. CTV-1 and K562 cells secreted undetectable levels of IFN-γ. 
4.4.2.2 IL-2R 
IL-2R was weakly secreted by resting NK cells (mean, 0.64 ± 2.4 pg/ml; n = 4). 
After 6 hours of co-incubation with CTV-1, IL-2R levels were significantly higher 
than levels detected in supernatants from resting NK cells (mean, 65.35 ± 80.42 
pg/ml; n=4, p=0.001). Overnight incubation with CTV-1 cells resulted in lower 
levels of IL-2R compared with that in supernatants harvested after 6 hours (mean, 
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52.05 ± 35.07 pg/ml; n=4). Co-incubation with K562 cells induced a moderate 
increase in IL-2R production after 6 hours compared with resting NK cells (mean, 
13.33 ± 1.35 pg/ml; n=4), and secretion levels further increased 6-fold after 
overnight incubation (mean, 82.61 ± 35.91 pg/ml; n=3). Similarly, IL-2 stimulation 
increased IL-2Rα production 33-fold after 6 hours compared with resting NK cells 
(mean, 33.48 ± 41.45 pg/ml; n=3, p=0.006), and levels detected after overnight 
incubation were a further 4-fold higher (mean, 147.16 ± 130.7 pg/ml; n=3). The 
activating cytokines IL-7, IL-12, IL-15 and IL-21 resulted in a 4-fold (mean, 129.38 
± 140.7 pg/ml; n=3, p=0.002), 6-fold (mean, 182.11 ± 217.6 pg/ml; n=3), 4-fold 
(mean, 121.31± 156.4 pg/ml; n=3) and 3-fold (mean, 81.85 ± 78.94pg/ml; n=3, 
p=0.004) increase in IL-2R secretion after overnight incubation, respectively, 
compared with resting NK cells. Supernatants collected from CTV-1 and K562 cells 
did not contain detectable amounts of IL-2R. 
4.4.2.3 IL-2, IL-4, IL-5 and IL-10 
IL-2, IL-4 and IL-5 were secreted at undetectable levels by resting NK cells, target 
cell-stimulated or cytokine-stimulated NK cells. IL-10 secretion by resting NK cells 
and target cell-stimulated NK cells was undetectable. However, low levels of IL-10 
were detected in supernatants from NK cells incubated with the activating cytokines 
IL-2 (mean, 19.35 ± 2.15 pg/ml; n=3), IL-7 (mean, 8.89 ± 2.78 pg/ml; n=3), IL-12 
(mean, 12.93 ± 5.09 pg/ml; n=3), IL-15 (mean, 6.87 ± 1.51 pg/ml; n=3), and IL-21 
(mean, 6.26 ± 1.55 pg/ml; n=3). The target cells CTV-1 and K562 did not secrete 
detectable levels of the cytokines IL-2, IL-4, IL-5 or IL-10.  
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Figure 4.5 Secretion of Th1/Th2 cytokines by resting and target cell-stimulated NK 
cells.  
Freshly isolated resting NK cells (2 x 10
5
) were incubated alone, with CTV-1 (4 x 10
5
), or 
K562 (4 x 10
5
) target cells in 200 μl CM. After a 6-hour incubation at 37°C and 5% CO2, 
supernatants were harvested and the cytokines IFN-γ, IL-2, IL-2R, IL-4, IL-5, and IL-10 
were quantified using a multiplex immunoassay. Graph represents mean values ± SD of 3-6 
donors, p values < 0.05 were considered statistically significant and are indicative of 
significant difference relative to unstimulated NK cells at the same time point. 
rNK indicates resting NK cells; *P<0.05; **P<0.005; ***P < 0.0005. 
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Figure 4.6 Secretion of Th1/Th2 cytokines by cytokine-stimulated NK cells.  
Resting NK cells (2 x 10
5
) were washed twice and mixed with  IL-2 (200IU/ml) IL-7, IL-15, 
IL-21 (10 ng/ml), or IL-12 (20 ng/ml).  After a 16-hour incubation at 37ºC, 5 % CO2 in CM, 
supernatants were harvested and the cytokines IFN-γ, IL-2, IL-2R, IL-4, IL-5, and IL-10 
were quantified using a multiplex immunoassay. Graph represents mean values ± SD of 3-6 
donors, p values < 0.05 were considered statistically significant and are indicative of 
significant difference relative to unstimulated NK cells at the same time point. 
LAK-2, -7, -12 and-15 indicate lymphokine-activated NK cells using IL-2, -7, -12 or -15; 
*P<0.05; **P<0.005; ***P < 0.0005.  
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Figure 4.7 Secretion of Th1/Th2 cytokines by target cells.  
CTV-1 or K562 cells (2 x 10
5 
in 200 l CM) were incubated at 37°C and 5% CO2 for 16 
hours. Supernatants were harvested and the cytokines IFN-γ, IL-2, IL-2R, IL-4, IL-5 and IL-
10 were quantified using a multiplex immunoassay. Graph represents mean values ± SD of 
3-6 replicates.  
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Figure Kinetics of NK cell secretion of Th1/Th2 cytokines upon stimulation with CTV-
1, K562 or IL-2.  
Freshly isolated resting NK cells (2 x 10
5
) were incubated with CTV-1 (4 x 10
5
), K562 (4 x 
10
5
) or IL-2 (200IU/ml) in 200 μl CM at 37°C and 5% CO2. Supernatants were harvested at 
6 hours and 16 hours and the concentrations of IFN-γ and IL-2R were determined by a 
multiplex immunoassay. Values represent the mean of 3–6 donors.  
NK+CTV-1_ 
NK+K562 
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4.4.3 Cytokines II  
Levels of the cytokines IFN-α, IL-7, IL-12p40, IL-13, IL-15 and IL-17 secreted by 
resting, target cell-stimulated and cytokine-stimulated NK cells are shown in Figures 
4.9 and 4.10, respectively. Cytokines II secretion levels of CTV-1 and K562 target 
cells are shown in Figure 4.11. Cytokines II secretion by NK cells after 6 hours and 
16 hours of stimulation are shown in Figure 4.12. 
4.4.3.1 IFN-α 
IFN-α was not detected in supernatants from resting NK cells or target cell 
stimulated NK cells.  Exposure to exogenous cytokines induced the secretion of trace 
amounts of IFN-α; IL-2 (mean, 1.049 ± 0.91 pg/ml; n=3), IL-7 (mean, 1.573 ±  0.4 
pg/ml; n=3), IL-12 (mean, 1.53 ± 0.78  pg/ml; n=3), IL-15 (mean, 1.41 ± 0.44pg/ml; 
n=3) or IL-21 (mean, 0.52 ± 0.34 pg/ml; n=3) of IFN-α. CTV-1 and K562 cells did 
not secrete detectable levels of IFN-α. 
4.4.3.2 IL-7 
IL-7 was secreted at undetectable levels by resting NK cells. Supernatants collected 
after 6 hours of target cell stimulation by CTV-1 (mean, 2.159 ± 7.16 pg/ml; n=3) or 
K562 (mean, 2.466 ± 5.801 pg/ml; n=3) showed low levels of IL-7. Supernatants 
collected after overnight incubation with CTV-1 did not show detectable levels of 
IL-7, whereas low levels (mean, 3.59 ± 6.63 pg/ml; n=3) were detected in the case of 
overnight incubation with K562. Overnight incubation with IL-12 (mean, 10.49 ± 
15.30 pg/ml; n=3) or IL-15 (mean, 21.76 ± 10.82 pg/ml; n=3) induced the highest IL-
7 secretion levels by NK cells. IL-2 and IL-21 had no effect on IL-7 production by 
NK cells. CTV-1 and K562 target cells incubated alone did not produce IL-7. 
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4.4.3.3 IL-12p40/p70 
IL-12p40/p70 was secreted at low levels by resting NK cells (mean at 6h, 1.137 ± 
0.81 pg/ml; n=4) (mean at 16h, 10.01 ± 1.04 pg/ml; n=4) by resting NK cells. Target 
cell stimulation with CTV-1 or K562 for 6 hours increased IL-12p40/p70 secretion 
8-fold (mean, 9.34 ± 2.69 pg/ml; n=3) and 4-fold (mean, 4.253 ± 1.084 pg/ml; n=3), 
respectively, compared with resting NK cells. Overnight incubation with CTV-1 
resulted in IL-12p40/p70 levels similar to those secreted by resting NK cells (mean, 
11.84 ± 3.18 pg/ml; n=3), whereas overnight incubation with K562 resulted in 
secretion levels that were slightly higher than resting NK cells (mean, 16.69 ± 4.16 
pg/ml; n=3). IL-2 stimulation for 6 hours induced a 7-fold increase (mean, 8.142 ± 
2.97 pg/ml; n=3, p=0.001) in IL-12p40/p70 levels compared with resting NK cells, 
which increased a further 3-fold after overnight incubation (mean, 27.31 ± 2.84 
pg/ml; n=3, p=0.004). Overnight exposure to IL-7, IL-12, IL-15 or IL-21 induced a 
6-fold (mean, 59.25 ± 21.90 pg/ml, p=0.003), 20-fold (mean, 204.8 ± 51.84 pg/ml; 
n=3), 6-fold (mean, 63.20 ± 86.93 pg/ml; n=3), and 3-fold (mean, 29.94 ± 35.57 
pg/m; n=3, p=0.007) increase in IL-12p40/p70 production compared with resting NK 
cells. Supernatants from CTV-1 and K562 cells incubated alone did not show IL-
12p40/p70 secretion.  
4.4.3.4 IL-13 and IL-17 
IL-13 was not detected in the supernatants of resting, target cell-stimulated, or 
cytokine-stimulated NK cells. IL-17 was secreted in low amounts by IL-12-activated 
NK cells (mean, 6.13 ± 7.218 pg/ml; n=3). CTV-1 and K562 cells secreted 
undetectable levels of IL-13 and IL-17.  
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4.4.3.5 IL-15 
Resting NK cells secreted undetectable levels of IL-15 after 6 hours and trace levels 
after overnight incubation (mean, 3.958 ± 4.764 pg/ml; n=3). Stimulation with CTV-
1 for 6 hours induced IL-15 secretion (mean, 3.816 ± 6.66 pg/ml; n=3), but 
supernatants collected after overnight incubation were similar to those of resting NK 
cells (mean, 4.09 ± 5.04 pg/ml; n=3). A 6-hour incubation with K562 induced 
moderate levels of IL-15 secretion (mean, 95.77 ± 36.54 pg/ml; n=3, p<0.0001), 
which increased a further 3-fold (mean, 285.1 ± 135 pg/ml; n=3, p<0.0001) after an 
overnight incubation. IL-2 stimulation induced low levels of IL-15 production 
(mean, 2.75± 5.15 pg/ml; n=3) after 6 hours of incubation with NK cells, and levels 
were a further 8-fold higher (mean, 16.85 ± 17.11 pg/ml; n=3) after overnight 
incubation. Overnight incubation with IL-7, IL-12, or IL-21 resulted in a 6-fold 
(mean, 24.10 ± 10.39 pg/ml; n=3), 6-fold (mean, 22.63 ± 22.33 pg/ml; n=3), and 3-
fold (mean, 12.94 ± 3.279 pg/ml; n=3) increase in IL-15 secretion, respectively, 
compared with resting NK cells. CTV-1 and K562 cells did not secrete detectable 
levels of IL-15. 
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Figure 4.8 Secretion of cytokines II by target cell-stimulated NK cells.  
Freshly isolated resting NK cells (2 x 10
5
) were incubated alone, with CTV-1 (4 x 10
5
), or 
K562 (4 x 10
5
) target cells in 200 μl CM. After a 6-hour incubation at 37°C and 5% CO2, 
supernatants were harvested and the cytokines IFN-α, IL-7, IL-12p40, IL-13, IL-15 and IL-
17 were quantified using a multiplex immunoassay. Graph represents mean values ± SD of 
3-6 donors, p values < 0.05 were considered statistically significant and are indicative of 
significant difference relative to unstimulated NK cells at the same time point. 
rNK indicates resting NK cells; *P<0.05; **P<0.005; ***P < 0.0005. 
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Figure 4.9 Secretion of cytokines II by cytokine-stimulated NK cells.  
Resting NK cells (2 x 10
5
) were washed twice and mixed with IL-2 (200IU/ml) IL-7, IL-15, 
IL-21 (10 ng/ml), or IL-12 (20 ng/ml).  After a 16-hour incubation at 37ºC, 5 % CO2 in CM, 
supernatants were harvested and the cytokines IFN-α, IL-7, IL-12p40, IL-13, IL-15 and IL-
17 were quantified using a multiplex immunoassay. Graph represents mean values ± SD of 
3-6 donors, p values < 0.05 were considered statistically significant and are indicative of 
significant difference relative to unstimulated NK cells at the same time point. 
LAK-2, -7, -12 and-15 indicate lymphokine-activated NK cells using IL-2, -7, -12 or -15; 
*P<0.05; **P<0.005; ***P < 0.0005.  
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Figure 4.10 Secretion of cytokines II by target cells.  
CTV-1 or K562 cells (2 x 10
5 
in 200 l CM) were incubated at 37°C and 5% CO2 for 16 
hours. Supernatants were harvested and the cytokines IFN-α, IL-7, IL-12p40, IL-13, IL-15 
and IL-17 were quantified using a multiplex immunoassay. Graph represents mean values ± 
SD of 3-6 replicates.  
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Figure 4.11 Kinetics of NK cell secretion of cytokines II upon stimulation with CTV-1, 
K562 or IL-2.  
Freshly isolated resting NK cells (2 x 10
5
) were incubated with CTV-1 (4 x 10
5
), K562 (4 x 
10
5
) or IL-2 (200IU/ml) in 200 μl CM at 37°C and 5% CO2. Supernatants were harvested at 
6 hours and 16 hours and the concentrations of IFN-α, IL-7, IL-12p40, IL-13, IL-15 and IL-
17 were determined by a multiplex immunoassay. Values represent the mean of 3–6 donors.  
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4.4.4 Chemokines  
Levels of chemokines eotaxin, IP-10, MCP-1, MIG, MIP-1α and MIP-1β secreted by 
resting, target cell-stimulated and cytokine-stimulated NK cells are shown in Figures 
4.13 and 4.14, respectively. Chemokine secretion levels of CTV-1 and K562 target 
cells are shown in Figure 4.15. Chemokine secretion by NK cells after 6 hours and 
16 hours of stimulation are shown in Figure 4.16. 
4.4.4.1 Eotaxin and MIG 
Eotaxin and MIG were not detected in supernatants from resting or target cell-
stimulated NK cells. Overnight stimulation with IL-2, IL-7, IL-12 or IL-21 induced 
NK cell secretion of trace amounts of MIG, but none of these cytokines induced 
detectable levels of eotaxin. IL-15 stimulation resulted in the production of moderate 
MIG levels by NK cells (mean, 13.66 ± 7.73 pg/ml; n=3), but did not induce eotaxin 
secretion. Supernatants from CTV-1 and K562 cultures showed undetectable levels 
of both chemokines.  
4.4.4.2 IP-10 
Trace amounts of IP-10 were detected in supernatants from overnight cultures of 
resting NK cells (mean, 7.78 ± 1.88 pg/ml; n=4). Target cell stimulation with K562 
or CTV-1 for 6 hours resulted in moderate (mean, 12.48 ± 6.94 pg/ml; n=4) and high 
(mean, 1060 ± 550.7 pg/ml; n=3, p<0.0001) levels of IP-10 production, respectively. 
Overnight stimulation with target cells resulted in a further 1.5-fold increase in IP-10 
secretion in the case of K562 (mean, 1541 ± 240 pg/ml; n=3, p<0.0001), whereas 
levels of IP-10 detected after overnight stimulation with CTV-1 were similar to those 
after 6 hours (mean, 12.87 ± 5.96 pg/ml; n=3). Exogenous cytokine stimulation with 
IL-2, IL-7, IL-12, IL-15 or IL-21 induced a 5-fold (mean, 40.74 ± 7.98 pg/ml; n=3), 
3-fold (mean, 25.1 ± 6.34 pg/ml; n=3), 7-fold (mean, 51.46 ± 12.22pg/ml; n=3), 22-
fold (mean, 172.51 ± 63.12 pg/ml; n=3) and 5-fold (mean, 37.3 ± 21.11 pg/ml; n=3) 
increase in IP-10 secretion, respectively, compared with resting NK cells. IL-2-
induced secretion of IP-10 was 4-fold higher after overnight incubation with NK 
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cells compared with levels detected at the 6-hour timepoint (mean, 10.9 ± 4.72 
pg/ml; n=3). IP-10 was not secreted by CTV-1 or K562 cells cultured alone.  
4.4.4.3 MCP-1 
Trace levels of MCP-1 were detected in supernatants from resting NK cells after 
overnight incubation (mean, 1.75 ± 2.02 pg/ml; n=3). Target cell stimulation by 
K562 (mean, 10.38 ± 6.55 pg/ml; n=3), but not CTV-1, induced the secretion of 
higher amounts of MCP-1. Stimulation with IL-2, IL-7, IL-15 or IL-21 induced a 2-
fold (mean, 4.02± 4.5 pg/ml; n=3), 16-fold (mean, 27.99 ± 42.45 pg/ml; n=3), 7-fold 
(mean, 11.91 ± 20.45 pg/ml; n=3) and 9-fold (mean, 16.55 ± 22.87 pg/ml; n=3) 
increase in MCP-1, respectively, compared with resting NK cells. Exposure to the 
activating cytokine IL-12 had no effect on MCP-1 production by NK cells (mean, 
1.54 ± 1.73 pg/ml; n=3). Trace or no amounts of the cytokine were detected in 
supernatants from CTV-1 or K562 cell cultures.  
4.4.4.4 MIP-1α 
MIP-1α was secreted in low or moderate amounts by resting NK cells (mean at 6h, 
2.37 ± 1.4 pg/ml; n = 4) (mean at 16h, 87.04 ± 147.7 pg/ml; n = 4). Co-incubation 
with CTV-1 or K562 cells for 6 hours, resulted in a 107-fold (mean, 253.2 ± 81.2 
pg/ml; n=4) and 14-fold (mean, 34.3 ± 32.76 pg/ml; n=4) increase in MIP-1α 
production, respectively, compared with resting NK cells. Overnight incubation with 
K562 resulted in a 4-fold increase in MIP-1α secretion by NK cells (mean, 137.6 ± 
109 pg/ml; n=3), compared with supernatants collected after 6 hours. In the case of 
CTV-1, however, lower levels were detected in supernatants from overnight co-
cultures (mean, 108.9 ± 147.7 pg/ml; n=3), compared with the 6-hour time point. IL-
2 stimulation of NK cells resulted in a 41-fold increase in MIP-1α secretion 
compared to resting NK cells after 6 hours  (mean, 97.8 ± 155.5 pg/ml; n=3) and a 
10-fold increase after overnight incubation (mean, 894.9 ± 1040 pg/ml; n=3, 
p=0.0002).  Overnight exposure to IL-7, IL-12, IL-15 or IL-21 resulted in 9-fold 
(mean, 780.1 ± 1217 pg/ml; n=3, p=0.002), 31-fold (mean, 2722 ± 3324 pg/ml; n=3, 
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p<0.0001), 11-fold (mean, 920 ± 1555 pg/ml; n=3) and 5-fold (mean, 425.4 ± 639.5 
pg/ml; n=3) increase in MIP-1α secretion by NK cells, respectively, compared to 
resting NK cells.  
4.4.4.5 MIP-1β 
MIP-1β was detected in moderate amounts in supernatants from resting NK cells 
(mean at 6h, 8.4 ± 4.2 pg/ml; n = 4) (mean at 16h, 49.77 ± 68.69 pg/ml; n = 4). 
Target cell stimulation induced a 124-fold (mean, 1042 ± 1367 pg/ml; n=4, 
p=0.0005) and 15-fold (mean, 125.1 ± 114.1 pg/ml; n=4) increase in MIP-1β 
secretion by CTV-1 and K562 cells, respectively, after 6 hours of co-incubation with 
NK cells. Lower levels of MIP-1β were detected in supernatants from overnight co-
cultures with CTV-1 (mean, 319.2 ± 438.9 pg/ml; n=4, p=0.001), compared with 
supernatants collected after 6 hours. In contrast, overnight NK cell co-cultures with 
K562, showed higher levels of MIP-1β (mean, 152.9 ± 145 pg/ml; n=4) than the 6-
hour timepoint. Cytokine stimulation with IL-2, IL-7, IL-12, IL-15 or IL-21 induced 
a 14-fold  (mean, 690.2 ± 709.6 pg/ml; n=3, p=0.002), 11-fold (mean, 555.8 ± 720.4 
pg/ml; n=3) , 33-fold (mean, 1632 ± 1911 pg/ml; n=3) , 17-fold (mean, 852.6 ± 1249 
pg/ml; n=3) and 7-fold (mean, 328.3 ± 383.3 pg/ml; n=3) increase in MIP-1β 
production compared with resting NK cells 
4.4.4.6 RANTES 
Low levels of RANTES were secreted by resting NK cells (mean at 6h, 4.5 ± 5.615 
pg/ml; n=3) (mean at 16h, 11.38 ± 5.88 pg/ml; n=3). Target cell stimulation induced 
a 22-fold (mean, 98.54 ± 108.3 pg/ml; n=3) and 3-fold (mean, 13.02 ± 6.16 pg/ml; 
n=3) increase in RANTES secretion by NK cells, after co-culturing for 6 hours with 
CTV-1 or K562 cells, respectively. Supernatants collected from NK cells co-
incubated with CTV-1 overnight, showed lower secretion levels of RANTES (mean, 
47.3 ± 64.82 pg/ml; n=3) than that detected after 6 hours. However, NK cells co-
incubated with K562 cells overnight, secreted higher levels of RANTES (mean, 
18.19 ± 16.82 pg/ml; n=3) compared with the 6-hour time point. Overnight exposure 
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to IL-2, IL-7, IL-12, IL-15 or IL-21 induced a 9-fold (mean, 102.54 ± 103.1 pg/ml; 
n=3), 3-fold (mean, 38.23 ± 48.58 pg/ml; n=3), 19-fold (mean, 220.37 ± 250.3 
pg/ml), 10-fold (mean, 116.22 ± 156.7 pg/ml; n=3) and 3-fold (mean, 33.92 ± 40.70 
pg/ml; n=3) increase in RANTES production by NK cells, respectively, compared 
with resting NK cells.  
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Figure 4.12 Secretion of chemokines by resting and target cell-stimulated NK cells.  
Freshly isolated resting NK cells (2 x 10
5
) were incubated alone, with CTV-1 (4 x 10
5
), or 
K562 (4 x 10
5) target cells in 200 μl CM. After a 6-hour incubation at 37°C and 5% CO2, 
supernatants were harvested and the cytokines eotaxin, IP-10, MCP-1, MIG, MIP-1α, MIP-
1β  were quantified using a multiplex immunoassay. Graph represents mean values ± SD of 
3-6 donors, p values < 0.05 were considered statistically significant and are indicative of 
significant difference relative to unstimulated NK cells at the same time point. 
 rNK indicates resting NK cells; *P<0.05; **P<0.005; ***P < 0.0005. 
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Figure 4.13 Secretion of chemokines by cytokine-stimulated NK cells.  
Resting NK cells (2 x 10
5
) were washed twice and mixed with  IL-2 (200IU/ml) IL-7, IL-15, 
IL-21 (10 ng/ml), or IL-12 (20 ng/ml).  After a 16-hour incubation at 37ºC, 5 % CO2 in CM, 
supernatants were harvested and the cytokines eotaxin, IP-10, MCP-1, MIG, MIP-1α, MIP-
1β and RANTES were quantified using a multiplex immunoassay. Graph represents mean 
values ± SD of 3-6 donors, p values < 0.05 were considered statistically significant and are 
indicative of significant difference relative to unstimulated NK cells at the same time point. 
LAK-2, -7, -12 and-15 indicate lymphokine-activated NK cells using IL-2, -7, -12 or -15; 
*P<0.05; **P<0.005; ***P < 0.0005.  
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Figure 4.14 Secretion of cytokines by target cells.  
CTV-1 or K562 cells (2 x 10
5 
in 200 l CM) were incubated at 37°C and 5% CO2 for 16 
hours. Supernatants were harvested and the cytokines IP-10, MCP-1, MIG, MIP-1α, MIP-1β 
and RANTES were quantified using a multiplex immunoassay. Graph represents mean 
values ± SD of 3-6 replicates. 
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Figure 4.15 Kinetics of NK cell secretion of chemokines upon stimulation with CTV-1, 
K562 or IL-2.  
Freshly isolated resting NK cells (2 x 10
5
) were incubated with CTV-1 (4 x 10
5
), K562 (4 x 
10
5
) or IL-2 (200IU/ml) in 200 μl CM at 37°C and 5% CO2. Supernatants were harvested at 
6 hours and 16 hours and the concentrations of IP-10, MIP-1α, MIP-1β and RANTES were 
determined by a multiplex immunoassay. Values represent the mean of 3–6 donors.  
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4.5 Discussion 
NK cells play an instrumental role in generating rapid immune responses upon 
recognition of infected or neoplastic cells. These responses are not limited to 
cytotoxic effector mechanisms, but also involve the secretion of immune modulatory 
cytokines and chemokines, which aid in the clearance of altered cells and the 
development of an adaptive immune response (Vivier et al. 2008). The set of 
experiments described in this Chapter aimed to define the cytokine and chemokine 
profiles of peripheral blood NK cells upon stimulation with tumour target cells or 
exogenous cytokines. 
NK cell effector responses are determined by the engagement of a multitude of 
germline-encoded receptors with specific ligands on the cell membrane of target 
cells. The combination and intensity of ligand expression dictate the degree of NK 
cell cytotoxic activity and the susceptibility of target cells to NK cell lysis (Bryceson 
et al. 2005;Bryceson et al. 2009;Lanier 2003). A similar hierarchy is observed for 
cytokine release upon NK cell interactions with target cells depending on variations 
in the degree of activating NK cell receptor engagement (Fauriat et al. 2010). Recent 
evidence suggests that NK cell cytokine secretion is distinct from cytotoxicity, as 
indicated by different signalling requirements (Bryceson et al. 2009), trafficking and 
secretion pathways, dependency on recycling endosomes (RE) and non-polarized 
release (Reefman et al. 2010). Thus, CTV-1 target cells expressing ligand 
combinations that are insufficient to trigger NK cell cytotoxicity can still induce 
ample production of cytokines in NK cells.  
An early feature of the NK cell immune response is the production of chemokines, 
which play a pivotal role in activating and directing other activated NK cells and 
leukocytes to target sites. Temporally, the secretion of chemokines has been shown 
to precede other cytokines and require less stimulation than cytokine production or 
degranulation (Bryceson et al. 2005;Fauriat at al. 2010). Engagement of individual 
activating receptors 2B4 or NKG2D on resting NK cells is sufficient to trigger 
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chemokine secretion and the co-engagement of additional receptors can accelerate 
and enhance the level of chemokines secreted (Fauriat et al. 2010). The results in this 
Chapter show NK cells that have completed the priming stage via stimulation with 
CTV-1 or exogenous cytokines demonstrate chemokine profiles that are distinct from 
NK cells that have completed the priming and triggering stages through target cell 
recognition of K562 cells. NK cells incubated with CTV-1 or exogenous cytokines 
produced ample amounts of MIP-1α, MIP-1β, and RANTES, but very low amounts 
of IP-10. Conversely, K562-stimulated NK cells produced high levels of IP-10, and 
low levels of MIP-1α, MIP-1β, and RANTES. This suggests that it is the activation 
stage, rather than the type of stimulus that is influencing the chemokine secretion 
profile observed. Notably however, CTV-1 stimulation consistently induced higher 
levels of chemokine production than IL-2 stimulation after 6 hours of co- incubation 
with NK cells, demonstrating that the kinetics of chemokine secretion is dependent 
on the type of stimulus. 
Secretion of the cytokines TNF-α and IFN-γ were previously reported to require 
greater receptor cooperation and occur at later time points after stimulation, relative 
to chemokine secretion (Bryceson et al. 2006 ;Fauriat et al. 2010). TNF-α secretion 
can be induced by the co-engagement of the activating receptors 2B4 and NKG2D, 
whereas IFN-γ secretion requires additional LFA-1-dependent signalling (Fauriat et 
al. 2010). In this Chapter, CTV-1 stimulation induced production of both cytokines, 
which suggests that the minimal requirements for receptor engagement are met. 
These results are inconsistent with studies by Bryceson et al. demonstrating that the 
minimal requirements for IFN-γ secretion are the same as natural cytotoxicity, since 
CTV-1 stimulation induces IFN-γ production but does not trigger cytotoxicity in NK 
cells. Strikingly, CTV-1 stimulated the release of TNF-α and IFN-γ at levels that 
were approximately 7-fold higher than K562 stimulation after a 6-hour incubation 
with NK cells. Co-stimulation of receptors by engagement of LFA-1 has been shown 
to accelerate and increase cytokine secretion in NK cells (Fauriat et al. 2010). CTV-1 
cells express the intracellular adhesion molecule (ICAM)-1, the natural ligand for 
LFA-1, whereas K562 cells do not. It is possible that CTV-1 has a better ligand 
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profile for the induction of cytokine secretion. It is also possible that NK cells that 
have been primed are more responsive in terms of cytokine secretion than NK cells 
that have gone through target cell priming and killing, as in the case of K562 
stimulation.  
Previous studies assessing the relationship between the production of chemokines 
and cytokines revealed that the production of TNF-α and IFN-γ were contained 
within the chemokine-producing NK cell subset (Fauriat et al. 2010).  The majority 
of IFN-γ producing NK cells were also shown to secret TNF-α, but not vice versa. 
This study showed the graded response in factor release by NK cells and established 
a hierarchy based on the different activation thresholds required for chemokine < 
TNF-α < IFN-γ release. Engagement of individual activating receptors on resting NK 
cells suffices for chemokine secretion, to alert and recruit other immune cells, 
whereas more complex interactions are required to induce TNF-α and IFN-γ 
secretion. Results in this Chapter show that the engagement of ligands on CTV-1 
target cells by activating NK cell receptors was sufficient to induce chemokine, TNF-
α and IFN-γ secretion. It is important to note that intracellular expression of 
cytokines can be induced with less stringent activating signals (i.e. individual 
receptor engagement) without detection of secretion (Fauriat et al. 2010a). This level 
of NK cell regulation that precedes cytokine exocytosis was not explored here, but 
deserves further investigation. 
When the relationship between degranulation and cytokine production was 
investigated previously, CD107a expression did not correlate with IFN-γ or TNF-α 
production (Fauriat et al. 2010a). Although this was justified by differences in 
response kinetics, accumulating evidence on the differential mechanisms of cytokine 
secretion and cytotoxicity in NK cells as well as the data highlighted here, suggest 
the need to view the two NK cell functions independently (Reefman et al. 2010). It is 
important to note that in contrast to other activating receptors, the engagement of 
CD16 is sufficient to induce the secretion of chemokines, IFN-γ and TNF-α and 
degranulation (Bryceson et al. 2006;Bryceson, et al. 2009;Fauriat et al. 2010). The 
strong propensity of CD16 to induce cytotoxicity and cytokine secretion in NK cells 
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is based on antibody-dependent mechanisms. Evidence that these effector functions 
are independently regulated, and that in some cases the amount of cytokine secretion 
does not relate to cytolytic activity of NK cells, suggests that it is possible to extend 
our view of antibody-dependent cellular cytotoxicity as distinct from antibody-
dependent cytokine secretion.  
Activation and proliferation of NK cells is influenced by direct contact with target 
cells as well as the local cytokine milieu. These cytokines provide a means of 
amplifying the effect of NK cells in the early phase of the immune response and act 
as co-stimulators with target cells to initiate NK cell cytotoxicity and further 
cytokine production. The Th1/Th2 and pro-/anti-inflammatory balance in the NK-
target cell microenvironment can modulate NK cell secretory responses toward 
tolerance or immunity (Elenkov and Chrousos 1999;Elenkov and Chrousos 2002). 
Type 1 cytokines such as IL-2, IL-12 and IL-15 are involved in Th1 immune 
responses and induce cell-mediated immunity. By contrast, type 2 cytokines such as 
IL4, IL-5, IL-6, IL-10 and IL-13 are involved in Th2 immune responses, which 
promote humoral immunity against tumours and/or immune tolerance. Consistent 
with previous findings, resting and target cell-stimulated NK cells did not secrete the 
cytokines IL-4, IL-5, IL-7, IL-10, IL-13, IL-17 or GM-CSF (Fauriat et al. 2010a). 
Some of these cytokines have previously been reported to be secreted by NK cells 
upon stimulation with exogenous cytokines (Warren et al. 1995;Warren et al. 1996), 
and the findings presented here demonstrate secretion of IL-7, IL-10, IL-17 and GM-
CSF, but not IL-4, IL-5 or IL-13, in response to exogenous cytokine stimulation. 
Other pro-inflammatory/Th1 cytokines such as IL-1β, IL-1RA, IL-6, IL-8, IL-12 and 
IL-15 were secreted by resting NK cells and augmented by target cell or exogenous 
cytokine stimulation. Notably, NK cells stimulated with CTV-1 produced the highest 
levels of IL-1β, IL-1RA and IL-12 after a short incubation, which suggests the 
specific induction of early-phase inflammatory signalling.  
Other than its role in enhancing in vivo anti-tumour inflammatory responses and 
promoting IFN-γ secretion (Trinchieri 1995a;Trinchieri 1995b), IL-12 is central to 
the generation of NK cells with memory-like features (Sun et al. 2012). NK cells can 
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be altered after in vitro priming to respond more robustly on subsequent stimulation. 
Evidence that NK cells can undergo clonal expansion and mediate secondary 
immune responses has been demonstrated following priming with viral targets or 
exogenous cytokines, as well as after sensitization with haptens (Min-Oo et al. 
2013;Sun et al. 2011). The precise signals that promote the generation of long-lived 
memory NK cells are not clearly defined and the mechanisms by which NK cells are 
modified after an initial activation to respond more vigorously on subsequent 
stimulation are not understood. NK cells primed with CTV-1 have been shown to 
maintain their primed status longer than cytokine-primed NK cells (North et al. 
2007;Sabry et al. 2011). In this chapter, CTV-1 stimulation was shown to induce the 
highest secretions of IL-12 after short incubation. The role of IL-12 in NK cell 
priming for the maintenance of tumour-activation signals and the development of NK 
memory-like features should be investigated in future experiments.  
Any immune challenge that threatens the stability of the internal milieu can be 
regarded as a ‘stressor’, which can activate the stress system to further modulate the 
local pro-/anti-inflammatory cytokine balance (Elenkov and Chrousos 1999;Elenkov 
and Chrousos 2002). As such, the presence of tumour cells can induce the release of 
stress hormones like glucocorticoids and catecholamines to directly influence in vivo 
NK cell responses toward suppression or activation. Alternatively, tumour cells can 
release cytokines to activate components of the stress system and indirectly shape 
NK cell cytokine secretion. NK cells primed by CTV-1 secreted high levels of IL-1β, 
IL-6 and TNF-α, which are the main cytokines associated with stress system 
activation. Tumour target cells used in these experiments were also observed to 
release several soluble factors like IL-1β, IL-6, IL-8, IL-12, IL-15 and IP-10. In most 
cases, K562 cells showed higher cytokine secretion than CTV-1, which can partly 
explain their greater susceptibility to NK cell-mediated immune responses However, 
evidence that the stress system can shift the equilibrium between anti-inflammatory 
and pro-inflammatory cytokines in either direction makes it difficult to determine the 
effect of target cell cytokine secretion on NK cell activity.  
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Recent studies have shown CD56
dim
 rather than CD56
bright
 NK cells to be more 
prominent producers of cytokines upon target cell recognition (Fauriat et al. 2010). 
The results described in this Chapter are mainly representative of CD56
dim
 NK cell 
responses, since they comprise the majority of PB NK cells. Data here further 
support evidence that CD56
dim
 NK cells are an important source of pro-inflammatory 
cytokines during early immune responses and can respond vigorously in terms of 
cytokine and chemokine production after contact with target cells or exposure to 
cytokines. CD56
dim
CD16
–
 NK cells were previously reported as the main subset 
exhibiting anti-tumoural activity (Fauriat et al. 2010;Penack et al. 2005, Chapter 3). 
NK cells primed with CTV-1 were shown in Chapter 3 to downregulate CD16 
expression. Thus, future investigations should aim to define the cytokine secretion 
profile of NK cell CD56
dim
CD16
+/-
 subsets.  
In conclusion, the results presented in this Chapter provide insight into the regulation 
of cytokine secretion in resting NK cells after activation with different stimulating 
mechanisms. NK cell secretory responses enable them to act as primary initiators of 
the immune response by relaying activating signals from other activated immune or 
stressed cells. Fauriat et al. previously showed that in contrast to cytokine 
stimulation, target cell recognition by resting NK cells induces a pro-inflammatory 
cytokine profile characterized by MIP-1α, MIP-1β, RANTES, TNF-α and IFN-γ. 
Interestingly, stimulation with CTV-1 cells consistently induced the secretion of 
these cytokines at a much higher rate than that of K562 cells after a short incubation. 
A possible explanation for enhanced CTV-1 stimulation of cytokine secretion is that 
CTV-1-stimulated NK cells that are primed but have yet to initiate the process of 
cytotoxic killing are more responsive than K562-stimulated NK cells that have gone 
through the full activation cycle of priming and triggering stages. Another 
explanation lies in the ligand expression profile of CTV-1 cells, which might hold 
the code for better synergy among NK cell activating receptors for optimal cytokine 
secretion. NK cell functional responses can be anti-viral, anti-tumoural or 
immunomodulatory, depending on the type of threat faced by the immune system 
and the activating NK cell signals received. The results in this Chapter demonstrate 
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significant differences in NK cell cytokine secretory responses to tumour target cells 
and exogenous cytokines. This should be taken into consideration in the development 
of strategies involving ex vivo stimulation of NK cells to enhance NK cell functional 
properties for use in cellular immunotherapy.  
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Chapter 5 Dissecting the tumour-priming signal 
5.1 Introduction 
NK cells express a wide array of activating cell surface receptors that can be engaged 
by various ligands on tumour cells to induce cytokine secretion and target cell lysis. 
Resting NK cells require the co-engagement of several activating receptors to 
progress through the priming and triggering stages of NK cell activation (Bryceson et 
al. 2006). Upon contact with a susceptible target cell, an NK cell goes through 
discrete events of cell adhesion, conjugate formation, lytic granule polarization and 
release (Orange 2008).  
 
Strong adhesion to target cells is mediated by the β2 integrin, lymphocyte function-
associated antigen (LFA)-1, which is a heterodimer of CD11a and CD18 (Carpen et 
al. 1991;Helander and Timonen 1998). Signaling through LFA-1 also contributes to 
early events in NK cell cytotoxicity, leading to granule polarization (Barber et al. 
2004;Bryceson et al. 2005). CTV-1 cells express the intercellular adhesion molecule 
(ICAM)-1, the natural ligand for LFA-1. Engagement of LFA-1 by ICAM-1 has been 
shown to be important for the formation of stable conjugates between NK cells and 
target cells, in order to create the synergy between activating receptors that is 
necessary for efficient target cell lysis (Barber et al. 2004;Bryceson et al. 2009). 
CTV-1 cells also express several other ligands for NK cell co-activation, including 
those for CD2 and NKG2D. Both these receptors have been shown to synergize with 
LFA-1 to enhance resting NK cell activation (Bryceson et al. 2006;Bryceson et al. 
2009;Katodritou et al.2011;North et al. 2007).  
 
In this Chapter, the critical priming ligands provided by CTV-1 for NK cell 
activation were investigated. In addition, a bead-based strategy to replicate the CTV-
1 priming signal was devised, with the objective of achieving activation of NK cells 
in the absence of tumour target cells.  
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5.2 Experimental Aims 
The aims of the set of experiments described in this Chapter were: 1) to identify the 
critical ligands provided by CTV-1 cells for the tumour-priming of resting NK cells; 
and 2) to devise methods to replace CTV-1-mediated priming of NK cells with bead-
mediated priming. Ligands for LFA-1, CD2 and NKG2D NK cell receptors were 
investigated to confirm their role in the delivery of the tumour-priming signal. 
Thereafter, methods of microbead-mediated stimulation targeting LFA-1, CD2 and 
NKG2D were optimized in order to replicate the tumour-priming signal in the 
absence of CTV-1. Parameters optimized included the type of bead, bead:NK cell 
ratios, ligand:ligand ratios and the co-incubation period.  
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5.3 Methods 
5.3.1 Blockade studies  
To investigate the involvement of LFA-1, CD2 and NKG2D in CTV-1-mediated NK 
cell priming, purified CD56
+
 NK cells from normal donors were pre-incubated for 30 
mins at room temperature in the presence or absence of saturating concentrations of 
antibodies. After washing with HBSS, and overnight co-incubation of NK cells (1 x 
10
6 
cells) with CTV-1 (2 x 10
6
 cells), immunophenotyping was carried out for the 
analysis of antigen expression (MACS Quant Analyzer) with isotype controls used 
for every experiment. NK cell activation was also determined by evaluating NK cell 
activity against NK-resistant RAJI cells in a 4-hour cytotoxicity assay. Statistical 
comparisons between treatments were performed using the multiple t-test, corrected 
for multiple comparisons with the Holm-Sidak method. Results are presented as 
mean ± SD. Corrected P values < 0.05 were considered statistically significant. 
Statistical analyses were performed with GraphPad Prism v.6 software. 
 
5.3.2 Bead Stimulation 
5.3.2. 1 Dynabeads Sheep anti-mouse IgG  
Dynabeads Sheep anti-Mouse IgG have a diameter of 4.5m. They are uniform 
superparamagnetic polystyrene beads coated with polyclonal Sheep anti-Mouse IgG 
antibodies. Dynabeads were washed before use by resuspending in the vial, 
transferring 50 l to a tube and adding 1ml of PBS buffer with 0.1% BSA, pH 7.4. 
The tube was placed in a magnet for 1 minute and the supernatant was discarded. 
After removing the tube from the magnet, the Dynabeads were resuspended in the 
same volume of buffer as the initial volume of Dynabeads used (50 l). Thereafter, 
washed beads were transferred to a tube and 1.5 g of each primary monoclonal 
antibody (mAb) added: anti-LFA-1 (R7.1), anti-CD2 (RPA 2.11) and anti-NKG2D 
(149810). After incubation for 1 hour at 4 ºC with rotation, the antibody-beads 
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complex was washed again by placing in a magnet for 1 min and discarding the 
supernatant. The beads were washed twice using 1ml of buffer. After removing the 
tube from the magnet, Dynabeads were resuspended in 50 l PBS buffer with 0.1% 
BSA, pH 7.4. Beads were then used to stimulate NK cells at a ratio of 8 beads per 
cell. Dynabeads (4 × 10
6
) coated with saturating amounts of mAb, were incubated 
with resting NK cells (5 × 10
5) in 500 μl RPMI supplemented with 10% human 
serum for the indicated duration at 37°C. The cultures were rotated end-over-end 
during the stimulation. For each primary mAb, coating of Dynabeads was ≥ 98% 
efficient as determined by flow cytometry.  
 
5.3.2. 2 Dynabeads Protein G  
Dynabeads coupled to Protein G were then used to generate an artificial priming 
signal so that cognate ligands, instead of mAbs, engaged activating NK cell 
receptors. Dynabeads Protein G have a diameter of 2.5m. Beads were resuspended 
by vortexing for >30 seconds and then transferred to a fresh tube. The tube was 
placed on a magnet to separate the beads from the solution, and the supernatant was 
removed. The tube was removed from the magnet, and 1.5 g of recombinant Human 
ICAM-1 Fc Chimera, recombinant Human MICA Fc Chimera, or anti-CD2 (RPA 
2.11) were added to the Dynabeads. CD15 was not used as it is not commercially 
available. The beads were then incubated for 30 minutes at room temperature with 
rotation. Thereafter, the tube was placed on a magnet and the supernatant removed. 
Beads were then used to stimulate NK cells at a ratio of 8 beads per cell. Dynabeads 
(4 × 10
6
) coated with saturating amounts of mAb, were incubated with resting NK 
cells (5 × 10
5) in 500 μl RPMI supplemented with 10% human serum for the 
indicated duration at 37°C. The cultures were rotated end-over-end during the 
stimulation. Coating of Dynabeads was ≥ 98% efficient as determined by flow 
cytometry.  
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5.4 Results 
5.4.1 Critical ligands provided by CTV-1 for tumour-priming 
5.4.1.1 LFA-1-mediated tumour priming of NK cells 
LFA-1 provides early signals in NK cell cytotoxicity leading up to granule 
polarization (Barber et al. 2004;Bryceson et al. 2005). Ligation of LFA-1 on NK 
cells to its ligand ICAM-1 on target cells specifically contributes to the stability of 
the immunological synapse with target cells (Bryceson et al. 2006;Bryceson et al 
2009). In the first set of experiments, the ability of anti-ICAM-1 mAbs to block 
LFA-1-mediated tumour priming of NK cells was investigated.  
 
Figure 5.1 shows that ICAM-1 blockade reduced CTV-1-mediated priming of NK 
cells, as measured by CD69 expression (mean decrease, 27.4 ± 5.48%, n=4; p = 
0.014) and CD25 expression (mean decrease, 34.1 ± 3.14%, n=4; p = 0.03). In 
addition, as shown in Figure 5.2, pre-incubation with anti-ICAM-1 mAbs 
significantly reduced the lytic activity of CTV-1-primed NK cells (mean decrease, 
24.0 ± 10.5%, n=4; p = 0.019). 
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Figure 5.1 Effect of ICAM-1 blockade on CTV-1-mediated priming of NK cells 
CTV-1 cells were pre-incubated with saturating concentrations of anti-ICAM-1 or anti-CD56 
mAbs and co-cultured with resting NK cells from normal volunteer donors for 16 hours. 
Resting and tumour-primed NK cells were then tested for: (A) CD69 expression; and (B) 
CD25 expression by flow cytometry. Data presented are the mean (± SD) percentage of cells 
expressing CD69 or CD25, respectively. 
rNK indicates resting NK cells; TpNK, tumour-primed NK cells by co-incubation with CTV-
1; *p < 0.05. 
  
(A) 
(B) 
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Figure 5.2 Effect of ICAM-1 blockade on lytic activity of CTV-1-primed NK cells. 
CTV-1 cells were pre-incubated with saturating concentrations of anti-ICAM-1 or anti-CD56 
antibodies and co-cultured with resting NK cells from normal volunteer donors  for 20 hours. 
Tumour-primed NK cells were then tested for lysis of NK-resistant RAJI cells in a 4-hour 
cytotoxicity assay. The data presented are the mean (± SD) percentage of RAJI cells lysed. 
rNK indicates resting NK cells; TpNK, tumour-primed NK cells; *p < 0.05. 
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5.4.1.2 CD2-mediated tumour priming of NK cells 
CD2 receptor-mediated activation of NK cells through engagement of its ligand 
CD15 was previously demonstrated by Warren et al., who showed that some anti-
CD15 mAbs that sterically block the CD2L site are able to block NK killing of 
otherwise susceptible target cells, including the prototypical NK cell target K562 
(Warren et al. 1996). CTV-1 cells express CD15, so it was hypothesized that CD2-
CD15 interactions contribute to the delivery of the tumour-priming signal.  
 
Figure 5.3 shows that pre-incubation of CTV-1 with anti-CD15 mAbs inhibited 
priming of NK cells as measured by CD69 expression (mean decrease, 30.1 ± 13.3% 
, n=4) and CD25 expression (mean decrease, 57.7 ± 7.78%, n=4; p = 0.03). The role 
of CD2 as the NK-associated ligand for CD15 was confirmed by the blockade of NK 
priming by anti-CD2 mAbs, which resulted in the reduced expression of CD25 
(mean decrease, 39.4 ± 5.69%, n=4). Combined blockade of CD2 and CD15 resulted 
in a decrease in expression of both activation markers (CD69: mean decrease, 46.3 ± 
14.4%, n=4). CD25: mean decrease, 88.3 ± 2.25%, n=4; p = 0.02). As shown in 
Figure 5.4, pre-incubation with CD15 inhibited lytic activity of tumour-primed NK 
cells against RAJI cells (mean decrease, 79.6 ± 4.1%; p = 0.007). CD2 blockade also 
resulted in a reduction of tumour-primed lytic activity (mean decrease, 59.1 ± 8.04%, 
n=4). Finally, combined blockade of CD2-CD15 interactions significantly reduced 
lysis of RAJI cells (mean decrease, 87.4 ± 3.03%, n=4; p = 0.01). 
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Figure 5.3 Effect of CD15 or CD2 blockade on CTV-1-mediated priming of NK cells. 
Resting human NK cells from healthy volunteer donors were incubated overnight with or 
without CTV-1 cells in the presence or absence of the indicated mAbs at saturating 
concentrations. After 20 hours, the cells were analyzed for expression of: (A) CD69 
expression; and (B) CD25 expression by flow cytometry. Data shown are the mean (± SD) 
percentage of CD69
+
 or CD25
+
 cells, respectively. 
rNK indicates resting NK cells; TpNK, tumour-primed NK cells; *p < 0.05. 
(A) 
(B) 
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Figure 5.4 Effect of CD15 or CD2 blockade on lytic activity of CTV-1-primed NK cells.  
CTV-1 cells were incubated with saturating concentrations of anti-CD15 (clone MEM158), 
anti-CD2 (OKT11), or anti-CD56 (clone NCAM16.2) mAbs and co-cultured with resting 
NK cells from normal volunteer donors (n = 5) for 20 hours. Tumour-primed NK cells were 
then tested for their ability to lyse NK-resistant RAJI cells in a 4-hour cytotoxicity assay. 
Data shown are the mean (± SD) percentage lysis of RAJI cells.   
rNK indicates resting NK cells; TpNK, tumour-primed NK cells; *p < 0.05; **p < 0.005. 
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5.4.2 Microbead-mediated priming of NK cells 
5.4.2.1 NK cell priming with antibody-coated microbeads  
In the next set of experiments, I set out to replace the CTV-1-mediated NK cell 
priming signal with an artificial priming system involving antibody-coated 
microbeads. Dynabeads coated with anti-LFA-1, anti-CD2 and anti-NKG2D mAbs 
were co-incubated with resting NK cells for 20 hours. NK cells were then assayed for 
priming using CD25 and CD69 activation markers. A modest up-regulation in CD69 
expression (mean increase, 7.51 ±7.2%, n=3) and CD25 expression (mean increase, 
7.02% ± 3.6; n=3) was observed compared with resting NK cells (Figure 5.5). 
Enhanced killing was not observed by NK cells co-incubated with the antibody-
coated beads (Figure 5.6). 
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Figure 5.5 Effect of antibody-coated microbeads on NK cell priming. 
Resting human NK cells from healthy volunteer donors were incubated overnight with CTV-
1 cells, microbeads coated with anti-(LFA-1+NKG2D+CD2) mAbs or uncoated beads. After 
20 hours, NK cells were analyzed for (A) CD69 and (B) CD25 expression by flow 
cytometry. Data shown are the mean (± SD) percentage of CD69
+
 cells and CD25
+
 cells, 
respectively. 
rNK indicates resting NK cells; TpNK, tumour-primed NK cells. 
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Figure 5.6 Effect of antibody-coated microbeads on the lytic activity of NK cells. 
Resting human NK cells from healthy volunteer donors (n = 3) were incubated overnight 
with CTV-1 cells, microbeads coated with anti-(LFA-1+NKG2D+CD2) mAbs or uncoated 
beads. After 20 hours, NK cells were tested for lysis of NK-resistant RAJI cells in a 4-hour 
cytotoxicity assay. Data shown are the mean (± SD) percentage lysis of RAJI cells. 
rNK indicates resting NK cells; TpNK, tumour-primed NK cells. 
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5.4.2.2 NK cell priming with CTV-1 ligand-coated microbeads 
Dynabeads pre-coated with recombinant Human ICAM-1 Fc Chimera, recombinant 
Human MICA Fc Chimera and anti-CD2 (RPA 2.11) were co-incubated with resting 
NK cells for 20 hours. NK cells were then assayed for priming using CD25 and 
CD69 activation markers. A modest upregulation in CD69 expression (mean 
increase, 10.6 ± 10.95%, n=3) and CD25 expression (mean increase, 14.7 ± 4.08%, 
n=3) was observed compared with resting NK cells (Figure 5.7). Beads coated with 
ICAM-1 formed a higher number of conjugates with NK cells compared with beads 
coated with anti-LFA-1 (mean increase, 74.1 ± 2.08%, n=3; p = 0.003) or anti-
NKG2D (mean increase, 84.7 ± 4.04%, n=3; p = 0.003). Enhanced killing was not 
observed by resting NK cells co-incubated with ligand-coated microbeads (Figure 
5.8). 
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Figure 5.7 Effect of CTV-1 ligand-coated microbeads on NK cell priming. 
Resting human NK cells from healthy volunteer donors (n = 3) were incubated overnight 
with CTV-1 cells, microbeads coated with recombinant Human ICAM-1 Fc Chimera, 
recombinant Human MICA Fc Chimera and anti-CD2 (RPA 2.11) or uncoated beads. After 
20 hours, NK cells were analyzed for (A) CD69 and (B) CD25 expression by flow 
cytometry. Data shown are the mean (± SD) percentage of CD69
+
 cells and CD25
+
 cells, 
respectively. 
rNK indicates resting NK cells; TpNK, tumour-primed NK cells. 
(A) (B) 
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Figure 5.8 Effect of CTV-1 ligand-coated microbeads on lytic activity of NK cells. 
Resting human NK cells from healthy volunteer donors (n = 3) were incubated overnight 
with CTV-1 cells, microbeads coated with recombinant Human ICAM-1 Fc Chimera, 
recombinant Human MICA Fc Chimera and anti-CD2 (RPA 2.11) or uncoated beads. After 
20 hours, NK cells were tested for lysis of NK-resistant RAJI cells in a 4-hour cytotoxicity 
assay. Data shown are the mean (± SD) percentage lysis of RAJI cells. 
rNK indicates resting NK cells; TpNK, tumour-primed NK cells. 
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5.5  Discussion 
NK cell-mediated natural cytotoxicity against tumour targets involves a wide array of 
activating NK cell receptors. Upon contact with a susceptible target cell, an NK cell 
undergoes discrete activation events, starting with LFA-1-dependent adhesion and 
culminating in the polarised release of cytotoxic granules into the immunological 
synapse (Bryceson et al. 2011). Conversely, an encounter with an NK-resistant target 
cell that fails to trigger NK cell cytotoxicity can be due to a deficiency in one or 
more of the signalling requirements for NK cell activation. CTV-1 is a leukemic cell 
line that primes resting NK cells to display enhanced effector functions, but fails to 
trigger NK cell cytotoxicity (North et al. 2007). In this Chapter, the CTV-1 ligands 
responsible for the delivery of the tumour-priming signal to NK cells were examined. 
The results presented indicate that the engagement of ICAM-1 and CD15 with their 
respective receptors on resting NK cells was shown to be critical for the NK cell 
priming process.  
 
LFA-1-dependent NK cell adhesion to target cells occurs through the activation of 
inside-out signals, which induce an open conformation in LFA-1 to promote ligand 
affinity and avidity (Barber and Long 2003). In T cells, LFA-1 does not signal on its 
own in the absence of TCR engagement (Luo et al. 2007), so it is not possible to 
dissect the relative contributions of TCR and LFA-1 signals, which collectively 
result in efficient granule polarization (Anikeeva et al. 2005). By contrast, inside-out 
signalling by other receptors for the binding of LFA-1 is not required in NK cells. 
Thus, the outcome of signalling by LFA-1 alone can be examined. Studies have 
shown that LFA-1 binding to purified ICAM-1 on beads or to ICAM-1 expressed on 
insect cells is sufficient to induce granule polarization in NK cells (Barber et al. 
2004;Bryceson et al 2005). A variety of activating receptors, including 2B4, 
NKG2D, DNAM-1, CD2 or LFA-1 itself, can rapidly induce inside-out signals for 
activation of LFA-1 in freshly isolated human NK cells to promote adhesion 
(Bryceson et al. 2009). Co-engagement of some of these co-activation receptors with 
ICAM-1 has been shown to enhance signalling in NK cells (Bryceson et al 
2005;Bryceson et al. 2009). Blockade of ICAM-1 on CTV-1 cells was shown here to 
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inhibit tumour-priming of resting NK cells as evidenced by downregulation of 
activation marker expression and reduced cytotoxicity against RAJI cells. It is 
possible that ICAM-1 blockade results in a decrease in the number of NK cells that 
overcome the signalling threshold for granule polarization. ICAM-1 is also required 
for the formation of organized natural cytotoxicity synapses (Liu et al. 2009). Thus, 
another explanation for the blockade of NK cell priming in the absence of ICAM-1 
signalling could be a decrease in the number of stable NK-target cell conjugates 
required for efficient killing by NK cells. Indeed, my observations confirmed a 
higher number of bead-NK cell conjugates was achieved when beads were coated 
with ICAM-1, compared to any other ligand or antibody.  
 
When screening for potential NK-activating ligands on CTV-1, our group had 
previously identified four other candidate molecules: CD58, CD48, CD38 and CD15 
(Sabry et al. 2011). Only CD15 was shown to have a significant effect on NK cell 
priming as measured by CD25 and CD69 expression (Sabry et al. 2011). Warren et 
al. had previously reported CD15 as a novel ligand for CD2, and CD2 is a known 
mechanism by which NK cell activation occurs (Bryceson et al 2006). Therefore, I 
hypothesized that CD15 on CTV-1 engages CD2 on NK cells to deliver part of the 
tumour-priming signal. I used the anti-CD15 mAb clone MEM158, instead of clone 
LeuM1, because the latter was previously reported to bind a site within CD15 that 
excludes the CD2L site (Warren et al. 1996). Pre-incubation of CTV-1 with anti-
CD15 mAb clone MEM158 significantly reduced the lytic activity of tumour-primed 
NK cells. Further work by our group confirmed that CD15
+
 tumour cell lines such as 
‘leukemic’ MV-411 and SEM, but not CD15– cell lines MOLT-16 and PF-382 are 
capable of priming NK cells. Induced expression of CD15 on the NK-resistant RAJI, 
through transfection with cDNA for fucosyltransferase (FUT)-4, the CD15 
synthesizing enzyme, renders it susceptible to lysis by resting NK cells (Sabry et al. 
2011). All of this confirms the involvement of CD15 in the priming of NK cells and 
suggests that CD15 is an important constituent of the NK-CTV-1 immune synapse.  
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When I set out to replicate the tumour-priming signal delivered to resting NK cells in 
the absence of CTV-1 cells with antibody-coated microbeads, anti-NKG2D mAbs 
were added to the stimulation cocktail (which also included anti-CD2 and LFA-1 
mAbs). NKG2D is an activating NK cell receptor that was consistently 
downregulated when I investigated the phenotypic properties of tumour-primed NK 
cells in Chapter 3. CTV-1 cells express the stress ligands for NKG2D, MICA and 
MICB. In addition, previous work by our group had shown that blockade of NKG2D 
suppresses the proportion of CD69
+
 NK cells and the intensity of CD69 expression 
(Sabry et al. 2011). First, beads of a diameter 4.5 m were coated with antibodies 
against the three NK cell receptors: LFA-1, CD2 and NKG2D. The NK cell 
activation achieved following bead stimulation was minimal as measured by 
activation marker expression. Since mAbs don’t recapitulate activation processes 
induced by physiological ligands, I sought to replace the artificial priming system 
with Protein-G coupled beads bound to fusion proteins of ICAM-1 and ULBP-1; the 
respective ligands for LFA-1 and NKG2D. Ideally, those beads would have been 
coated with CD15 as well, but since it isn’t commercially available, I used anti-CD2 
mAbs. These experiments again resulted in some upregulation of NK cell activation 
markers, but it is clear that the methodology remains to be optimized such that 
priming equivalent to cell contact is achieved. It is possible that simultaneous co-
engagement of receptors is a crucial requirement for the replacement of target cell 
stimulation as previously suggested (Bryceson et al. 2009). It is also possible that 
other receptor combinations are more optimal for NK cell activation synergy 
(Bryceson et al. 2006).  
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Chapter 6 General Discussion 
6.1 NK Cells and tumours: a few burning questions 
With a wide array of cell surface receptors designed for robust immune surveillance 
and protection against the wide variety of threats faced by the immune system, NK 
cells are strongly equipped to act as initiators of immune responses upon recognition 
of stressed or aberrant cells. The innate ability of NK cells to mediate cytotoxicity 
against tumour cells co-evolved alongside tumour escape mechanisms, by which 
tumour growth and development can take place without triggering the NK cell 
threshold for full activation. Tumour resistance to lysis by NK cells may be 
overcome by priming NK cells with cytokines or by binding NK activating receptors 
to ligands expressed on target cells. In this Thesis, the activation profiles of NK cells 
upon tumour-priming with the NK-resistant leukaemia cell line CTV-1 were defined, 
and the NK cell receptors involved in the delivery of the tumour-priming signal were 
identified. The results presented here demonstrate that NK cell responses to CTV-1 
tumour-priming are distinct from those induced by exogenous cytokine-priming, and 
from those induced by the NK-sensitive target cell line K562. This supports the 
hypothesis that NK cell responses differ according not only to the type of stimulus, 
be it an exogenous cytokine or a target cell, but also depending on the ligand 
combination presented by the target cell and the threshold for NK cell activation 
achieved. 
 
In contrast to inhibitory receptor expression, which is to a great extent genetically 
determined , recent evidence suggests that activation receptor expression is heavily 
influenced by the environment (Horowitz et al. 2013). Therefore, NK cells may be 
reliant on inhibitory receptor expression for mechanisms of self-tolerance, while 
using adaptable expression patterns of activating receptors and strict requirements for 
co-activation to regulate responses to other immune threats such as tumourigenesis. 
It is also possible that regulation of NK cell responses is exerted on multiple levels 
that include the presence of inhibitory receptors and the specificity of activation 
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requirements. In any case, the exact mechanisms regulating NK cell effector 
responses remain poorly understood and the signalling pathways are still undefined. 
The experiments described in this Thesis aimed to improve our understanding of how 
NK cells regulate their effector responses against tumours, in order to facilitate the 
clinical use of NK cells for immunotherapy. With this in mind, a few burning 
questions pertaining to NK cell biology remain, and these are discussed in the 
following sections. 
6.2 Tumour-associated NK Cells: impaired or tumour-primed? 
It is widely thought that cancer patients have NK cell dysfunctions that are secondary 
to the presence and progression of cancer (Kiessling et al. 1999). Commonly 
reported traits of tumour-associated NK cells include decreased cytotoxic activity 
(Bauernhofer et al. 2003;Campos et al. 1998;Carrega et al. 2008;Frassanito et al. 
1997;Jinushi et al. 2005;Katrinakis et al. 1996;Koda et al. 2003;LeFever and 
Funahashi 1991;Lutgendorf et al. 2005;Mocchegiani et al. 1999;Rajaram et al. 
1990;Tajima et al. 1996;Taketomi et al. 1998;Wakiguchi et al. 1994), 
downregulation of activating receptor expression (Costello et al. 2002;El-Sherbiny et 
al. 2007;Fauriat et al. 2007;Jinushi et al. 2005;Konjevic et al. 2007) and intracellular 
signalling molecules (Buggins et al. 1998;Healy et al. 1998;Kono et al. 1996;Lai et 
al. 1996;Nakagomi et al. 1993), defective proliferation (Gati et al. 2004;Pierson and 
Miller 1996;Tsukuda et al. 1993), poor infiltration, decreased cell counts and 
defective cytokine production (Chang et al. 1989; Tajima et al. 1994). It is important 
to note that studies since the late 1980s have demonstrated the reversal of these 
tumour-associated NK cell traits after a few days of ex vivo culturing alone or with 
IL-2, suggesting the absence of any inherent NK cell defect per se (Lotzova et al. 
1987). Instead, I propose based on the data presented here regarding the antigen 
expression and secretory profiles of tumour-primed NK cells that these observations 
are indicative of a tumour-specific NK cell response. This is proposed bearing in 
mind that the tumour must have undergone selective pressure to downregulate NK 
cell functions in order to grow within an immunocompetent setting (Dunn et al. 
2002). 
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The weakened capacity of NK cells to kill tumour targets has previously been shown 
to be ‘corrected’ with the addition of activating stimuli, blockade of inhibitory 
factors, or when tested against an allogeneic tumour (Gati et al. 2004;Pierson et al. 
1996). The observation that NK cell-mediated killing of tumour target cells occurs 
without having undergone any restorative measures is in itself evidence against NK 
cell functional impairment or incapacity. Loss of CD3-ζ expression is the most 
frequently cited example of a defective NK cell phenotype (Buggins et al. 
1998;Healy et al. 1998;Kono et al. 1996;Lai et al. 1996;Nakagomi et al. 1993) and 
since some of the most important NK cell activating receptors involved in tumour 
killing are associated with CD3-ζ, including CD16 (Wirthmueller et al. 1992) and 
several NCRs(Nagakomi et al. 199; Anderson et al. 1990;Vitale et al. 1998) , a 
generalized loss of function is expected. However, tumour-primed NK cells, which 
were shown here and elsewhere (North et al. 2007) to have enhanced effector 
functions relative to resting NK cells, also exhibit marked downregulation of 
numerous activating receptors. Specifically, changes in NK cell phenotype after 
tumour-priming included a significant loss of CD16, NKG2D, NKp46 and DNAM-1. 
Several studies have reported better killing of tumour targets by NK cell subsets with 
downregulated receptors such as CD16 or NKp46 compared with their counterparts 
with normal expression (Gati et al. 2004;Penack et al. 2005). My data supported this 
observation by demonstrating that the CD56
dim
CD16
–
 NK cell subset that arises in 
response to tumour-priming is the main degranulating subset in a 4-hour cytotoxicity 
assay against tumour cell targets (Chapter 3). This argues that ligand-induced 
downregulation of NK cell activating receptors is part of a specific NK cell response 
to tumour stimulation, as has been previously reported (Groh et al. 2002;Huard and 
Karlsson 2000;Linsley et al. 1993;Valitutti et al. 1997), rather than a marker of 
dysfunction. When Romee et al. (Romee et al. 2013) investigated the expression of 
NK cell activating receptors following cytokine stimulation, they observed that none 
of the NCRs, or co-activation NK cell receptors CD2, DNAM-1, NKG2D and CD57 
were down-regulated in response to cytokine-priming (Romee et al. 2013). The 
results shown here confirm this observation, demonstrating that many of these 
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activating receptors are uniquely down-regulated in response to CTV-1, but not after 
activation with IL-2, IL-7, IL-12 or IL-15. This further supports the specificity of the 
NK cell response to target cell stimulation and more specifically priming with CTV-
1. It is likely that target cell stimulation specifically induces NK cell responses 
through shedding of these receptors. It is also possible that these receptors are shed 
following stimulation to complete the tumour-priming stage of NK cell activation, 
with other receptors being involved in the ‘triggering’ stages. In any case, based on 
these observations, it would be inaccurate to link this change in phenotype following 
stimulation with tumour cells with NK cell impairment.  
 
Another commonly reported observation linked to NK cell impairment in cancer is a 
weakened capacity for IFN-γ release (Chang et al. 1989; Tajima et al. 
1996;Wakiguchi et al. 1994). Recent studies have highlighted hierarchies in the 
strength of the activating stimuli required for different NK cell responses (Bryceson 
et al. 2005;Bryceson et al. 2009;Fauriat et al. 2010). Signals for LFA-1-dependent 
NK cell adhesion and release of chemokines such as MIP-1β, exhibit a low threshold 
for activation, which in some cases can be met through the engagement of a single 
NK cell activating receptor. Degranulation and the release of other cytokines such as 
TNF-α require stronger activating stimuli. IFN-γ release has the highest activation 
threshold for NK cell receptor cooperation (Bryceson et al. 2011a). Thus, defective 
cytokine production by tumour-associated NK cells, which is often reported as a 
decrease in INF-γ release, can be explained by the absence of sufficient activating 
signals necessary for its secretion. As shown in Chapter 4, in the case of CTV-1 
stimulation, the ligand combination presented by the tumour cells is sufficient to 
meet the activation threshold for chemokine, TNF-α and INF-γ secretion, as 
demonstrated by the secretory profiles of tumour-primed NK cells, but not for 
degranulation. Fauriat et al. (Fauriat et al. 2010) previously showed that in contrast 
to cytokine stimulation, target cell recognition of K562 cells by resting NK cells 
induces a pro-inflammatory cytokine profile characterized by MIP-1α, MIP-1β, 
RANTES, TNF-α and IFN-γ. Interestingly, stimulation with CTV-1 cells consistently 
induced the secretion of these cytokines at a much higher rate compared with K562 
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cells after a short incubation period (Chapter 4). A possible explanation for the 
enhanced cytokine secretion following CTV-1 stimulation is that NK cells that are 
primed but have yet to progress through the triggering stages are more responsive 
than NK cells that have gone through the full activation cycle. Another explanation 
lies in the ligand expression profile of CTV-1 cells, which might hold the code for 
better synergy among NK cell activating receptors for optimal cytokine secretion. 
Either way, using a cytokine that has the highest requirement for NK cell receptor 
cooperation after degranulation, as a measure of defective cytokine production by 
NK cells can be misleading.  
 
In a similar manner to NK cells, tumour-associated T lymphocytes can recognize and 
eliminate autologous tumours after ex vivo culture with IL-2 (Lai et al. 1996; 
Matsuda et al. 1995; Mulder et al. 1997), or anti-CD28 and anti-CD3 mAbs (Renner 
et al. 1996), despite their inability to kill those targets in situ. Chronic stimulation of 
T cells, in the absence of a second activation signal, has also been shown to decrease 
T cell receptor expression, proliferative capacity and responsiveness (Correa et al. 
1997). It can be easily envisaged that chronic stimulation of NK cells by tumours or 
any other inflammatory setting, results in a similar reduction in proliferation and 
response. Collectively, the observations discussed above argue against the commonly 
reported conclusion of NK cell dysfunction. Instead, these observations argue for a 
tumour-specific NK cell response, and suggest the absence of sufficient activating 
signals for full NK cell effector function in the tumour microenvironment. A tumour-
primed NK cell waiting for the second signal to trigger killing, is likely to have 
down-regulated receptors involved in the priming stage, but is still functional and 
ready for killing upon receipt of secondary stimulation. In the following section, the 
NK cell receptors involved in the tumour-priming stage are elucidated.  
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6.3 What are the activating signals involved in tumour-priming? 
Upon contact with a susceptible target cell, resting NK cells progress through the 
discrete activation events of adhesion, stable conjugate formation, granule 
polarization and exocytosis in order to mediate effective natural cytotoxicity. 
Resistance to NK cell-mediated killing can be attributable to a deficiency in any of 
the signalling requirements for the events leading to granule exocytosis. Activating 
NK cell receptors contain highly divergent cytoplasmic signalling domains and 
belong to a number of different receptor families, many of whose signalling 
pathways are not well defined (Bryceson et al. 2006a;Watzl and Long 2010). 
Tumour-priming data from this Thesis are discussed below in the context of data 
from studies investigating activation requirements for distinct NK cell events and the 
effect of interference from inhibitory signals.  
6.3.1 Contact/Adhesion 
The initial contact between an NK cell and a target cell may involve any of a number 
of receptors that induce LFA-1-dependent adhesion through ‘inside-out’ signals 
(Bryceson et al. 2009). Inside-out signals augment ligand affinity by inducing an 
open conformation in the LFA-1 receptor. In NK cells, LFA-1 can provide its own 
inside-out signal to promote a signal-dependent increase in binding of NK cells to 
ICAM-1 (Barber and Long 2003). This is in contrast to T cells, in which LFA-1 
remains in a closed conformation unless the TCR or a chemokine receptor transmits 
inside-out signals that induce an extended conformation (Luo et al. 2007). Other NK 
cell receptors including CD2, 2B4, NKG2D, and DNAM-1 can also signal upstream 
of LFA-1, even in the absence of its ligands, to induce inside-out signals and 
promote NK cell adhesion to targets (Bryceson et al. 2009). Co-engagement of LFA-
1 through its ligand ICAM-1, with some of these receptors results in a higher 
frequency of open LFA-1 relative to individual ligation, as shown in experiments 
using Drosophila S2 cells expressing individual and combined ligands for NK cell 
receptors (Bryceson et al. 2009). CTV-1 cells express ligands for at least three of 
these receptors: LFA-1, CD2 and NKG2D. Thus, it is likely that this ligand 
combination is responsible for synergistic NK cell adhesion and completion of the 
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first event in NK cell activation. LFA-1 is expressed at uniformly high levels on 
resting NK cells, as shown with conformation-independent mAbs in this Thesis 
(Chapter 3). Other studies using conformation-dependent mAbs 327C and mAb24 
demonstrated heterogeneous staining of open-LFA-1(Bryceson et al. 2009). The 
guanine exchange factor and actin regulator, VAV-1, has been postulated to be a 
common denominator of signalling pathways downstream of LFA-1 inside-out 
signals (Bryceson et al. 2011b). Interestingly, VAV-1 phosphorylation also provides 
a point at which interference by inhibitory receptor signals can oppose signals from 
activating receptors to abrogate target cell adhesion. Specifically, this is thought to 
occur through the recruitment of SHP-1, which binds phosphorylated VAV-1 
(Stebbins et al. 2003).  
6.3.2 Conjugate/Synapse formation 
Another critical role of LFA-1 in NK cells is the organization of the cytotoxic 
immunological synapse (Long et al. 2013). Specifically ICAM-1 ligation has been 
shown to be crucial for the formation of stable NK cell-target cell conjugates (Barber 
et al. 2004;Bryceson et al. 2005;Bryceson et al. 2009). Studies by Liu et al. (Liu et 
al. 2009) imaging human primary NK cells on lipid bilayers carrying ligands of 
activation receptors have also shown that the formation of an organized natural 
cytotoxicity synapse to be dependent on the presence of ICAM-1. Additionally, 
ICAM-1 ligation is a requirement for the formation of a stable central zone at the 
synapse where active membrane internalization occurs and where exocytosed 
lysosome-associated protein (LAMP)-1 molecules are retrieved into an endocytic 
compartment, presumably for the recycling of lytic granule membranes (Liu et al. 
2009). Again, the presence of ICAM-1 on CTV-1 cells is likely to play an important 
role in the formation of stable immunological synapses and the completion of the 
second event required in the progression of NK cells towards natural cytotoxicity. In 
the bead stimulation experiments (Chapter 5), beads coated with ICAM-1 formed 
more conjugates with NK cells than beads coated with ligands for NKG2D, CD2 or 
even anti-LFA-1, which supports the observation that ICAM-1 is important for the 
formation of stable conjugates with NK cells.  
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6.3.3 Granule Polarization 
Finally, LFA-1 promotes the polarization of perforin-containing granules towards the 
target cell, facilitating efficient cytotoxicity (Barber et al. 2004;Bryceson et al. 2005). 
Granule polarization towards the immune synapse is the result of two different 
molecular processes. First, granules rapidly converge in a dynein-dependent manner 
to the microtubule-organizing centre (MTOC) (Mentlik et al. 2010) as initially 
described in T cells (Mentlik et al. 2010). In the NK cell line YTS, blockade of LFA-
1 with antibodies results in an impairment of granule convergence at the MTOC 
upon target cell contact, suggesting that this process is LFA-1 dependent (Mentlik et 
al. 2010). Second, following granule convergence the MTOC and granules polarize 
towards the interaction site in a talin/paxillin-dependent manner (Bryceson et al 
2005;Mentlik et al. 2010). Blockade studies and bead stimulation experiments 
(Chapter 5) demonstrated the involvement of ICAM-1 as presented by CTV-1 cells 
in the tumour-priming of resting NK cells. Results in this Thesis suggest that ICAM-
1 plays an important role in the tumour-priming signal. According to the literature 
discussed thus far ICAM-1 engagement should lead to the completion of NK cell 
activation events up to granule polarization. Future work should confirm that CTV-1 
ligation by resting NK cells results in cytotoxic granule polarization.   
6.3.4 Granule maturation and exocytosis 
Vesicle exocytosis is the last requirement in NK cell activation events leading up to 
the triggering of natural cytotoxicity (Bryceson et al. 2006b). NK cells mediate target 
cell killing by polarised release of the contents of cytotoxic granules at the 
immunological synapse towards their target cells. In human NK cells, signals for 
granule polarization and for degranulation can be uncoupled, and the binding of 
LFA-1 to ICAM-1 is sufficient to induce polarization but not degranulation (Barber 
et al. 2004;Bryceson et al. 2005;Bryceson et al. 2009). This is in contrast to CD16, 
the engagement of which triggers degranulation, but not polarization (March and 
Long 2011). Recent studies in PLC-γ knockout mice have demonstrated an essential 
role for PLC-γ in granule exocytosis (Caraux et al. 2006;Tassi et al. 2005). NK cells 
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from these mice adhered to target cells and polarized their granules, but failed to 
mediate cytotoxicity. This is similar to the ability of CTV-1 cells to prime resting NK 
cells to activate, without triggering degranulation or NK cell-mediated killing of 
targets. Based on the ligand combination presented by CTV-1 tumour cells to resting 
NK cells, it is possible that CTV-1 stimulation overcomes the threshold for VAV-1 
signalling, but not PLC-γ activation. NK cells from patients with mutations in either 
STIM1 or ORAI1 display defective degranulation, demonstrating a requirement for 
ORAI1-mediated store-operated Ca
2+
 entry (SOCE) for lytic granule exocytosis 
(Maul-Pavicic et al. 2011). This defect occurred at a late stage of the signalling 
process, because activation of LFA-1 and cytotoxic granule polarization were not 
impaired. How signals for PLC-γ activation by LFA-1 and CD16 selectively induce 
polarization or granule release, respectively, remains to be elucidated (March and 
Long 2011). The involvement of ICAM-1 in the delivery of the tumour-priming 
signal by CTV-1 as confirmed by blockade data (Chapter 5) suggests that the third 
event in NK cell activation (granule polarization) leading up to granule exocytosis 
should be complete. However, because CTV-1 cells are not susceptible to NK cell-
mediated killing and resting NK cells do not degranulate in response to CTV-1 
stimulation (Chapter 3), it is likely that tumour-priming by CTV-1 induces the 
progression of NK cell activation events up to granule polarization only. Upon 
additional stimulation, and the possible overcoming of the signalling threshold for 
PLC-γ, granule exocytosis and therefore NK cell killing is triggered. Figure 6.1 
outlines the activation events discussed in this section coupled with their signalling 
requirements.  
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Figure 6.1NK cell activation events and receptor requirements for natural cytotoxicity 
Resting NK cells progress through distinct activation events starting with contact/adhesion to 
target cells, followed by conjugate formation, and finally granule polarization and 
exocytosis. The requirement for receptor engagement for each activation event and the 
measurement assay for each distinct step are outlined.  
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6.3.5 Tumour-priming model for NK cell activation 
In NK cells, the outcome of signalling by LFA-1 alone is sufficient to induce granule 
polarization (Barber et al. 2004; Bryceson et al. 2005; Bryceson et al. 2009). 
Individual engagement of the co-activation receptors CD2, 2B4 or NKG2D can 
induce LFA-1 inside-out signals for NK cell adhesion, independently of LFA-1 
(Bryceson et al. 2009). However, co-engagement of LFA-1 by ICAM-1 on target 
cells, with any of those co-activation receptors results in enhanced activation signals. 
The final event in NK cell-mediated natural cytotoxicity seems distinct in its 
signalling requirements. Specifically, co-engagement of LFA-1+ 2B4 +NKG2D has 
been demonstrated as the minimal requirement for receptor cooperation in resting 
NK cells. Pre-activation with an exogenous cytokine such as IL-2 can reduce the 
signalling requirement for natural cytotoxicity to LFA-1 engagement only (Bryceson 
et al. 2009). This implies that priming by cytokines, which may be similar to the 
concept of ‘general priming’, decreases the threshold for full NK cell activation, but 
still requires the specificity of integrin co-engagement (Daniel Davis, verbal 
communication). Tumour-priming by CTV-1 circumvents this requirement, because 
it provides the activation signals needed for tumour cell killing specifically. Our 
group had previously hypothesized a two-stage hypothesis for tumour killing with 
distinct ‘priming’ and ‘triggering’ stages for NK cell activation by tumours (North et 
al. 2007). In this Thesis, I show through blockade and bead stimulation experiments 
that interactions between LFA-1-ICAM-1, CD2-CD15, and NKG2D-MICA/B are 
crucial for the delivery of the tumour-priming signal. The second ‘triggering’ signal 
can be provided upon subsequent stimulation with a target cell, as demonstrated by 
cytotoxicity assays with NK-resistant RAJI cells. Tumour-primed NK cells are then 
capable of killing previously-resistant targets as shown here, and in other studies by 
our group (North et al. 2007; Sabry et al. 2011). After NK cell-mediated killing of a 
tumour target cell is achieved, it can be envisaged that an NK cell is able to restart 
the activation cycle with the next target cell encounter, such as in the case of IL-2-
activated NK cells, which have the capacity to serially hit up to 4 target cells (Bhat 
and Watzl 2007). Figure 6.2 demonstrates the proposed tumour-priming model. 
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Figure 6.2 NK cell activation stages and events. 
Resting NK cells require an initial priming signal delivered by an activating cytokine or a 
target cell expressing the ligands necessary to induce adhesion, conjugate formation and 
granule polarization. Co-stimulation of additional NK cell activating receptors by the 
triggering ligands results in NK cell-mediated cytotoxicity against target cells through 
granule exocytosis.  
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6.4 Is it time to replace the missing-self hypothesis? 
The ‘missing-self’ hypothesis was proposed in 1990 based on the observation that 
NK cells kill targets with reduced or absent self MHC class-I molecules, a 
phenomenon common to virally-infected and transformed cells (Karre et al. 
1986;Ljunggren and Karre 1990). The subsequent characterization of NK cell 
inhibitory receptors supported this hypothesis by explaining the molecular 
mechanisms by which NK cells sensed the downregulation of MHC class I 
expression (Brooks et al. 1997;Carretero et al. 1997;Colonna and Samaridis 
1995;D'Andrea et al. 1995;Karlhofer et al. 1992;Lazetic et al. 1996;Moretta et al. 
1994;Phillips et al. 1996;Sivori et al. 1996;Wagtmann et al. 1995). However, when 
studies began to show that the absence of MHC class I molecules on tumour cells 
was insufficient to trigger NK cell lysis, it became clear that our understanding of 
NK cell target recognition was incomplete (Costello et al. 2002;Ruggeri 2002). As a 
wide array of activating receptors started to be discovered, the ‘dynamic equilibrium’ 
hypothesis was formulated, postulating that the integration of opposing signals from 
activating and inhibitory receptors determines the functional outcome of NK cell 
activity (Brumbaugh et al. 1998).  
 
NK cells are negatively regulated by KIRs, which bind HLA-A, -B and -C, and C-
type lectins, which form CD94/NKG2 receptor complexes recognizing HLA-E 
(Moretta et al. 2003). The role of HLA-mediated inhibition in regulating NK cell 
activity is evidenced by studies showing that transfection of appropriate HLA-C 
alleles into NK-susceptible target cells, such as K562, can render them resistant to 
NK-mediated lysis (Addison et al. 2005;Ciccone et al. 1992). Additionally, NK-
resistant tumours such as the B lymphoma cell line RAJI are known to constitutively 
express type I and II HLA-C alleles. In the clinical setting, HSC transplantation 
across HLA barriers has been shown to trigger donor NK cell alloreactivity if the 
recipient lacks KIR ligands that are present in the donor, which is known as a ‘KIR-
ligand mismatch’ (Farag et al. 2002;Parham and McQueen 2003). Studies involving 
acute myeloid leukaemia (AML) patients demonstrated that donor alloreactive NK 
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cells eliminate not only residual leukaemic cells but also host T cells and antigen-
presenting cells, thereby preventing the development of GVHD (Ruggeri 2002). 
However, the impact of KIR-mismatch in other clinical settings remains very 
controversial with several studies showing no advantage of KIR-ligand 
incompatibility for survival or engraftment (Davies et al. 2002;Malmberg et al. 
2005). Pre-incubation of NK cells with an activating cytokine such as IL-2, can result 
in NK cell killing of targets that were previously resistant. Tumour target cells can 
also be used to activate NK cells in a manner analogous to IL-2, as demonstrated in 
this Thesis and in other studies using the acute lymphoid leukaemia cell line CTV-1 
(North et al. 2007; Sabry et al. 2011). Tumour-priming of NK cells has been shown 
here to generate NK cells that are able to lyse the NK-resistant tumour cell line RAJI, 
and other studies have extended these findings to primary leukaemias and solid 
tumours, in HLA-matched, allogeneic or autologous settings (North et al. 2007; 
Katodritou et al. 2011;Sabry et al. 2011). Moreover, transfection of resistant, HLA-
expressing RAJI cells with specific ligands for NK cell-activating receptors renders 
them susceptible to NK cell lysis (Sabry et al. 2011). Similarly, blockade of certain 
tumour ligands for activating NK cell receptors on non-HLA expressing, sensitive 
K562 cells makes them resistant to NK cell-mediated killing.  
 
Recent evidence has shown that when the minimal requirements for NK cell 
cytotoxicity are met, tumour killing can occur irrespective of the presence of 
inhibitory signals, which suggests that proponents of the missing-self theory might 
have been overstating their case. Upon contact with susceptible cells, a multiplicity 
of activating receptors can produce signals for NK cell-target cell adhesion. 
Engagement of the integrin LFA-1 mediates firm adhesion, provides signals for 
granule polarization and orchestrates the structure of an immunological synapse that 
facilitates efficient target cell killing. Other activating receptors signal for lytic 
granule exocytosis, a process that requires overcoming a threshold for activation of 
phospholipase C-γ, which in turn induces SOCE entry as well as exocytosis mediated 
by SNARE-containing perforin syntaxin-11 and regulators thereof. Recent studies 
investigating the effect of licensing on different steps in NK cell cytotoxicity have 
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demonstrated that the involvement of inhibitory receptors in the determination of NK 
cell responsiveness is limited to the first event in NK cell activation. Only proximal 
signals, such as inside-out signalling by activating receptors, but not integrin outside-
in signalling for granule polarization were affected by MHC class I engagement 
(Long et al. 2013). Unlicensed NK cells did not form as many stable conjugates with 
target cells, but for those unlicensed NK cells that did form conjugates, LFA-1-
dependent granule polarization was similar to that in licensed NK cells. Thus, 
providing NK cells with the appropriate combination of activating stimuli unleashes 
full effector function, such that an NK cell can kill tumour targets even in the 
presence of strong inhibitory signalling. 
6.5 Is NK cell priming different from NK cell memory? 
A clear consensus on how the term ‘memory’ is defined in NK cell biology is 
currently lacking. Rolle et al. (Rolle et al. 2013) defined NK cell memory in the 
context of viral infections as the ability to respond more potently to a second 
challenge with the same antigen. Alternatively, the term ‘memory-like’ was proposed 
to describe long-lasting functional alterations that are induced by cytokines without 
clear evidence of antigen involvement. In the context of tumourigenesis, cytokine-
priming induces long-term changes that can be considered memory-like traits in NK 
cells. For example, NK cells stimulated with the γ-chain cytokines used in this Thesis 
responded more potently to subsequent challenges, and secreted a plethora of 
cytokines that affect the tumour microenvironment and further regulate immune 
responses (Chapter 4). On the other hand, NK cell responses to tumour-priming are 
antigen-induced, and thus, according to this definition cannot be considered to have 
memory-like properties. Instead, tumour-primed NK cells fall somewhere in between 
memory and memory-like NK cells, because although they have undergone antigen-
induced long-lasting functional changes, they do not necessarily respond more 
potently to a second challenge with the same tumour antigen initially encountered. In 
fact, it is likely, based on the evidence discussed in previous sections, that a primed 
NK cell requires further engagement of different, non-redundant receptors to 
overcome the signalling threshold for the triggering stage. This necessitates a new 
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definition that distinguishes priming from memory, and accommodates the 
involvement of antigens in the anti-tumoural processes of NK cells.  
 
NK cells undergo clonal expansion after priming with viral targets or exogenous 
cytokines, as well as after sensitization with haptens (Min-Oo et al. 2013;Sun et al. 
2011). Tumour-priming of NK cells was also demonstrated here to result in the 
expansion of NK cell subsets with downregulated expression of specific receptors 
such as CD16 and CD62L (Chapter 3). In humans, most reports suggesting the 
existence of NK cell memory highlight the increased proportion of NKG2C
+
 NK 
cells in viral infections (Della et al. 2012;Foley et al. 2012a;Foley et al. 
2012c;Lopez-Verges et al. 2011). The broad range of viruses that are reported to 
trigger the expansion of the NKG2C
+
 NK cell subset suggests that this phenomenon 
relies on an induced or altered self-ligand rather than on a shared pathogen-derived 
structure. It is possible that NKG2C is functionally involved in the anti-viral immune 
response (Beziat et al. 2012;Bjorkstrom et al. 2011;Brunetta et al. 2010;Petitdemange 
et al. 2011). In the case of tumours, the increase in proportion of specific NK cell 
subsets after co-incubation with CTV-1 suggests that these receptors are functionally 
involved in anti-tumoural responses and can be used as markers for NK cell tumour-
specific responses. Further studies investigating the phenotype of resting NK cells 
after co-incubation with different tumours can build the activation profiles of anti-
tumoural NK cells and identify tumour-specific markers.  
 
The expansion of certain human NK cell subsets observed in various viral or 
tumoural responses might also reflect a first step in the subsequent generation of 
memory NK cells. For example, in the case of CMV responses, the expanded 
NKG2C
+
 NK cells were shown to be more potent producers of IFN-γ, express higher 
levels of CD57, and respond faster to secondary stimulation (Foley et al. 2012; 
Lopez-Verges et al. 2011). NK cells primed with CTV-1 were previously shown by 
our group to maintain their primed status longer than IL-2-stimulated NK cells, even 
after cryopreservation, as measured by NK cell-mediated killing upon subsequent 
stimulation. The mechanisms involved in maintaining the tumour-primed status are 
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unknown. Some studies have shown IL-12 to be central to the generation of NK cells 
with memory-like features (Sun et al. 2012). Other studies with both mouse and 
human NK cells indicate that a short in vitro exposure to a combination of IL-12, IL-
15 and IL-18 yields memory-like NK cells that display superior effector function and 
longevity in vitro and in vivo, and that these properties were also inherited by 
daughter cells (Cooper et al. 2009;Ni et al. 2012;Romee et al. 2012). It is possible 
that these cytokines, which were shown to be secreted by tumour-primed NK cells 
(Chapter 4) play a role in NK-NK cell priming maintenance of tumour-activation 
signals and the development of memory-like features. It is also possible that antigen 
exposure during the tumour-priming process drives the formation of memory-like 
NK cells that contribute to protection against re-challenge with tumour cells in a 
manner that resembles anti-viral NK cell responses. The specific antigens that drive 
the expansion of NK subsets and the formation of NK memory, as well as the 
involvement of cytokines for the generation of long-lived NK cell populations with 
superior effector function should be investigated further.  
6.6 Conclusion: The remaining questions 
Upon their discovery, NK cells were viewed as ‘null’ cells because they were 
thought to lack any defining cell surface markers and because their origins in 
relationship to other immune cells were not understood. In a recent study, Blish and 
colleagues (Horowitz et al. 2013) revealed the presence of 6,000–30,000 
phenotypically distinct NK cell subsets in the blood of any single human. This 
provides an instant perspective on the extensive heterogeneity that exists within the 
PB NK cell population. Moreover, NK cells in the spleen, liver, bone marrow, lymph 
nodes, lung, and decidual tissues are known to be phenotypically different from PB 
NK cells. This diversity may have evolved to generate the various NK cell responses 
observed in different biological frameworks. Other than their role in tumour 
immunosurveillance, NK cells play important roles in the control of pathogen 
infections, maintenance of homeostasis in the lymphoid system as well as 
reproduction. The heterogeneity observed in NK cell responses to tumour-priming 
compared with cytokine-priming in this study, substantiates evidence for the 
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specificity of NK cell responses to varying stimuli and ligand combinations 
presented by target cells. This display of heterogeneity stresses the importance of re-
evaluating certain concepts in NK cell biology. For example, the criteria used to 
describe NK cell impairments in cancer need to take into account the signalling 
requirements for different NK cell effector functions. The specificity of NK cell 
responses to varying stimuli should also be taken into consideration in the 
application of strategies involving ex vivo culture of NK cells to enhance NK cell 
functional properties. In the case of cancer immunotherapy, studying tumour-specific 
responses of NK cells should be the focal point for better specificity and efficacy of 
treatments.  
Another important aspect in the design of NK cell-based immunotherapeutic 
strategies is interference from inhibitory NK cell receptors. Inhibitory signalling by 
NK cells was traditionally viewed as the dominant regulatory mechanism for NK cell 
activity, but recent studies have demonstrated that inhibitory signalling can only 
exert influence on early events of NK cell activation. NK cells primed with CTV-1 
were shown here to overcome inhibitory signalling by MHC class I molecules on 
RAJI cells and, thereby, kill target cells that were previously resistant to NK cell 
cytotoxicity. Thus, further work on defining NK cell activation is critical for the 
development of novel NK-based therapeutic strategies for the treatment of cancer. 
NK cell activation relies on synergy between NK cell activating receptors, rather 
than a single dominant receptor for activation. This allows NK cells flexibility in 
sensing and responding to changes in the tumour environment. Further work should 
investigate the optimal pairing of NK cell receptors to achieve better synergy in the 
clinic, and shed light on the specific pathways instigated by different activating NK 
cell receptors. Other important questions in NK cell activation include what happens 
after triggering of NK cell killing? And how do NK cells detach from a target cell to 
restart activation events? This facet of NK cell biology is important to understand so 
that serial killing by NK cells is optimized in translational applications. The precise 
signals involved in the different priming mechanisms also remain to be elucidated 
and the relationship between priming and memory needs to be further defined. One 
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question that still remains is why NK cells manifest different responses upon target 
cell recognition or cytokine stimulation. Whether there is differential regulation of 
the signal transduction pathways downstream of the activating receptors involved in 
priming requires further study. Finally, it remains to be determined how these 
observations apply to the in vivo microenvironment, where NK cells, cytokines and 
target cells coexist with various activating and inhibitory factors. Progress in our 
understanding of how NK cells function in vivo is absolutely critical if NK cells are 
to be used successfully in cancer immunotherapy.  
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Index I: Standard curves for cytokine concentration: 
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